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Halfway the twentieth century the first reports appeared on viruses isolated 
from the gastrointestinal tract of seemingly healthy persons. These viruses were 
grouped together under the name ECHO viruses. The term ECHO viruses being 
an acronym for enteric cytopathogenic human orphan viruses. Some of the ECHO 
viruses turned out to be less innocent and were ultimately linked to diseases. 
These viruses are now categorised as members of the Enterovirus genus (Picorna-
viridae) [1].
Other isolates in the ECHO virus group are now known as Mammalian 
 orthoreoviruses (or shortly: reoviruses), based on their larger size. The ECHO virus 
type 10 is capable of inducing pathological effects in newborn mice and producing 
lesions in the brain, the myocardium and the liver. The Mammalian ortho-
reoviruses were categorised into three antigenically different serotypes by neutra-
lisation and hemagglutinin-inhibition tests. The ECHO 10 virus became the 
 prototype of reovirus serotype 1, “Lang” (T1L) [1, 2]. The prototype of serotype 2, 
“Jones” (T2J) strain was derived from a child with diarrhoea and was originally 
an unclassified D5 variant of echovirus type 10 [3]. The third prototype of sero-
type 3 was also isolated from a child with diarrhoea and was called the “Dearing” 
strain (T3D). This strain is commonly used in different laboratories around the 
world and in the work described in this thesis. In this context “wild-type” reo-
virus refers to the T3D reovirus strain. 
In 1977 the group of Hashiro was one of the first to observe that for their repli-
cation reoviruses discriminate between tumour cells and normal diploid cells [4]. 
These first experiments were performed with T2J, but later it became clear that 
also T3D and T1L exhibit oncolytic properties. Of the three strains T3D is thought 
the most potent for use in anti-cancer therapies as will be explained in the next 
section. This section provides an introduction into the reovirus biology and its use 
as an oncolytic agent in the form of a review, published in the journal Expert 
 Opinion on Biological Therapy in 2009. It explains two methods used in virology 
to isolate viruses with a different phenotype; viz. bioselection of viruses with 
desirable phenotypes or rational design of new genotypes by genetic modifica-
tion. The final section of this chapter discusses the developments and insights in 
the reovirus field after 2009. 
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1.2 Modification of mammalian reoviruses for use as 
 oncolytic agents 
1.2.1 Abstract
The Reoviridae constitute a family of viruses with a non-enveloped icosahedral 
capsid and a segmented double-stranded RNA genome. Prototypes of the mam-
malian Orthoreoviruses have been isolated from the human respiratory and 
enteric tracts and are not associated with serious human disease. One of these, 
human reovirus type 3 Dearing (T3D), is studied frequently and usually serves as 
a model for the family. In the last decade the mammalian Orthoreoviruses, espe-
cially T3D, have been evaluated as an oncolytic agent in experimental cancer ther-
apy. This is primarily based on the observation that reoviruses induce cell death 
and apoptosis in tumor cells, but not in healthy non-transformed cells. To-date, 
several clinical trials have been initiated in Canada, the United States, and the 
United Kingdom, to study the feasibility and safety of such an approach to cancer 
treatment. Due to the segmented structure of their double-stranded RNA 
genomes  genetic modification of Reoviridae has been notoriously difficult. Several 
new techniques have been described recently that facilitate the genetic modifica-
tion of reovirus genomes. The basis for reverse genetics of reovirus is the discov-
ery in 1990 that reovirus RNA is infectious. Subsequently, it took ten years before 
a foreign gene was introduced into the reovirus genome. Here we will review the 
different methods for reovirus modification and their use for generating new reo-
virus-derived oncolytic agents.
1.2.2 Introduction
In the battle to fight cancer, a large variety of new therapeutic approaches are 
being explored. One such approach is the use of biological strategies. For this, 
 viruses have been considered as oncolytic agents for more than a century. Clinical 
reports of cancer regressions that were coincidental with natural virus infections 
appeared throughout the first half of the twentieth century [5]. Based on these 
anecdotal observations, early clinical trials were performed with viral oncolytic 
agents [6, 7]. Often, the host immune response prevailed, but occasionally, the 
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 infection persisted and the cancer regressed. These studies provided proof of 
 concept for the use of viruses as oncolytic agents [5].
Currently, many natural viral isolates, as well as their genetically-modified 
 derivatives, are evaluated as oncolytic agents in clinical studies. These include 
adenovirus, herpes simplex virus, vaccinia virus, measles virus, Newcastle disease 
virus, and reovirus. Many of these viruses preferentially replicate in and kill 
tumor cell lines [5-8]. In the tumor the virus can trigger a systemic immune 
 response against the tumor cells, potentially further boosting therapeutic efficacy 
[9-16]. The viruses’ intrinsic selectivity for tumor cells can be further enhanced by 
genetic modification [17]. 
1.2.3 Human reoviruses
The family
The Reoviridae constitute a family of viruses with a non-enveloped icosahedral 
capsid and a segmented double-stranded RNA genome. The family name is an 
acronym of Respiratory Enteric Orphan viruses. The term “orphan virus” indi-
cates that a particular virus is not associated with any known disease in humans. 
Prototypes of the mammalian Orthoreoviruses have been isolated from the 
human respiratory and enteric tracts and are not associated with serious human 
disease [18]. In contrast to the Orthoreoviruses rotaviruses are pathogenic and are 
the major etiologic agents of serious diarrhoeal illness in children throughout the 
world [19]. Despite the fact that some members of the Reoviridae family are associ-
ated with disease, the original name is still used [18]. There are three types of 
human Orthoreoviruses (called reoviruses here), which can be differentiated sero-
logically. The three serotypes are each represented by prototype strains isolated 
from a human host: type 1 Lang (T1L), type 2 Jones (T2J), and type 3 Abney (T3A) 
and type 3 Dearing (T3D). Reoviruses have a wide geographic distribution, and 
virtually all mammals, including humans, can serve as hosts for infection [18]. 
While reoviruses are considered non-pathogenic in humans, newborn mice are 
very sensitive to reovirus infection and have been used to study reovirus patho-
genesis. Following inoculation of newborn mice, both T1L and T3D invade the 
central nervous system, albeit with different routes and with distinct pathology. 
Whereas T1L spreads to the CNS hematogenously and infects ependymal cells, 
leading to hydrocephalus, T3D reaches the CNS by neural routes and causes lethal 
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encephalitis. Studies using T1L x T3D reassortant viruses have shown that the 
 pathways of viral spread and tropism for neural tissues segregate with the viral S1 
gene, which encodes attachment protein σ1 [20].
Capsid structure
The reovirus’ icosahedral capsid is composed of an outer and inner protein 
shell. Its genome contains 10 double-stranded RNA segments which are grouped 
into three categories corresponding to their size: L (large), M (medium) and S 
(small). Segments range from ~ 3.9 kbp – 1.2 kbp and each segment encodes one or 
two proteins. The viral capsid proteins are denoted by the Greek character 
 corresponding to the segment it was translated from, the L segment codes for λ 
proteins, the M segment codes for μ proteins and the S segment codes for σ pro-
teins, each protein numbered according to its relative mobility on SDS-PAGE. On 
the vertices, σ1 trimers of the protein form the spike. In the capsid the λ2 mole-
cules reside as pentameric turrets that serve as the insertion site for the σ1spike 
[18]. A model of the reovirus capsid and its segments is provided in Figure 1. 
Receptors
Wild-type reovirus T3D can use distinct receptors for binding to target cells. 
Sialic acids were the first molecules identified to bind reovirus T3D [21, 22]. 
 Barton and co-workers described in 2001 that reovirus attachment to cells is a 
multi-step process [23]. In this process reovirus protein σ1 binds with the shaft 
domain to surface sialic acids with low affinity, before the head domain of σ1 
 connects to a cellular receptor with a higher affinity. The Junction Adhesion Mole-
cule-A (JAM-A, also known as Junction Adhesion Molecule 1, or JAM-1) has been 
identified as the high-affinity receptor for reovirus T3D and can mediate virus 
attachment and infection [24, 25]. JAM-A is an integral tight junction protein of 
the immunoglobulin superfamily and contains two extracellular immunoglobu-
lin-like domains and a short cytoplasmic tail. A region in the globular head of σ1 
of reovirus T3D interacts with JAM-A [26].
Replication cycle
The start of a productive viral infection is docking to the target cell. The reo-
virus spike can establish a low-affinity interaction with sialic acids on the cell sur-
face. Subsequently, the head domain of the spike binds JAM-A with high affinity. 
After engagement of JAM-A a secondary interaction is established between 
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A. Schematic representation of mammalian reovirus Type 3 Dearing. Depicted are the 
 structure of the intact virion, the infectious sub-viral particle, and the core  particle.  
The various capsid proteins are indicated.
B. Representation of the  genomic segments of reovirus type 3  Dearing, and their  encoded 
 proteins. Pictures are courtesy of ViralZone. All pictures in ViralZone are copyright of 
the SIB Swiss  Institute of Bioinformatics.
 ViralZone www.expasy.ch/viralzone, Swiss Institute of Bioinformatics.
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 cellular β1-integrins and the λ2 protein. This leads to endocytotic internalization 
of the particle [27]. Upon acidification of the endosome, the particles are partially 
uncoated, yielding so called infectious subviral particles (ISVP). In the ISVP the 
inner core protein μ1 is proteolytically cleaved resulting in formation of 
hydropho bic peptides which penetrate and locally disrupt the membrane [28]. In 
the  cytoplasm, early transcription of the dsRNA genome by viral polymerase 
occurs. Full-length plus-strand transcripts from each of the dsRNA segments are 
synthesized, which are used as templates for translation. The translation products 
are  concentrated in distinct cytoplasmic regions, the so called-viral factories (Fig-
ure 2), in which the transcripts are precisely assorted in newly formed subviral 
particles [22]. The packaging of the 10 genomic segments is well orchestrated since 
each viral core must contain a single copy of each of the plus-strand transcripts. 
Recent studies suggest that sequences contained within the 130 nucleotides (nt) at 
the 5’ terminus serve as identity label for each of the segments [29, 30]. The plus-
strand RNAs contain the tetranucleotide sequence ‘GCUA’ at the 5’ end and the 
pentanucleotide sequence ‘UCAUC’ at the 3’ end, which may have a role in the 
encapsidation process [31]. In the newly formed core minus-strand synthesis 
 ensues, producing double-stranded RNA genomes. Secondary transcription may 
amplify the genome copy number in the cell. The viral particles are matured and 
can be  released after host cell membrane breakdown [32].
1.2.4 Reovirus and its relation with tumor cells
Preference for transformed cells
The human reovirus Type 3 Dearing is an interesting candidate because of its 
well documented inherent preference for replication in transformed cells. Reo-
virus type 3 was isolated from the intestinal tract from an apparently health indi-
vidual. Serology demonstrates that most humans are exposed to human reo-
viruses before that age of 5, presumably with an asymptomatic infection [18, 33]. 
The impetus for the use of human reovirus T3D as an oncolytic agent has been the 
observation that although reovirus T3D is non-pathogenic, it preferentially lyses 
tumor cells, especially those with an activated Ras signaling pathway. 
The human reovirus’ preference for replication in transformed cells has been 
much studied [33]. A hallmark study was published by Patrick Lee’s group which 
showed that activation of the Ras signaling pathway can sensitize cells to reovirus 
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replication [34]. This study revealed the essential role of the double-strand-
ed-RNA-dependent protein kinase (PKR). In normal cells, the double-stranded 
reovirus RNA activates a PKR response and leads to PKR phosphorylation. This 
triggers phosphorylation of eukaryotic initiation factor 2α, which in turn, inhibits 
translation of mRNA. Strong and coworkers demonstrated that Ras signaling 
 inhibits PKR phosphorylation, allowing translation of the reovirus plus-strand 
RNA’s [34]. Further studies implicated the Ras/RalGEF/p38 signaling in the 
 regulation of reovirus replication and cytolysis [35]. These data offered an expla-
nation for the reovirus’ preferential cytolytic effects on transformed cells. This 
 renewed the interest in the use of reovirus as oncolytic agent. Already in 1978, 
Theiss, Stoner, and Kniazeff reported that infusion of reovirus type 3 into the 
lungs of mice reduced the progression of chemically induced pulmonary adeno-
mas, and that multiple infusions enhanced the antitumor effect [36]. More 
 elaborate studies confirmed the feasibility of reovirus-based cancer therapeutics 
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FIGURE 2. 
Schematic representation of the reovirus life cycle. Both the endocytotic pathway of the 
 intact virions, and the cytoplasmic membrane penetration routes of the  infectious subviral 


























[37, 38], and boosted the interest for developing reoviruses as an oncolytic agent 
[39], as is evident from a boost in the number of publications on this topic (Figure 
3). In Canada, the company Oncolytics Biotech Inc. was founded, which is com-
mitted to explore the oncolytic capability of reovirus as oncolytic agent [40]. 
The relation between Ras signaling and reovirus replication has been much 
 debated [41-43]. The PKR relation should not be taken too dogmatically as also 
other steps in the replication cycle may determine the cell’s susceptibility to reo-
virus-mediated cytolysis. Kranenburg and collaborators demonstrated that activa-
tion of the Ras pathway sensitized the cells to reovirus-induced apoptosis, both in 
mouse [44] and in human tumor models [45]. However, virus yield was not 
affected by ras status. Reovirus T3D was strongly cytopathogenic in cells with 
activated Kras, but not in cells in which the activated Kras gene was inactivated. 
Similarly, viral uncoating is critical in determining the cells sensitivity to reovirus 
infection. Efficient uncoating is dependent on cellular proteases, such as cathepsin 
B and L. The expression of these proteases is often upregulated in tumor cells [46, 
47]. Conversely, down-regulation of cathepsin L leads to reovirus resistance as 
Published in: Expert Opinion on Biological Therapy 2009, 9(12), 1509-1520
D.J.M. van den Wollenberg (LUMC) , S.K. van den Hengel (LUMC/EMC), I.J.C. Dautzenberg (LUMC), 



























Cumulative number of entries found in PubMed using (reovirus AND oncoly*) as  search 
term. The Y axis represents the number of entries with a publication date  before January 1st 
of the indicated year. The diamonds and the solid line represent the total number of 
 publications and the circles and dashed line indicated the number of reviews on this topic . 
Note that approximately 30% of the publications  represent review papers.
Data gathered on August 25, 2009.










this thwarts reovirus disassembly [48]. Also late events in the reovirus life cycle, 
such as the assembly of infectious viral particles, are correlated with Ras status 
[49]. It should be noted here, that it is probable that not the Ras-status itself, but 
rather the functional consequences of Ras signaling, are sensed by the reoviruses. 
Rubin and collaborators set up a gene-trap method to identify cellular genes 
 involved in virus infection and cell killing. Intriguingly, the screen suggests that 
expression of the insulin-like growth factor II (IGF-II) gene could confer resistance 
to reovirus infection [50, 51]. Along similar lines the reovirus S4 gene may affect 
the efficiency of virus replication in Ras transformed cells [52]. 
Clinical studies: evidence for safety
The combination of the apathogenicity in humans and the preferential replica-
tion in, and cytolysis of, transformed cells lead to the initiation of at least 13 clini-
cal trials in Canada, the US and the UK using human reovirus Type 3 Dearing [53-
55]. So far the application of replicating wild-type reoviruses has been safe. In 
none of the studies reported on to date, dose-limiting toxicity has been encoun-
tered [55]. Recently, a series of reviews discussed the clinical results that have 
been obtained so far [53-55]. In the early-phase cancer gene therapy approaches 
clinical efficacy has not yet been demonstrated, although anecdotic evidence for 
antitumor efficacy exists. As with other oncolytic viruses several factors may limit 
effectiveness, including antiviral immunity, inefficient vector delivery to the 
tumor, limited vector spread within the tumor, and inefficient infection of tumor 
cells. Whereas some of these factors are inevitable, others may be circumvented by 
alterations to the therapeutic virus.
The reovirus receptor JAM-A is limiting transduction 
While the reovirus receptor is widely expressed in several tissues, some tumor 
cells may have down regulated the receptors on their cell surface. For instance, 
Kranenburg and collaborators described that none of the 13 freshly isolated tumor 
fragments from patients with colorectal metastases were susceptible to reovirus 
T3D infection [56]. This is probably due to absence or inaccessibility of the reo-
virus receptor JAM-A on the tumor cells. Immunohistochemistry on tissue 
 microarrays showed that JAM-A was expressed at very low levels in liver metas-
tases and improperly localized in the cytoplasm of colorectal tumor cells. Remark-
ably tissue fragments and single-cell populations isolated from human colorectal 
tumor biopsies were susceptible to ISVPs, which have the capacity to directly 
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 penetrate the cell membrane independent of reovirus receptors [56]. Similarly, 
 infectivity of the non-permissive human glioblastoma cell line U118MG could be 
restored by transfer and expression of a JAM-A cDNA clone [57]. This confirms 
that the receptor scarcity contribute to the resistance of tumor cells to reovirus 
T3D. This may be specific to particular tumor types. A recent study shows that 
reovirus T3D induces regression of human breast cancer primary tumor samples 
xenografted in immunodeficient mice. In addition, reoviruses not only eradicated 
the differentiated breast tumor cells, but also the cancer stem cells [58]. Interest-
ingly, expression of the JAM-A molecule has suggested as a prognostic factor in 
breast cancer. JAM-A has been suggested to function as a key negative regulator 
of cell migration and invasion. While JAM-A is robustly expressed in normal 
human mammary epithelium, its expression is down-regulated in metastatic 
breast cancer tumors. MDA-MB-231 cells, which are highly migratory, expresses 
low amounts of JAM-A. Forced overexpression of JAM-A in MDA-MB-231 cells 
inhibited both migration and invasion through collagen gels, whereas knockdown 
of JAM-A using short interfering RNAs enhanced the invasiveness. These data 
suggest that JAM-A serves as a negative regulator of breast cancer cell invasion 
and possibly metastasis [59]. Similarly, recent data suggest a role for JAM1-A in 
progression of renal cell carcinoma [60] and endometrial carcinoma [61]. In con-
trast, based on patient survival studies and in vitro studies, McSherry and collabo-
rators (2009) come to the opposite conclusion [62]. They suggest a correlation 
between increased JAM-A expression and reduced survival of breast cancer 
patients. 
Taken together the data summarized above demonstrate that particular aspects 
of tumor biology, such as receptor availability, Ras signaling, cathepsin expres-
sion, antiviral immunity, etcetera, may affect the anti-tumor efficacy of reo virus-
mediated oncolytic strategies. So how do we go from here, and how can we gener-
ate modified reoviruses with enhanced anti-tumor efficacy?
1.2.5 Generating improved oncolytic reoviruses
Bioselection
In virology two approaches are available to isolate viruses with distinct pheno-
types. The classic approach involves bioselection for the desired phenotype, and 
subsequent characterization of the mutants, including the characterization of the 
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genetic changes that underlie the new phenotype. In human reoviruses this 
 method has been employed successfully, and has been used to select receptor 
 mutants, interferon-resistant mutants, and temperature-sensitive mutants [63, 64]. 
Studies on such mutants provided insight in the biology of reoviruses. Starting 
with an isolate of T3D that could not be passaged in murine erythroleukemia 
(MEL) cells, Dermody and colleagues isolated mutants that were adapted to grow 
in MEL cells [64]. Reassortants were used to demonstrate that this trait is segre-
gated with the S1 segment that encodes the σ1 protein. Sequence analysis mapped 
these mutations in part of the S1 segment that codes for amino acids 198-204 of σ1. 
The MEL-adapted mutants, but not the parental strain could hemagglutinate 
human and bovine erythrocytes. In addition, the binding of the mutants to MEL 
cells could be abolished by neuraminidase treatment. These data suggest that the 
MEL-adapted reoviruses employ sialic acid molecules as their receptor [64]. In 
 addition, it demonstrates that receptor mutants of reoviruses can be selected for 
with relative ease. It should be noted however, that in these studies a phenotype 
was selected for that is present in many of the T3D isolates. Therefore it remains 
to be seen whether reoviruses with completely novel receptor specificities can be 
isolated with similar ease. Along similar lines Lemay and colleagues isolated T3D 
mutants with varying interferon sensitivity. One of the mutants had an interferon -
hypersensitive phenotype. Interestingly this mutant was more dependent on Ras 
signaling than other viral isolates [65]. These data demonstrate that bioselection 
may be used to isolate reovirus mutants that are more efficient as oncolytic agent. 
Rational design
In addition to the classical approach for isolating mutants, reverse genetics 
 approaches have become feasible. For a long time the segmented dsRNA genomes 
of Reoviridae thwarted the use of genetic modification for constructing reovirus 
mutants. Pioneering experiments performed in the Joklik lab demonstrated that 
reovirus RNA is infectious. Transfection of T3D RNA (either plus strand or 
 double-stranded RNA) into L929-cells yield T3D virus, but only if the cells were 
 super-infected with a slow-plaqueing T2J virus as a helper [66]. This technique 
was used to create a T3D mutant with two temperature sensitivity mutations [67], 
and eventually the S2 segment was modified to carry the chloramphenicol acetyl-
transferase (CAT) gene [68]. This involved the in vitro synthesis of the heterol-
ogous S2, in vitro capping of this RNA, enzymatic degradation of the parental S2 
segment, and co-transfection of S2-CAT RNA with single-stranded (plus-
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stranded) and/or double-stranded RNAs of the other nine segments. Although 
this  experiment constituted a breakthrough and a single recombinant reovirus 
was  generated, the method is inefficient and cumbersome. 
Also in other members of the Reoviridae reverse genetics strategies have been 
developed. Roy and collaborators demonstrated that bluetongue virus RNA was 
infectious and infectious bluetongue virus (BTV) could be recovered from in 
 vitro-synthesized RNA [69, 70]. BTV belongs to the genus Orbivirus and like mam-
malian reoviruses has a segmented genome consisting of 10 linear dsRNA mole-
cules. This technique allowed replacement of individual segments with segments 
that were synthesized in vitro using synthetic T7-produced RNAs. A similar 
approach had been described for rotaviruses [71]. While the latter study described 
successful rescuing of a rotavirus with an artificial segment, the method is pur-
portedly inefficient and needs to be improved. 
An alternative approach has been used to generate genetically targeted T3D 
reoviruses [57]. The propagation of wild-type reoviruses on cells expressing a 
 modified σ1-encoding segment embedded in a conventional RNA polymerase II 
transcript led to frequent substitution of the wild-type genome segment by the 
modified version. This technique allowed generating reoviruses that are geneti-
cally targeted to U118MG cells that express a single-chain Fv capable of binding a 
HIS-tag as an artificial receptor. The U118MG cells lack JAM-A and therefore 
 resist infection by wild-type T3D. The targeted reoviruses were engineered to 
carry an HIS tag as ligand for this receptor fused at the C terminus of the σ1 spike 
protein. This demonstrates that the C terminus of the σ1 protein is a suitable 
 locale for the insertion of oligopeptide ligands and that targeting of reoviruses is 
feasible. The genetically targeted viruses can be propagated using the 
 receptor-modified U118MG cells as helper cells [57].
All methods described above require the use of helper viruses or viral core 
particles for generating infectious viruses. Recently, Kobayashi and collaborators 
described a new helper-free method for generating of recombinant reovirus T3D 
from cloned genome segments [72]. The method appears robust and productive 
viral infection could be established in approximately 1 in 105–106 cells transfected 
with plasmids encoding the ten reovirus gene segments. The method was used to 
engineer changes in S1 and S4. In addition, the enhanced green fluorescent (eGFP) 
gene was introduced into the S4 segment, demonstrating that the technology 
allowed the incorporation of heterologous transgenes in the reovirus genome. 
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Since this virus lacks a normal S4 segment, the σ3 encoded by S4 needs to be pro-
vided in trans. Therefore the T3D/S4-GFP virus could only be propagated in cells 
genetically modified to produce the σ3 protein [72]. These data show that viruses 
with otherwise lethal mutations can be produced on helper cells that trans-com-
plement the missing factor. 
To summarize the data above, reoviruses are amendable both by classic genetic 
and by reverse-genetic approaches. With this a robust platform for generating 
specific cancer-targeted can be generated. This poses new questions. What charac-
teristics of reoviruses should be modified to improve the safety and their efficacy 
of reovirus-derived oncolytic agents? And in what fields are new developments 
necessary to fulfil the promise of efficacious reovirus-derived oncolytic vectors? 
Toward targeted reoviruses
In some tumors the reovirus receptor is not expressed or inaccessible. This may 
limit the efficacy of treatment. Amending reoviruses to use a receptor different 
than the canonical receptor JAM-A may enhance the efficacy. To this end both 
bioselection strategies, as well as genetic modification strategies may be 
employed. Similar to the studies with the MEL adapted virus mentioned above, 
reoviruses could be adapted to grow in tumor cells that lack JAM-A on their sur-
face. Isolation of a series of mutants that were selected for replication in human 
glioblastoma cell lines has already been reported [73]. Sequence analysis demon-
strated the presence of mutations in the S1 segment in all mutants, although the 
receptor used by these mutants is still enigmatic. Alternatively, the viruses may be 
genetically modified to encode new receptor binding ligands in one of their capsid 
proteins. In an elegant study, Rouault and Lemay used epitope tagging to identify 
regions in the σ3 protein that permit insertion of heterologous peptides [74]. The 
N-terminus of σ3 appears a promising location for such ligands. Similarly, the 
C-terminus of the σ1 was demonstrated as a feasible location, and peptide 
sequences inserted here could engage a single-chain Fv expressed on target cells 
as alternative receptor. These locations are as well attractive for insertion of small 
targeting peptides. Such peptides could be the integrin-binding ‘RGD’-containing 
oligopeptides that have been inserted successfully in the fiber of the adenovirus 
and facilitate adenovirus-receptor independent infection of cells [75]. It remains to 
be determined, however, whether these sites tolerate inserting larger targeting 
peptides. If this proves feasible, then targeting ligands that have been successfully 
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incorporated in the capsids of other non-enveloped oncolytic viruses may be 
 incorporated in reoviruses. Such ligands could include single-chain Fv domains, 
single-chain T-Cell Receptors, or so-called affibodies [76]. 
Another class of modifications that are most useful in oncolytic reoviruses is 
modifications that reduce infection of non-target tissues. This could be accom-
plished by detargeting the virus, i.e. by preventing association with non-target 
cells. Such mutations should block the reovirus spike’s capacity to bind JAM-A. 
The crystal structure of both the reovirus head domain of the σ1 spike and of the 
extracellular domain of the JAM-A have been reported [77, 78]. More recently also 
the σ1 spike in complex with JAM-A has been reported [79]. Based on this 
 structure, amino acids in the spike that are critical for ligation to JAM-A were 
identified. The system of Kobayashi and collaborates [72] was used to generate 
mutant reoviruses harboring single amino acid changes in critical amino acids. 
Several of these mutants, i.e. T380A, G381A and D423A, exhibited strongly 
reduced binding to JAM-A in surface plasma resonance analyses, as well as to 
neuraminidase-treated HeLa cells [79]. Interestingly, these mutants were viable 
and could be propagated on L929 cells, infecting the cells presumably via direct 
association with sialic acid residues. These mutants can facilitate the development 
of oncolytic reoviruses with reduced infectivity of normal tissues. However, since 
no significant toxicity has been noted in the clinical studies reported on to date, it 
is not yet clear reoviruses de-targeting will be necessary.
1.2.6 Where do we go from here?
With these tools and techniques available and with evidence of excellent safety 
of the wild-type reoviruses in clinical studies we may further define key factors 
that may limit clinical efficacy. In what fields are new developments necessary to 
ful-fill the promise of efficacious cancer targeted reovirus vectors? 
Cells for delivery
Many preclinical and clinical studies demonstrated that delivery of viral 
 vectors to the tumor is often disappointingly inefficient. As outlined above, the 
 expression of the reovirus receptor JAM-A may be low, or the receptor proteins 
are inaccessible to the virus particles. In addition, the high interstitial fluid 
 pressure within most tumors causes a convective flow away from the tumor. This 
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inhibits the passive diffusion of viral particles into the tumor. Moreover, the extra-
cellular matrix may form physical barriers that prevent efficient spread of viral 
vectors [80, 81].
Given the inefficiency of virus delivery to tumor cells, new delivery methods 
are essential. An attractive option is to use cells with the capacity to migrate to 
 umors as delivery vehicles of oncolytic viruses. In this strategy the tumor target-
ing cells are loaded with viruses and administered to the patient. After migration, 
the cells should hand off the cell-associated viruses to the tumor cells. Several cell 
types can migrate to tumors in vivo, including cytokine induced-killer cells, 
 tumor-antigen specific T cells, macrophages, endothelial progenitor cells, and 
 mesenchymal stem cells [82]. 
Cellular delivery may also circumvent the effects of neutralizing immunity [12, 
83]. This is evidenced in a recent study that employed human reovirus T3D as 
 oncolytic agent. In reovirus-naïve mice with B16tk lymph node melanoma metas-
tases, free reovirus or reovirus delivered through mature Dendritic Cells (DC) or 
T cells was detected in the tumor-draining lymph nodes 3 days after treatment. 
Here, these viruses could eradicate local tumor cells. Only T cells carrying reo-
virus generated anti-tumor immune responses and long-term tumor clearance. In 
reovirus-immune mice, however, the results were different. Delivery of free 
 reo virus was ineffective as a therapy, but if mature DC as well as T cells were 
used as carriers, reovirus was effectively delivered to melanoma in vivo [12]. These 
data show that whereas systemically administered reoviruses may not be suitable 
for therapy, DC may be an appropriate vehicle for delivery of significant amounts 
of reovirus to tumors. This and several other studies suggest that cellular delivery 
is feasible and may be applicable for delivery of viral oncolytic agents at the 
tumor sites. However, cellular delivery also adds a new level of complexity to the 
clinical studies, and are logistically challenging.
What cells to target?
With the aid of genetic modification and bioselection strategies new reo virus-
derived cancer gene therapeutics can be developed that ensure efficient infection 
of cells within the tumor. It is known that tumors are usually markedly hetero-
geneous, consisting of complex mixtures of cancer cells with various grades of 
 differentiation. A cell type that has attracted much attention in recent years is the 
tumor-initiating cell, or cancer stem cell. The tumor-initiating cell is a cell with the 
capacity to self-renew and differentiate into any of the lineages of cancer cells that 
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comprise a tumor [84]. Presumably the tumor-initiating cells are derived from 
organ stem cells [85]. The latter are long-lived and change over the course of time 
by accumulating (epi)genetic alterations. In this model, the characteristics of 
 cancer initiating cells and therefore of the resulting tumor, depend (in part) on 
these alterations. The cancer stem cell population in a tumor may not only govern 
tumor progression, but may also be responsible for the establishment of distant 
clones (metastases) [84, 86]. Therapeutic efficacy may therefore be directly related 
to the efficiency with which a particular treatment eradicates the cancer stem cell 
population. It may therefore be important to ensure that new reoviral oncolytic 
agents have the capacity to transduce and kill cancer stem cells [58]. It may even 
be desirable to generate reovirus variants that specifically target the cancer stem 
cell population, rather than the more differentiated tumor cells.
1.2.7 Conclusion
Recent years have witnessed a re-emergence of the oncolytic virus approach to 
cancer treatment. Initial clinical safety studies have demonstrated the validity of 
the concept, and feasibility of current approaches. The reovirus T3D used in the 
clinical studies reported on so far are well tolerated and safe. In the past years the 
knowledge on mammalian reoviruses, their biology and their interaction with the 
host have expanded rapidly. Whereas genetic modification of reoviruses’ seg-
mented double-stranded RNA genomes was notoriously difficult, new techniques 
 facilitate the development of genetically modified variants. These techniques can 
be used to generate new tumor targeted oncolytic reoviruses that will hopefully 
be as safe as current ones, but more efficacious. 
1.2.8 Expert opinion
Reovirus-based oncolytic virus therapies have been safe, but so far the efficacy 
is limited. As with other oncolytic viruses the efficacy may be enhanced by com-
bining the oncolytic virus approach with more conventional therapeutic 
approaches such as radiation and chemotherapy [87, 88]. This concept is now 
being explored clinically [89]. 
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In parallel, the new techniques for reverse genetics together with more classical 
genetic approaches can be used to overcome some of the hurdles that thwart 
 efficacious oncolytic virus therapy. Several factors limit the efficacy of treatment 
with oncolytic viruses. These include the inefficient delivery of oncolytic viruses 
to the tumors, the limited infectivity of the cancer cells within the tumors, pre-
existing immunity in the patient population, and the marked heterogeneity of 
many tumor types. With the new (reverse-) genetics techniques, new tumor- 
targeted  oncolytic reoviruses can be generated with improved efficacy and appli-
cability. Hereby, the gene therapist can be guided by our knowledge in parallel 
fields. In this respect, the large body of knowledge on oncolytic adenoviruses may 
be extremely valuable. Despite the differences in their genomic constitution, 
adeno viruses and reoviruses have several aspects in common. Although reovirus 
T3D and human adenovirus-C (HAdV-C) recognize different receptors, there are 
overt structural similarities between the T3D spike and the adenovirus fiber [77, 
90]. Hence for developing tumor-targeted reoviruses it may be useful to parallel 
the approaches that have been explored so successfully in the oncolytic adeno-
virus field [76, 91, 92]. 
Transient immune suppression may overcome immunological barriers that 
 impede the effective reovirus delivery [93, 94], although it should be realized that 
this approach should be taken with caution. Reovirus infection can be associated 
with severely morbidity in immune compromised NOD/SCID mice [95]. Interest-
ingly, it may be possible to select mutants with significantly reduced viral patho-
genesis in immune compromised animals [96]. On the other hand, the immune 
system is an important mediator of anti-tumor activity, and the oncolytic virus 
 infection may activate antitumor immune activity [15, 97].
The reverse genetic techniques can be used to generate reoviruses carrying 
 heterologous genes [68, 72]. Transgenes may be included to arm the oncolytic 
 viruses, for instance by including transgenes encoding cytokines for activating the 
immune system. This may increase the anti-tumor efficacy [17]. Also the replica-
tion of reoviruses may be reduced by insertion of microRNA target sequences, 
 similar to the method used to prevent replication of adenoviruses in hepatocytes 
[98, 99]. Already, Dermody and colleagues demonstrated that RNA interference 
can be used to inhibit reovirus replication [100]. However, it remains to be estab-
lished whether reoviruses carrying foreign sequences (i.e. transgenes, microRNA 
targets) are genetically sufficiently stable to allow production of clinical grade 
 batches.
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In cases where the use of mutants may be ineffective, other changes to the 
virus particles could be used. One such hurdle is the occurrence of reovirus 
 immunity in the human population. While it is unlikely that mutants can be iso-
lated which are insensitive to preexisting immunity, polymer shielding may be 
used to mask the epitopes in the capsid. This approach has been found extremely 
effective to protect adenovirus vectors, and it seems reasonable to anticipate that 
this strategy will also be effective in reoviruses [101]. 
Despite the new opportunities there is one factor that may potentially limit use 
of genetically targeted reoviruses. Reoviruses display a high mutation rate com-
pared to many DNA viruses. As a result, during prolonged passage reovirus 
 mutants have a tendency to change or revert, forming so-called quasispecies. This 
genetic drift may be reduced by propagating the viruses under appropriate selec-
tive pressure. For large-scale production of reoviruses for clinical use, product 
consistency is important. Therefore, it is essential to design culture conditions that 
limit the expansion of mutants or revertants in the vector preparation. It remains 
to be seen whether that is feasible for novel tumor-targeted oncolytic reoviruses 
with new phenotypes. It is anticipated that the development of new production 
systems may be necessary, and should be developed in parallel with appropriate 
pre-clinical testing methods. This can warrant safe clinical application of new 
 oncolytic reoviruses. With these we can keep the gene therapists’ promise of pro-
viding new and effective treatment for malignant neoplastic disease.
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1.3 Update on reovirus modifications
Bioselection
The reovirus receptor JAM-A is thought to play an important role in the entry 
of reoviruses into tumour cells. However, a few years ago we discovered that this 
is mainly true for tumour cells in monolayer cultures (see Chapter 3). In a 3D 
 spheroid model, the absence of JAM-A does not seem to influence the entry of 
wild-type reoviruses in cells that lack the receptor, which may have important 
consequences for the in vivo situation at a tumour site.
Although the JAM-A receptor may not be as important as expected, in vitro 
reovirus mutants have now been isolated that can enter independently of the 
 canonical receptor in monolayers of cells that resist wild-type T3D reoviruses (see 
Chapter 2) These mutants are called Junction Adhesion Molecule-A Independent 
(jin) mutants. 
Besides the entry route of the reovirus other factors involved in the replication 
cycle of reoviruses play a role in the sensitivity of cells to reovirus infection and 
cell death. Some tumour types are corrupted in their cell death pathways and are 
therefore difficult to defeat with chemotherapy. This may also have implications 
for the sensitivity of cells to reovirus cytotoxicity. Several cell lines derived from 
squamous carcinomas of the head and neck resist reovirus induced apoptosis 
 mediated cell death [102]. The relationship between sensitivity to reovirus infec-
tion, replication, and induced cell death has not yet been fully resolved and seems 
quite complex. A tool that could assist in this quest is to use the ability of the reo-
virus to adapt to its environment. Upon forced entry and patience by the scientist 
mutants with more potent cytotoxicity can be selected from the wild-type reo-
virus-resistant cell types, as is done for the jin mutants. These viruses can provide 
new insights in the mechanisms involved in the different types of cell death 
(apoptosis, autophagy, necrosis; for a mini review on cell death, see [103]). They 
can also be evaluated for other tumour types with disrupted death pathways. 
A different approach to select for reovirus variants was done in the lab of 
 Patrick Lee [104]. They infected reovirus sensitive cells with all three reovirus 
serotypes (T1L, T2J and T3D) simultaneously and isolated two variants with 
larger plaques than T3D as a measure for improved infectivity. The two isolated 
reovirus variants turned out to be only of T3D origin, with additional mutations 
in the S1 (T3v2) or L1, L2 and L3 segments (T3v1). In the permissive cancer cells 
both variants produced larger plaques compared to the wild-type T3D. In the B16 
 melanoma mouse model the two variants show also superior oncologic activities 
over the wild-type T3D virus. The specificity for cancer cells in vitro remained and 




The availability of the plasmid-based reverse genetics system [105] inspires 
reovirus scientists to discover more on reovirus biology and to improve the reo-
virus efficacy in oncolytic cancer therapies. Most of the reports that appeared after 
the introduction of the system belong to the first category and resolve issues 
where reovirus segments are involved in apoptosis, assembly or disassembly, cell 
tropism and pathogenesis in mice [106-117]. 
Only a few reports deal with the addition of exogenous polypeptides added to 
gene segments. In 2011 Brochu-Lafontaine et al. [118] published about adding 
 heterologous polypeptides to σ1, as we did with our first approach to modify σ1 
with the addition of a His(6)-tag and the need to use a helper reovirus to generate 
the S1His reovirus (see Chapter 4). They showed that addition of a sequence of 
750 nucleotides at the C-terminus of σ1 was not tolerated and managed to add a 
sequence of about 40 nucleotides to σ1.
Demidenko et al. added longer tandem repeats and used a tetra virus 2A 
 element for exogenous polypeptide expression in three other segments (S3,M1 
and L1). The total length of heterologous sequences they added in the reovirus 
 genome was 1500 nucleotides divided over two segments (L1 and M2). This tech-
nique could be useful in the vaccine development [119], also regarding the simul-
taneous expression of peptides on different segments. They only showed that the 
modified reoviruses created were genetically stable for three passages in L929 
cells. It remains to be seen what will happen if the viruses are propagated for 
 additional rounds on L929 cells. 
As explained in section 1.2 there are reports on the expression of exogenous 
proteins in reovirus segments, the techniques replaced the ORF of the segments 
and required that the viruses were propagated on cell lines that complement for 
the missing reovirus proteins [105, 120]. Slowly more becomes known about the 
different signals that are important for the replication of the segments and the 
virus. However, so far no one has found a location for inserting exogenous genes 
without losing the fitness of the virus. In Chapter 5 we describe the expression of 
a small fluorescent protein at the location of the JAM-A binding region in σ1 as a 
proof for autonomously replicating genetic modified reoviruses. Based on this 
 location it is possible to add small genes that express proteins with oncolytic 
properties or immune stimulating factors. 










1.4 Aims and outline of this thesis
Aims
Exploring manipulation of reovirus T3D to enhance its oncolytic properties by:
1. a bioselection procedure. We aim at bypassing the Junction Adhesion Mole-
cule-A (JAM-A) as a receptor for entry into JAM-A deficient glioblastoma 
cells. This would allow us to expand the tropism of reoviruses to cells that 
are  difficult to infect with wild-type reovirus T3D due to a scarcity of JAM-A 
reovirus receptors. 
2. a genetic modification strategy. We aim at evaluating the S1 segment as a loca-
tion for inserting small foreign genes in the dsRNA genome of reovirus T3D.
Outline
Chapter 2 describes the isolation of reovirus mutants through bioselection in 
cells that lack the canonical reovirus receptor, Junction Adhesion Molecule-A 
(JAM-A). All three so-called jin mutants harbour mutations in the S1 segment 
 resulting in amino acid alterations in the tail part of the S1-encoded attachment 
protein σ1. Besides the U118MG glioblastoma cells the jin mutants can infect other 
cells that resist wt reovirus T3D infection, including chicken and hamster cells, but 
not primary human fibroblasts. This expanded tropism makes the jin mutants 
 useful as oncolytic agents in tumours that are difficult to infect by the wtT3D reo-
virus, as is shown with U2OS (osteosarcoma cell line) and STA-ET2.1 (Ewing 
 sarcoma) cells. 
JAM-A may not be the only important player in the context of tumours, as is 
shown in Chapter 3, where wtT3D reovirus is capable of infecting 3D-cultures of 
U118MG cells, independent of this receptor. Cells in spheroid cultures secrete 
 factors (among others the extracellular proteases cathapsin B and L) that can 
 convert reovirus particles into intermediate subviral particles (ISVPs). ISVPs are 
normally formed during the endocytosis process, but if generated outside cells 
(for example in the intestines by proteases present in the environment) ISVPs 
 infect cells independently of the JAM-A receptor. In the microenvironment of 
 tumours there is evidence for the presence of extracellular proteases and this 
should be taken into account when using reoviruses as oncolytic agents, since 
these proteases can enhance the oncolytic effectivity. 
Genetic modification of reovirus T3D is the topic of Chapters 4 and 5. Chapter 
4 describes the first attempt to alter the S1-segment resulting in a σ1 protein with 
a His(6)-tag attached to the C-terminus. In this method, 911 cells transduced with 
the modified S1-His segment in the context of a RNA-polymerase II transcript and 
CMV-promoter are infected by wild-type reovirus. A subsequent selection step in 
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U118MG cells expressing an artificial receptor binding the His(6) tag eliminates 
the wild-type virus, which cannot enter the JAM-A negative U118MG cells from 
the modified reovirus population. A disadvantage of this system is the need for 
wild-type reovirus as a helper with the possibility to generate different mutants 
and losing the desired modified reovirus.
Another method for genetic modification of reovirus, omitting wild-type reo-
virus as a helper virus is described in Chapter 5. Based on the data with the jin 
mutants, the S1-sequence encoding the head domain of σ1 is replaced by a trans-
gene encoding a small fluorescent protein, called iLOV. To employ the expanded 
tropism, the mutation found in S1 of jin-3 is introduced into the sequence encod-
ing the tail part of the σ1 spike. The truncated σ1 part is fused to a His(6)-tag and 
the iLOV protein is placed behind a porcine teschovirus-1 2A element to avoid 
 incorporation of iLOV into the virus capsid. This recombinant S1His-2A-iLOV 
segment is placed in an expression plasmid under the control of a T7-promoter 
and a HDV ribozyme at the 3’ end to generate a genuine 3’-UTR. The modified 
reovirus plasmid is co-transfected with expression plasmids containing the other 9 
reovirus segments into mammalian cells that stably express T7 RNA Polymerase. 
The rS1His-2A-iLOV virus proved viable and replication-competent despite the 
loss of its “head”. Previously, foreign genes were inserted in the ORFs of one seg-
ment and this system requires helper cells for the trans-complementation of the 
deleted functions. Here, the S1 segment has been shown to be a feasible candidate 
location for the insertion of small genes. This strategy is currently being explored 
for the development of oncolytic reoviruses with improved antitumor activity. 
A general discussion is provided in the final chapter, Chapter 6.
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Tweaking Reovirus T3D to Boost the Oncolytic Potency
2.1 Abstract
Mammalian Reovirus is a double-stranded RNA virus with a distinctive pref-
erence to replicate in and lyse transformed cells. On that account, Reovirus type 3 
Dearing (T3D) is clinically evaluated as oncolytic agent. The therapeutic efficacy 
of this approach depends in part on the accessibility of the reovirus receptor Junc-
tion Adhesion Molecule-A (JAM-A) on the target cells. Here, we describe the iso-
lation and characterization of reovirus T3D mutants that can infect human tumor 
cells independent of JAM-A. The JAM-A-independent (jin) mutants were isolated 
on human U118MG glioblastoma cells, which do not express JAM-A. All jin 
 mutants harbour mutations in the S1 segments close to the region that encodes the 
sialic acid-binding pocket in the shaft of the spike protein. In addition, two of the 
jin mutants encode spike proteins with a Q336R substitution in their head 
 domain. The jin mutants can productively infect a wide range of cell lines that 
 resist wt reovirus T3D infection, including chicken LMH cells, hamster CHO cells, 
murine endothelioma cells, human U2OS and STA-ET2.1 cells, but not primary 
human fibroblasts. The jin-mutants rely on the presence of sialic-acid residues on 
the cell surface for productive infection, as is evident from wheat germ agglutinin 
(WGA) inhibition experiments, and from the jin-reovirus resistance of CHO-Lec2 
cells, which have a deficiency of sialic-acids on their glycoproteins. The jin 
 mutants may be useful as oncolytic agents for use in tumors in which JAM-A is 
absent or inaccessible.
2.2 Introduction
The Reoviridae constitute a family of viruses with a non-enveloped icosahedral 
capsid and a segmented double-stranded RNA genome. Prototypes of the mam-
malian Orthoreoviruses were isolated from the human respiratory and enteric 
tracts and have not been associated with serious human disease. The human reo-
virus type 3 Dearing (T3D) is frequently studied and often serves as a model for 
the family. The reoviruses have a lytic replication cycle and preferentially induce 
cell death and apoptosis in tumor cells but not in diploid, non-transformed cells 
[1-3]. In transformed cells reovirus uncoating and replication are stimulated [4-8]. 
In addition, Ras signalling sensitizes the cells to reovirus-induced apoptosis [9]. 
Based on these observations, reovirus T3D is a promising candidate for use as 




Reovirus attachment to cells is a multi-step process. The reovirus spike protein 
σ1 binds with a region of its shaft domain to cell surface-bound sialic acids with 
low-affinity, before the head domain of σ1 engages the high affinity receptor Junc-
tion Adhesion Molecule-A (JAM-A, also known as JAM-1) [14, 15]. Following 
 receptor binding, virions become internalized by a mechanism involving the cap-
sid protein λ2 binding to β1 integrins [16, 17]. An alternative entry pathway can be 
employed upon proteolytic removal of the reovirus outer capsid protein σ3 and 
cleavage of μ1/μ1C, yielding intermediate (or infectious) subviral particles 
(ISVPs). The ISVPs can directly penetrate the cellular membrane independent of 
the presence of JAM-A [18, 19]. The ISVPs are similar to the disassembly interme-
diates formed during cellular entry via the endocytosis pathway. 
The reovirus receptor JAM-A is expressed in epithelial and endothelial cells of 
several tissues including lung, kidney, pancreas, heart, brain, intestine and lymph 
nodes [20] but some tumor cells have down-regulated the JAM-A receptors on 
their cell surface, thereby limiting the susceptibility to reovirus T3D. JAM-A 
 expression was found significantly down-regulated in clear-cell renal carcinoma 
cells [21]. Also, cells grown from freshly isolated colorectal tumor metastases  resist 
reovirus infection. Immunohistochemistry demonstrated that JAM-A is not accessi-
ble at the cell surface, although JAM-A is detectable intra-cellularly [22]. Further-
more, there is an inverse correlation of JAM-A expression in breast cancer cells and 
their ability to migrate. JAM-A is expressed in normal human mammary epithelial 
cells but in metastatic breast cancer tumors the expression is down- regulated [23]. 
Here we describe the isolation and characterization of reovirus T3D mutants 
that are adapted to propagation in JAM-A negative, reovirus-T3D resistant cell 
lines. The first was identified as a spontaneously occurring mutant in one of our 
batches genetically retargeted reovirus [24]. Subsequently two other mutants were 
isolated by selection on JAM-A negative human glioblastoma cells. We demon-
strate that these JAM-A-independent (jin) mutants employ an as yet unidentified, 
but apparently ubiquitous receptor, which is present on a wide variety of cell 
types. Their potential use as novel oncolytic tools against tumor cells in which 
JAM-A is absent or inaccessible is discussed.
2.3 Results
Isolation of a JAM-A independent reovirus mutant
Previously we described a system for generating genetically modified reo-
viruses. The modification strategy relies on the exchange of a genome segment 
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 modified viruses can be selected and propagated on U118scFvHis cells. This cell 
line is a derivative of the JAM-A negative human glioblastoma cell line U118MG 
and expresses a single-chain Fv (scFv) on its surface that is capable of binding the 
His-tag. The scFv serves as an artificial receptor for the σ1-His containing viruses 
[24]. 
In one of the batches of σ1-His modified reoviruses, we noted that a cytopathic 
effect (CPE) was not only induced in the U118scFvHis cells, but also in the paren-
tal U118MG cells. This suggested that this batch contains viruses that are capable 
of infecting cells independent of the presence of JAM-A and independent of the 
artificial scFv-His receptor.
The first mutant virus isolated, which was called jin-1 (JAM-A independent), 
was further propagated on U118MG cells. The jin-1 mutant virus was compared 
to our lab reference wtT3D reovirus. In contrast to the wtT3D reovirus, the jin-1 
virus induces CPE in U118MG cells as is evident from a WST-1 cell viability assay 
(Figure 1A). Both viruses are equally cytolytic to 911 cells which do contain 
JAM-A [24]. Immunofluorescence assays using an antibody against the major cap-
sid protein σ3 confirmed the presence of σ3 in U118MG cells infected with jin-1, 
but not with wtT3D (Figure 1B). To further verify that U118MG cells support the 
replication of the jin-1 mutant, a metabolic labelling with [35S]-Methionine was 
performed. As a positive control the U118-HAJAM cell line was included. This 
U118MG-derived cell line had been transduced with a lentivirus to overexpress an 
HA-tagged version of the JAM-A receptor. In U118-HAJAM and in 911 cells, 
 exposure to the wtT3D as well as to jin-1 reoviruses established infection as is 
 evident from the synthesis of reovirus proteins. In contrast, in U118MG cells the 
reoviral protein synthesis was only detectable upon infection with the jin-1 virus 
but not with our wtT3D (Figure 1C). These data demonstrate that the jin-1 reo-
virus, in contrast to wtT3D, is capable of infecting and replicating in the JAM-A 
negative cell line U118MG.
Sequence analysis of the reovirus mutants 
The jin-1 mutant originated from the U118scFvHis cell line. Since this mutant 
can infect JAM-A negative U118MG cells, we speculated that the attachment pro-
tein σ1 was altered. After one round of plaque purification and further propaga-
tion for eleven passages on U118MG cells, the complete genome was sequenced. 
The primers used (for this) are listed in the supplementary table S1. The PCR 
products were purified and used for sequence analysis. In the S1 segment two 
mutations occurred. The mutation led to a threonine-to-methionine change at 
position 193 (T193M) and a glutamine-to-arginine change at position 336 of the 




Reovirus mutant jin-1 is able to infect the JAM-A negative cell line U118MG. 
A. Viability assay (WST-1) on 911 and U118MG cells. Cells were mock infected (black bar) 
or infected with wtT3D (white bar) or jin-1 virus (grey bar) with an MOI of 10, six days 
post infection. Means (±standard deviation) from three wells.
B. Detection of outer capsid protein σ3 in 911 and U118MG cells after addition of wtT3D or 
jin-1 virus with an MOI of 5. 40 hr post infection cells were stained with a monoclonal 
antibody directed against σ3 (4F2) and visualised with a fluorescein isothiocyanate  
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FIGURE 1.
Reovirus mutant jin-1 is able to infect the JAM-A negative cell line U118MG. 
C. Assessment of reoviral protein synthesis in jin-1 or wtT3D infected cells. Indicated cells 
were infected with wtT3D or jin-1 virus and labeled with [35S]-methionine once CPE 
 became apparent. 911 cells were infected with an MOI of 1 and U118MG or  U118HAJAM 
cells with MOI of 5. Indicated are the positions of the reoviral λ, μ and σ proteins.  
m represents mock infected cells; wt: wtT3D infected cells and jin-1: jin-1 infected cells.
TABLE 1. 
Amino acid differences in reovirus proteins of the jin mutants and the wtT3D  reovirus 
strain.
RNA segment (protein) AAposition wt jin-1 jin-2 jin-3
S1 (σ1)  187 Gly Arg
 193 Thr Met
 196 Gly Arg
 336 Gln Arg Arg
S2 (σ2)  254 Ser Phe
S3 (σNS) No changes
S4 (σ3)  177 Ser Phe
 198 Gly Glu
 357 Met Thr
M1 (µ2) No changes
M2 (µ1)  388 Lys Arg
 530 Thr Ala
M3 (µNS)  705 Ala Val
 706 Asp Ala
 708 Val Ala
L1 (λ3)  413 Ile Ser
L2 (λ2)  1101 Met Ile
L3 (λ1)  201 Thr Ala
 703 Arg Gly




To expand the pool of mutants, we repeated the procedure and exposed the 
U118scFvHis cells with our wild-type virus before further expansion on U118MG 
cells. After the first selection rounds in the U118scFvHis cells, we again found the 
Q336R mutation in the σ1 head domain. Upon prolonged propagation (10 
 passages) on U118MG cells an additional mutation was found in S1, resulting in a 
G187R change. This mutant strain, carrying mutations resulting in a Q336R and 
G187R change was named jin-2. Based on the findings in jin-2 S1 in the earlier 
 passage, we analyzed S1 of an earlier passage of jin-1 as well (prior to plaque 
purification) and also in this S1 segment the only mutation present was the one 
resulting in the Q336R change in σ1. 
Another mutant reovirus (jin-3) was obtained after direct exposure of U118MG 
cells at very high MOI to wtT3D reovirus. This virus was blindly passaged (i.e. the 
cells were lysed without signs of overt CPE at the time of virus harvest) for 6 
rounds on U118MG cells. After 6 rounds in U118MG cells, CPE became apparent. 
After plaque purification on 911 cells and 10 additional passages on U118MG the 
complete genome of the jin-3 mutant was sequenced. Only one mutation was 
found in the S1 segment, resulting in a G196R alteration. Table 1 gives a summary 
FIGURE 2. 
Schematic representation of mutations in Sigma-1.
Model of the σ1 protein (adapted from Chappel et al, 2009). Arrows indicate the  positions 
of the mutations.
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of all the amino acid changes found in the mutants, compared to our wtT3D. A 
schematic overview of the amino acid changes in σ1 is depicted in Figure 2. In all 
jin mutants the amino-acid alterations in the shaft of σ1 are located close to the 
 sialic acid (SA) binding motif [6, 15, 25, 26]. 
Primary human fibroblasts (VH10 cells) do not support replication 
of the jin mutants or wtT3D
To study whether the jin mutants acquired the capacity to replicate in normal, 
non-transformed human cells, we exposed diploid human foreskin fibroblasts 
(VH10 cells) to wtT3D and to the jin mutants. The skin fibroblasts were chosen 
 because primary human fibroblasts do not express JAM-A [27]. We studied the 
yields of the jin viruses and compared these with the yields of wtT3D on VH10 
 fibroblasts and on U118MG cells. As expected U118MG cells yielded high titers of 
the jin reoviruses, while wtT3D virus yields were below the amounts of virus 
added to the cells (Figure 3A). On VH10 fibroblasts, neither the wtT3D reovirus 
nor the three jin-mutants yielded significant titers (Figure 3B). Furthermore in the 
VH10 cell cultures no apparent signs of cell death were observed (data not 
shown). These data suggest that, like wtT3D our jin mutants do not replicate in 
normal non-transformed diploid fibroblasts.
During the plaque assays on 911 cells for the determination of viral yields, we 
noted that the plaques formed by the jin-1 virus and jin-3 virus were consistently 
smaller than those of the wtT3D virus; the plaque surface area of the initial jin-1 
virus and jin-3 virus is approximately 10-fold lower (Figure 3C), suggesting 
reduced cell-to-cell spread of the mutants. 
The jin-2 virus also has a reduced plaque size compared with the wt virus, but 
the variation within the population is larger, which suggests heterogeneity in the 
population. Sequence analysis of the S1 segment of both the smaller and the larger 
jin-2 plaques revealed that the smaller plaques contained the mutations for the 
G187R and Q336R change, while the larger plaques only contained the mutation 
that yield the Q336R alteration in σ1 (data not shown).
Protease inhibitor E64d blocks entry of jin-1 virus
Reoviruses enter cells by receptor-mediated endocytosis after attachment of 
the 1 protein to the JAM-A receptor [16, 28]. Subsequently, the viral λ2 protein 
binds cellular integrins leading to endocytosis. In the endosomes the particle 
 undergoes conformational changes by partial proteolysis, leading to intermediate 
subviral particles (ISVPs). The outer capsid proteins 3 and μ1/μ1C are cleaved by 
cellular proteases and 1 undergoes a conformational change. In vitro, this process 
can be mimicked by proteolytic treatment of complete virions. The generated 
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ISVPs are capable to enter cells independent of the JAM-A receptor by penetration 
of the cytoplasmic membrane [18, 19, 29]. One possible explanation for the JAM-A 
independent entry of the jin-1 virus could be a premature transition to ISVPs prior 
to entry into the cell. To test whether the jin-1 virus is still dependent on cellular 
proteases the protease inhibitor E64d was used. If cells are exposed to E64d prior 
to infection, intact virions are trapped in the endosome while ISVPs can complete 
the replication cycle [30, 31]. To confirm that wt ISVPs are JAM-A independent we 
exposed the U118MG cells to wtT3D ISVPs and to intact T3D virions (Figure 4A). 
As expected, only in the cells exposed to the ISVPs, viral protein σ3 synthesis is 
FIGURE 3. 
Comparison of wtT3D with jin-viruses in terms of plaque size, yield in U118MG cells and 
primary human fibroblasts (VH10 cells).
A. Yield of wtT3D and jin-1, jin-2 and jin-3  mutants from U118MG cells infected with MOI 
10 per virus. Yields were determined 72 hours post infection by plaque assays on 911 
cells. The graph shows yields (Log10 PFU) of two independent U118MG cell infections: 
first one is shown as a white bar and  second as a grey bar. The dashed line  represents the 
input amount of the initial infection.
B. Yield of wtT3D and jin-1, jin-2 and jin-3  mutants from VH10 cells infected with MOI 10 
per virus. Yields were determined 72 hours post infection by plaque assays on 911 cells. 
The graph shows yields (Log10 PFU) of two  independent VH10 cell infections: first one is 
shown as a white bar and second as a grey bar. The dashed line represents the input 
amount of the initial infection. 
C. Plaque sizes of wtT3D and jin-1, jin-2 and jin-3 mutants in 911 cells. Surface areas of 10 












Tweaking Reovirus T3D to Boost the Oncolytic Potency
 detected, evidencing virus entry and viral protein synthesis. In 911 cells both the 
jin-1 virus and wtT3D virus are inhibited by E64d (Figure 4B), while σ3 was 
detected in both the jin-1 and wt ISVP infected cells. Also in the U118MG cells, the 
jin-1 virus entry is blocked by the presence of E64d, but not the jin-1 ISVP entry. 
These data demonstrate that like wtT3D reovirus, the reovirus mutant jin-1 
exploits the endocytotic pathway to enter U118MG cells. 
jin-1 σ1 forms trimers
The change at amino-acid position 336 is located close to the domain that has 
been implicated in trimerization of σ1 [32]. Although the Q336R alteration is 
located at the outward surface-exposed side of every monomer in the trimeric 
conformation (Figure 5A, R336 is shown in red) it is essential to confirm that the 
Q336R alteration does not interfere with trimer formation. To this end an in vitro 
trimerization assay was performed as described by Leone at al. [33]. For this wt 
σ1, σ1-Q336R and σ1-Y313A proteins were synthesized in vitro. The Y313A change 
FIGURE 4. 
Effect of the cysteine protease inhibitor E64d on jin-1, wtT3D virus, and ISVP entry into 
cells.
A. U118MG cells were exposed to purified wtT3D virus and wtT3D ISVP ( 2*103 particles  
per cell). Lysates were made 24 hours post-infection and analyzed by SDS-PAGE and 
 western-blotting. The reovirus σ3 proteins were detected by the anti-reovirus σ3 
 antibody 4F2 and an anti-Actin serum was used to detect actin as a loading  control. 
B. Effect of 100 μM E64d on the entry of particles compared to entry of ISVPs. Cells, treated 
(+) or untreated (-) with 100 μM E64d, were exposed to jin-1 (U118MG and 911 cells) or 
wtT3D (911 cells) virus or ISVPs (2*103 particles per cell). Lysates were made 24 hours 
post-infection. Equal amounts of protein were loaded on 10% SDS-polyacrylamide gel 





abolishes the capacity of σ1 to form trimers [32]. The σ1 products were analysed 
by mild PAGE at 4°C (Figure 5B). Whereas the σ1-Y313A protein does not form 
 mature trimers, both the wtT3D σ1 and σ1-Q336R do. Intermediate trimers, which 
consist of σ1 molecules in which only the shaft is trimerized while the head 
 domain is in a monomeric configuration, are detectable in all σ1 variants tested. 
Our data show that the Q336R alteration that occurs in the jin-1 and jin-2 viruses 
does not affect the formation of mature σ1-trimers in vitro.
jin-1 and jin-2 have selective advantages over wild-type reovirus in 
U118MG cells
To confirm that jin-1 and jin-2 viruses have a selective advantage over wtT3D 
in U118MG cells, we mixed jin-1 or jin-2 with a 100-fold excess of wtT3D prior to 
infection of cells. Cultures of 911 cells were infected at an MOI 10 with the 
 mixtures to allow reassortment of genome segments to take place. Two days 
post-infection, the virus was harvested by three freeze-thaw cycles and used to 
infect U118MG cells. While no CPE for jin-1/wt mixtures was observed at 7 days 
post-infection in the U118MG cells, the cells were freeze-thawed and the lysate 
FIGURE 5. 
Analysis of Sigma-1 trimers synthesized in vitro.
A. Top view of σ1-trimer, with colored monomer units (green, turquoise, orange).  Position 
of the Q336R mutation in each monomer is indicated as red CPK symbol (Chappell et al., 
2002); PDB ID: 1KKE. The software used for the 3D graphs is Viewerlite 5.0 from 
 Accelrys.
B. [35S]-methionine labelled in vitro transcribed and translated products of plasmids  
pDGC-S1wt (S1wt), pDGC-S1Q336R (S1Q336R) and pDGC-S1Y313A (S1Y313A) were  
incubated for 30 minutes at 37°C (to stabilize the mature trimers) or boiled for 5 minutes 
(to  disrupt the trimers), before loading on a 10% SDS-polyacrylamide gel at 4°C.  
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was used to infect fresh U118MG cultures. In U118MG cells infected with jin-2/
wtT3D mixture the virus was harvested after 4 days, with visible signs of CPE. 
This procedure was repeated for two more times. At passage 3 clear CPE was 
 observed four days post infection in both jin-1/wt and jin-2/wt selections. Sequenc-
ing of PCR products after reverse transcription PCR of the S1 segment after 
the third selection on U118MG cells were compared with the S1 sequences of 
wtT3D, jin-1 and jin-2 (Figure 6). S1 of the jin-1/wt end population contains a T at 
 nucleotide position 590 and a G at position 1019, identical to the jin-1 S1 segment. 
FIGURE 6. 
S1-sequence analysis of the jin-1/wtT3D and jin-2/wtT3D selection assay on U118 MG cells. 
The jin-1 or jin-2 viruses were mixed with a 100-fold excess of wtT3D virus with regards to 
MOI. 911 cells were exposed to the mixtures first, before propagation on U118MG cells for 
three more passages. Reovirus RNA was isolated from the virus derived from the third 
 passage on U118MG cells and subjected to RT-PCR to obtain the S1  products from the total 
population (jin-1/wt end or jin-2/wt end). Sequence  histograms of the indicated regions 
were compared to the S1 sequences of the input reoviruses. Arrows indicate the nucleotide 




 Sequence results for S1 of the jin-2/wt end population revealed an A at position 
571 and a G at position 1019 and this is identical to jin-2 S1 sequence. From these 
findings we conclude that in U118MG cells σ1 proteins from jin-1 or jin-2 provide 
a strong  selective advantage over wtT3D σ1. These data provide evidence that the 
amino-acid alterations in σ1 provide the jin mutants with the capacity to infect 
and  replicate in JAM-A-negative cells.
jin-1 reoviruses infect cells that are non-permissive for wtT3D
To study whether the jin-1 mutant has expanded its tropism beyond the 
U118MG cell line, we evaluated whether this virus can replicate in a panel of cell 
lines that resists infection with wtT3D virus. These cell lines include chicken 
hepatoma cell line LMH [34], murine endothelioma cell line Eoma [35], human 
bone osteosarcoma cell line U2OS [36] and human Ewing sarcoma cell line 
STA-ET2.1 [37]. In parallel the cell lines 911 and U118-HAJAM were included as 
positive  controls for infection. Each of the cell lines were exposed to wtT3D or 
jin-1 viruses with an amount of virus corresponding to 8 PFU/cell as determined 
in 911 cells. While no major capsid protein 3 was detected in the wtT3D-resistant 
cell lines  exposed to wtT3D, exposure of these cells to jin-1 resulted in the detec-
tion of the 3 protein at 36 hr post infection (Figure 7A). In 911 and U118HA-JAM 
cells, the 3 protein is present in wtT3D infected cells as well as in the jin-1 infected 
cells. 
To verify that wtT3D resistant cells could support replication of the jin-1 virus, 
the virus yields were determined in some of these cell lines (Figure 7B). In 911 
cells both viruses give a similar yield, but in three other cell lines (U118MG, U2OS 
and LMH) more progeny virus was produced with the jin-1 virus than with wt 
virus. The amount of wtT3D produced per cell did not rise above the amount 
added to the cells (MOI of 10, dashed lines). From these data we conclude that the 
jin-1 virus is able to productively infect our panel of wtT3D resistant cells.
Cell entry of reovirus jin-1 and jin-3 relies on sialic acids 
Apart from the Q336R mutation, the other mutations found in the S1 segments 
of the jin mutants are located close to the region involved in SA binding [6, 15]. 
Recently the crystal structure of the sialic acid – σ1 complex was elucidated [26]. 
There is a remarkable heterogeneity in the amino acid sequence of the SA-binding 
domains of different T3D and T1L strains. Some isolates cannot bind SA as deter-
mined on JAM-A negative murine erythroleukemia (MEL) cells. The forced selec-
tion of such strains yielded mutants that could infect MEL cells probably via the 
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FIGURE 7. 
Reovirus mutant jin-1 can infect cell lines that resist wtT3D reovirus infection. 
A. Several cell lines were infected with wtT3D or jin-1 and 32 hr post-infection cells  
were lysed. Protein samples (30 μg) were analyzed by 10% SDS-polyacrylamide gel 
 electrophoresis. For the immunodetection anti-reovirus σ3 (4F2) was used. The cell lines 
911 and U118-HAJAM are included to serve as positive controls for the  infectivity of 
wtT3D. The cells were mock-infected (m); wtT3D infected, or jin-1  infected. 
B. Virus production of wtT3D and jin-1 in the different cell lines. Cells were exposed to 
virus at MOI of 10 for one hour, washed with PBS and immediately lysed (1 hour time 
point) or left for 48 or 72 hours. For 911 cells an additional harvest point at 32 hours 
post-infection was included. The viral titers in the samples were determined by plaque 
assays on 911 cells. The graph shows a representative example of the assay. Open circles: 
wtT3D(o), crosses: jin-1(x). The dashed line represents the input amount of the initial 





The wtT3D that was used in our studies has an amino-acid sequence of the sial-
ic-acid binding pocket that is identical to strains capable of binding sialic acid. The 
S1 mutations found in the jin mutants are not located in the region coding for the 
SA-binding pocket of σ1 (viz. amino acids 198-204; ref [15, 26]), but are located in 
close proximity of this region. Nevertheless, it is conceivable that the amino acid 
alterations in the jin mutants affect the affinity or avidity of SA binding. To inves-
tigate the involvement of SA in binding of our mutant viruses we used Lec2 cells. 
Lec2 cells have a strongly reduced (by about 90%) amount of sialic acids on their 
cell surface [39, 40]. Lec2 cells are mutants derived from Chinese Hamster ovary 
(CHO) cells, which are poorly infected by wtT3D reovirus [41, 42]. In  contrast, 
both the jin-1 and jin-3 mutants efficiently infect CHO cells (Figure 8A). The 
wtT3D nor jin-1 and jin-3 infect Lec2 cells, as is evidenced by lack of detectable σ3 
FIGURE 8. 
Lec2 cells are poorly infected by reovirus mutants jin-1 and jin-3.
A. CMP-sialic acid transporter defective Lec2 cells and parental cell line, CHO, were 
 exposed to wtT3D, jin-1, and jin-3 at MOI of 10. Protein lysates were made 32 hrs  
post-infection and analyzed by SDS-polyacrylamide gel electrophoresis. For the 
 immunodetection of σ3 the anti-reovirus σ3 antserum 4F2 was used, and anti-actin 
(human) was used to detect actin as a loading control. 
B. Virus production of wtT3D and jin-1 in CHO and Lec2 cells. Cells were exposed for one 
hour to the viruses at MOI of 10, washed with PBS and immediately lyzed (1 hour time 
point), or incubated at 37°C for 48 hrs and 72 hrs. Virus yields were  determined by 
plaque assays on 911 cells. The graph shows a representative  example of the assay.  
Open circles: wtT3D(o), crosses: jin-1(x). The dashed line  represents input amount of 
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in the cells exposed to these viruses (Figure 8A). Also the replication of jin-1 in the 
Lec2 cells is markedly reduced compared with the yields obtained in the parental 
CHO cells (Figure 8B). This suggests that the expanded tropism of jin is 
 dependent on the presence of SA on the cell surface. To support the utilization of 
SA by the jin-1 mutant, we shielded the SA on the surface of the cells by pre-incu-
bating the cells with wheat germ agglutinin (WGA). WGA is a lectin with a strong 
affinity to a broad range of sialoconjugates. To confirm that WGA effectively 
binds to the cell lines 911, U118MG and CHO, but not to Lec2, we employed 
FITC-labeled WGA on fixed cells grown on cover slips (Figure 9A). For the com-
petition experiments we blocked the sialic acids with WGA prior to the binding of 
jin-1 to the cells. The addition of WGA to the cells inhibited entry of jin-1 in 
U118MG and CHO cells (Figure 9B). Also in 911 cells, jin-1 and wtT3D infection 
FIGURE 9. 
WGA inhibits binding of reovirus to cells.
A. Detection of Sialic acids in cell lines (911, CHO, U118MG and Lec2) by FITC-labeled 
WGA immunofluorescence. 
B. WGA inhibition of reovirus  infection. Prior to exposure of reovirus jin-1, the cells 
(U118MG, CHO, and Lec2) were mock-treated (-) or treated with 100 μg/ml WGA for 
1 hr. at 37°C (+). After exposure of the cells to the virus at 4°C the cells were washed with 
PBS and incubated for an additional 32 hours in a CO2 incubator  before  protein lysates 
were made. For the immunodetection of the σ3 protein the anti-reo virus σ3 (4F2) was 
used and anti- actin was used as a  loading control.





are inhibited (Figure 9C). This confirms the dependency of wtT3D on SA for cell 
binding and entry. Our data demonstrate that also the jin-1 mutant relies on SA 
binding for cellular entry.
2.4 Discussion
The use of tumor-selective oncolytic viruses for killing tumor cells that resist 
conventional therapeutic approaches is conceptually attractive. Human reoviruses 
are one of the promising candidates for use as replicating oncolytic agent [7, 43, 
44]. Reoviruses preferentially induce cell death and apoptosis in tumor cells, but 
not in diploid, non-transformed cells [1-3]. However, in some tumor cells expres-
sion of the JAM-A receptors is down-regulated and absent on the cell surface, 
 thereby limiting the susceptibility of the cells to reovirus T3D infection. 
Here we report the isolation of JAM-A independent T3D reoviruses with an 
 expanded tropism. These mutants, designated as jin mutants, may be considered 
as oncolytic agents in those tumor types that lack accessible JAM-A on their sur-
face [21-23, 45]. Although we encountered the first jin mutant in a batch of S1-His 
modified reovirus after selection in the U118MG-scFvHis cell line [24], the jin 
 mutants are not genetically modified viruses in the formal sense since they 
resulted from spontaneous mutations in T3D viruses. 
In three independent virus batches we identified jin mutants. Two of these 
(jin-1 and jin-2) carried an identical mutation in the head domain of the spike pro-
tein σ1. The mutation replaces the glutamine (Q) residue at position 336 by an 
 arginine (R). The amino acid 336 is located at a surface exposed position, close to 
the region involved in the trimerization of the 1 spikes [32]. The alteration renders 
the area more positively charged. This could potentially result in conformational 
changes that may disturb the formation of 1-trimers. However, the results of a 
 trimerization assay (depicted in Figure 3) revealed that altered σ1 of jin-1 still 
forms mature trimers, showing that the Q336R alteration in S1 of the jin-1 and 
jin-2 viruses does not affect trimer formation of this domain. 
While the jin mutants were isolated on human glioblastoma cell line U118MG, 
we found that the jin-1 mutant efficiently infects a variety of reovirus T3D resist-
ant cell lines, including the chicken hepatoma cell line LMH, but not non-trans-
formed primary human skin fibroblasts (VH10) This expanded tropism, together 
with the small-plaque phenotype observed in the JAM-A positive cell line 911, is 
reminiscent of changes observed in other virus families. Adaptation to cell culture 
conditions can result in selection of viruses that acquired the capacity to bind 
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bind strongly to heparan sulfate in vitro, show small plaques on BHK cells and 
these variants are attenuated in cattle. Furthermore, they have a decreased ability 
to spread from the site of inoculation [48]. Alternatively, mutants of Sindbis Virus 
that exhibit a reduced binding to heparan sulfate give rise to larger plaques in 
vitro and are more virulent in vivo with slower clearance from the circulation [46]. 
However, the Q336R change in jin-1 and jin-2 does not yield a typical linear 
 hep arin-binding domain consensus -X-B-B-X-B-X- and -X-B-B-B-X-X-B-X- in which 
B is a basic residue (mainly K or R ) and X a hydropathic residue [49-51]. It should 
be noted that the presence of a linear consensus sequence is not a strict prerequi-
site for glycosaminoglycan binding. Some of Venezuelan equine encephalitis virus 
(VEE) mutants bind heparan sulfates (HS) through a conformational domain and 
do not contain the linear HS-binding domain [52]. Our observation that reovirus 
jin-1 entry into U118MG cells cannot be inhibited by incubation with heparin or 
heparan sulphate (data not shown) suggests that binding to glycosaminoglycans 
is not responsible for the broadened tropism of jin-1 and jin-2. It therefore remains 
to be established if and how the Q336R change contributes to the expanded 
 tropism. Also with respect to sialic acid binding, in some DNA viruses mutations 
in the SA-binding pocket resulted in changes in plaque morphology [53, 54]. 
Upon continued serial passaging of jin mutants in U118MG cells, additional 
amino acid alterations accumulated in spike protein σ1, T193M in jin-1 and G187R 
in jin-2. For the jin-3 mutant, a single mutation in S1 resulted in G196R substitu-
tion in σ1. Those changes are located in close proximity of the region implicated in 
sialic acid binding [6, 15, 25, 26]. This is in line with the previous observation that 
passaging of reoviruses incapable of binding SA on mouse erythroleukemia cells 
yielded mutants capable of binding sialic acids [38]. In co-crystalization experi-
ments of σ1 in complex with SA it was shown that the changes were mapped in 
the σ1 region between amino acids 198 and 204 [26].
Also outer capsid protein σ3 plays an important role in the process of reoviral 
entry [16, 18, 55, 56]. A mutation found in so-called persistent-infection reoviruses 
leads to an amino acid change Y354H in the σ3 protein. This alteration has been 
linked to the reoviral resistance to the protease inhibitor E64d [57]. A mutation in 
jin-1 results in M357T in σ3, which is in close proximity of position 354. However, 
no such mutations are found in jin-2 and jin-3. Moreover, jin-1 is sensitive to E64d, 
demonstrating that the jin-1 virus still depends on cysteine proteases for uncoat-
ing and infection. This suggests that the jin-1 virus enters JAM-A negative cells 
via the endocytic pathway, like wtT3D in JAM-A expressing cells.
So far, we have evaluated the jin mutants in in vitro studies only and it remains 
to be elucidated what the effect will be in vivo, both with regards to safety, as well 
as to their oncolytic efficacy.
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While we cannot exclude the possibility of the recruitment of secondary 
 receptors, our data suggest that the jin mutants rely on sialic acid binding for 
 internalization. It is tempting to speculate that a changed affinity for sialic acids 
underlies the changed tropism of our jin viruses, since they show a decreased 
 ability to spread in cultured cells, exhibit a small plaque phenotype, and shielding 
SA moieties with WGA prevents the jin viruses to enter cells. It remains to be 
established if the mutation in S1 affects reovirus pathology in mice. In this respect, 
it is noteworthy that the pathology of reoviruses is, in part, dependent on the σ1 
protein [58]. 
2.5 Materials and methods
Cell lines
Cell lines 911 (generated previously in our lab, see reference [55]), U118MG 
(obtained from ATCC), U2OS (obtained from ATCC, see reference [29]), CHO 
 (obtained from ATCC), Eoma (obtained from ATCC, see reference [28]) and VH10 
(primary human foreskin fibroblasts, provided by B. Klein [59]) were cultured in 
Dulbeco’s Modified Eagle Medium (DMEM) containing high glucose (Invitrogen, 
Breda, The Netherlands), supplemented with penicillin, streptomycin (pen-strep) 
and 8% fetal bovine serum (FBS) (Invitrogen, Breda, The Netherlands). The 
U118-HAJAM cells were cultured in DMEM plus 8% FBS and pen-strep, supple-
mented with 200 μg/ml G418. LMH cells (obtained from ATCC, see reference [27]) 
were grown on collagen I coated dishes (Rat Tail collagen, 2.5 μg/cm2, Invitrogen, 
Breda, The Netherlands) in DMEM plus 8%FBS and pen-strep. STA-ET2.1 cells 
were grown on collagen I coated dishes (5.0 μg/cm2) in RPMI 1640 medium (Invit-
rogen, Breda, The Netherlands), supplemented with pen-strep and 10% FBS. Lec2 
cells (derived from ATCC, see reference [33]) were cultured in alpha-MEM 
 (Invitrogen, Breda, The Netherlands) with 8% FBS. All cells are cultured in an 
 atmosphere of 5% CO2 at 37°C.
Reovirus propagation
The wild-type T3D virus strain R124 (see accession numbers) was isolated 
from a reovirus T3D stock obtained from the American Type Culture Collection 
(stock VR-824) by two rounds of plaque purification on 911 cells. The 911 cells 
were used to propagate R124 (referred to as wtT3D in the text) as described 
 previously [60]. Briefly, cells were exposed to reovirus in DMEM plus 2% FBS for 
2 hours at 37°C, 5% CO2. Subsequently, the inoculum was replaced by DMEM 
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ing the cells in phosphate-buffered saline (PBS) with 2% FBS and subjecting the 
 suspension to three cycles of freezing and thawing. The sample was cleared by 
centrifugation for 10 minutes at 800 g. For the mutant jin viruses, U118MG cells 
were used to propagate the viruses after one round of plaque purification on 911 
cells. The jin viruses were routinely harvested from U118MG cells 72 hours post 
infection. The experiments were done with virus-containing freeze-thaw lysates, 
unless otherwise indicated. The infectious reovirus titers of the strains were deter-
mined by plaque assay on 911 cells. 
Origin of the jin-mutants
jin-1 is derived from U118scFvHis cells during our experiments on genetically 
modifying reovirus [24]. The jin-1 virus was first grown on U118scFvHis cells for 
two propagations, before three passages on U118MG cells (first point of S1- sequence 
analysis). The virus was subjected to one round of plaque purification on 911 cells 
to obtain a homogenous population. This was further propagated on U118MG 
cells for 11 rounds before analysis of the complete genome sequence (Table 1).
jin-2 was isolated from U118scFvHis cells infected with wtT3D reovirus and 
passaged twice in these cells. The S1 segment was sequenced from this passage. 
Subsequently it was passaged 10 times on U118MG cells. After plaque purifica-
tion, the complete genome sequence was determined (Table 1). 
jin-3 was isolated from U118MG cells exposed to wtT3D virus followed by 
blindly passaging the virus for 6 rounds. From the resulted preparation a virus 
was isolated by plaque purification and following by 10 additional passages on 
the U118MG cells. (Table 1).
Yield determinations
To determine the replication of wtT3D, jin-1, jin-2 and jin-3 in U118MG and 
VH10 cells (Figure 3), cells were seeded in 24-well plate with a cell density of 
1*105 cells/well. Viruses (in DMEM plus 2% FBS) were added to the cells with an 
MOI of 10, two wells per virus. After an exposure of one hour in incubator (37°C, 
5% CO2) the inoculum was removed and the cells were washed once with PBS 
and fed by fresh DMEM plus 2% FBS. Reoviruses were harvested from medium 
and cells by 3 cycles of freeze-thawing, 72 hours after infection. Yields were deter-
mined by plaque assays on 911 cells. 
For the replication of wtT3D or jin-1 in 911, U118MG, LMH, U2OS, CHO and 
Lec2 cells (Figure 7B and 8B), cells were seeded in 6 well plates with a density of 
1.5*106 cells/well. Wild-type T3D or jin-1 was added to 4 wells in case of 911 cells 
and 3 wells for the other cell lines with an MOI of 10 (in DMEM plus 2%FBS). 
After one hour of exposure in incubator, the viruses were washed from the cells 
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and medium was replaced. From one well, immediately after washing once with 
PBS, cells in medium were collected and subjected to freeze-thaw cycles (1 hour 
time point). 32 Hours (911 cells only), 48 and 72 hours after infection cells and 
 medium were collected and subjected to freeze-thaw cycles. Viral yields were 
 determined by plaque assays on 911 cells.
Cell viability assay
WST-1 reagent (Roche, Almere, The Netherlands) was used to assay the viabil-
ity of cells after reovirus infections. U118MG and 911 cells in 96-well plate were 
mock-infected or infected with wtT3D or jin-1 with an MOI of 10, in triplo. Six 
days post infection WST-1 reagent was added, according to the manufacturer’s 
manual. The viability measurements in mock-infected cell cultures, were set to 
100%. 
[35S]-Methionine labelling
Infected cells (911 cells infected at MOI = 1; U118MG and U118-HAJAM with 
MOI = 5) or mock-infected cells were incubated with TRAN35S - LABEL™ (10mCi/
ml; MP Biomedicals, Eindhoven, The Netherlands) for 4 h; one day (911 cells) or 
two days (U118MG and U118HA-JAM cells) post infection. Cells were washed 
once with phosphate-buffered saline and lysed in Giordano Lysis Buffer (50 mM 
Tris HCl pH 7.4, 250 mM NaCl, 0.1% Triton, 5 mM EDTA) containing protease 
 inhibitors (Complete mini tablets, Roche Diagnostics, Almere, The Netherlands). 
The labelling assays were performed in 24-well plates with 5 μl (50 μCi) TRAN35S 
- LABEL™ per well. The cells were lysed with 100 μl lysis buffer. After addition of 
sample buffer, 50 microliters per lysate was loaded in the wells of a 10% 
 SDS- polyacrylamide gel. Gels were dried and exposed to a radiographic film to 
visualize the labeled proteins.
Immunofluorescence assay 
For immunofluorescence assays, U118MG and 911 cells were grown on glass 
coverslips in 24-well plates before infection with wtT3D or jin-1 with an MOI of 5 
or no virus. One day post infection the cells were fixed with cold methanol (15 
 minutes, 4°C), washed with PBS containing 0.05% Tween-20, and incubated with 
antibody 4F2 directed against reovirus σ3 (monoclonal antibody developed by 
T.S. Dermody [61]; obtained from the Developmental Studies Hybridoma Bank 
developed under the auspices of the NICHD and maintained by The University of 
Iowa, Department of Biology, Iowa City, IA 52242), diluted in PBS containing 3% 
BSA. After incubation at room temperature the cells were washed (PBS, 0.05% 
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conjugated goat anti-mouse serum for 30 minutes at room temperature. The 
mounting solution consisted of glycerol containing 0.02 M Tris HCl pH8.0, 2.3% 
1,4-diazabicyclo-[2.2.2]-octane and 0,5 μg/ml 4’,6-diamidino-2-phenylindole 
(DAPI) to visualize the nuclei. 
RT-PCR and sequencing
Total RNA was isolated (Absolutely RNA miniprep kit; Stratagene, Agilent 
Technologies, Amstelveen, The Netherlands) from U118MG cells infected with the 
different reovirus mutants (jin-1 or jin-3), one day post infection. For wtT3D total 
RNA was isolated from infected 911 cells. Primers used for the RT-PCR proce-
dures are listed in Table S1. DNA synthesis of all the segments started with the 
unique endR primer designed for every segment, using SuperScript III (Invitro-
gen, Woerden, The Netherlands) for the reverse transcription process. For the 
PCR, PFU polymerase (Promega, Leiden, The Netherlands) was used with the 
primer combinations unique for every segment. PCR products were first cleaned 
with Sureclean (Bioline, London, UK), according to the manual, before direct 
 analysis of the  sequence. In some cases the resulting PCR products were cloned 
into plasmid pJet1 (GeneJet, PCR cloning kit; Stratagene, Agilent Technologies, 
Amstelveen, The Netherlands) and their DNA sequences were determined. All 
sequence data were generated by The Leiden Genome Center (LGTC, Leiden, The 
Netherlands).
In vitro transcription-translation and trimerization assay
All primer sequences can be found in table S1. With DualSHFor and 
 DualSHRev primers, S1 PCR product was generated from plasmid pCDNART3S1 
[24], according to manual of the pDual-GC vector (Stratagene, Agilent Technolo-
gies, Amstelveen, The Netherlands). The resulting construct (pDualS1His) 
 contained no stop codon, meaning that the Myc-His tag was present behind S1. To 
introduce a stop codon behind the S1 ORF in pDualS1His, the DualS1st for and 
rev primers were used in a mutation PCR, with EXL polymerase (Stratagene, 
 Agilent Technologies, Amstelveen, The Netherlands). This resulted in the plasmid 
pDGC-S1delTag, which was used for the trimerization assay and as start to gener-
ate the pDGC-S1QR and pDGC-S1Y313A (with S1-QRmut2Rev and For combi or 
S1-Y313AmRev and For combi, respectively) also with EXL polymerase. For the in 
vitro transcription-translation (ITT) part, TNT® T7 Quick Coupled Transcription/
Translation kit (Promega, Leiden, The Netherlands) was used. Input for the ITT 
assays were the plasmids pDGC-S1delTag, pDGC-S1QR and pDGC-S1Y313A. The 
total reaction volume was 15 μl, scaled according to the manual (in the presence 
of 6 μCi TRAN35S - LABEL™; MP Biomedicals, Eindhoven, The Netherlands). For 
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the trimerization Assay, one fifth of every ITT reaction per construct was used 
and incubated with Sample buffer (final concentrations: 10% glycerol, 2% SDS, 60 
mM Tris HCl pH 6.7, 2.5% β-mercaptoethanol and 2.5% bromophenol blue) for 30 
minutes at 37°C to stabilize the trimers or boiled for 5 minutes 96°C to disrupt the 
trimers. After incubation the samples were loaded on a 10% SDS-polyacrylamide 
gel, which was kept at 4°C during the run. Gels were dried and exposed to a 
 radiographic film to visualize the labeled proteins.
Plaque assay and size measurements
Plaque assays were performed in a standard assay as previous described for 
adenoviruses [62] with minor modifications. Briefly, virus stocks were serial 
 diluted in DMEM containing 2% FBS. The dilutions were added to near-confluent 
911 cells in six-well plates. Four hours after infection, medium was replaced with 
agar-medium. Agar-medium consists of (final concentrations) 0.5% agarose 
 (Ultrapure™, Invitrogen, The Netherlands),1x minimal essential medium (MEM), 
2% FBS, 12.5 mM MgCl2, 2 mM GlutaMAX™ (Invitrogen, Almere, The Nether-
lands) and 1x pen-strep antibiotic mixture (Invitrogen, Almere,The Netherlands). 
Plaques are counted six days post infection. Plaques sizes were measured four 
days post infection. For the measurements a CKX41 Olympus microscope was 
used and the plaque area was measured with the software of Olympus: Olympus 
DP-soft.
Western analysis
Cell lysates were made in Giordano Lysis Buffer supplemented with protease 
inhibitors (Complete mini tablets, Roche Diagnostics, Almere, The Netherlands). 
Total amount of protein in the lysates was measured (Bradford, Biorad, 
Veenendaal, The Netherlands) and the same amount of lysate (30 μg) was loaded 
into the wells of a 10% SDS-polyacrylamide gel after addition of western sample 
buffer (final concentrations: 10% glycerol, 2% SDS, 50 mM Tris HCl pH 6.8, 2.5% 
β-mercaptoethanol and 0.025% bromophenol blue). The proteins were transferred 
to  Immobilon-P (Millipore, Etten-Leur, The Netherlands) and visualized using 
standard protocols. Antibodies used in this study: 4F2 directed against reovirus 
σ3; β-Actin antibody: ImmunO anti-Actin clone C4 (MP Biomedicals, Eindhoven, 
The Netherlands).
E64d inhibition
E64d (Sigma Aldrich, Zwijndrecht The Netherlands) was dissolved in DMSO 
before use. U118MG and 911 cells were seeded in 24 well plates; half of the cells 
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jin-1 virus and ISVPs (approximately 2*103 particles per cell) were added to the 
cells and left for one hour at 4°C; cells were washed with PBS and transferred 
back to 37°C, 5%CO2 in the absence or presence of E64d, for 36 hours. Lysates 
were made as described in Western analysis. For the immunodetection the anti-3 
antibody (4F2) and β-Actin antibody were used.
Generation of ISVPs
wtT3D or jin-1 virus ISVPs are freshly prepared by treating CsCl purified 
 virions [60] with chymotrypsin. Purified viruses were diluted to a concentration 
of 1011 PFU/ml in Reovirus Storage Buffer (10 mM Tris HCl pH 7.5, 150 mM NaCl, 
10 mM MgCl2) and  treated with 200 μg/ml Chymotrypsin (TLCK treated, Sigma 
Aldrich, Zwijndrecht The Netherlands; C3142) at 37°C for 1 hour. Reaction was 
stopped by adding 5 mM phenylmethyl-sulfonyl fluoride (Sigma Aldrich, Zwijn-
drecht The Netherlands). 
Wheat germ agglutinin (WGA) binding and competition 
 experiment 
For the detection of sialic acids in the different cell lines, FITC-labeled WGA 
(Sigma Aldrich, Zwijndrecht The Netherlands) was used. Cells (grown on round 
glass coverslips in 24-well plate) were fixed with ice-cold Methanol (15 minutes, 
4°C) and washed with PBS containing 0.05% Tween-20. WGA-FITC was added to 
the cells at a concentration of 5 μg/ml in PBS containing 3% BSA and incubated for 
1 hour at room temperature. Excess of unbound WGA-FITC was washed away 
with PBS containing 0.05% Tween-20. Nuclei were visualized by DAPI in the same 
mounting solution as is described for the immunofluorescence assay.
WGA competition experiment was done by exposing cells (in 24-well plate 
wells) to WGA at a concentration of 100 μg/ml in culture medium for one hour in 
CO2 incubator at 37°C. The pre-incubation medium was removed and wtT3D or 
jin-1 virus was added to the cells with an MOI of 10 in DMEM containing 2% FBS 
at 4°C for one hour. Cells were washed with ice-cold PBS and normal culture 
 medium was added to the cells. Cells were left for 32 hr in CO2 incubator (37°C) 
before lysates were made as described in Western analysis. For the immunodetec-
tion the anti-σ3 antibody (4F2) and β-Actin antibody were used.
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Tweaking Reovirus T3D to Boost the Oncolytic Potency
3.1 Abstract
In the canonical pathway, infection of cells by the wild-type mammalian ortho-
reovirus Type 3 Dearing (T3D) is dependent on the interaction of the viral spike 
protein σ1 with the high-affinity cellular receptor Junction Adhesion Molecule-A 
(JAM-A). We previously demonstrated that the human glioblastoma cell line 
U-118 MG does not express JAM-A and resists reovirus T3D infection in standard 
cell culture conditions (SCCC). Heterologous JAM-A expression sensitises U-118 
MG cells to reovirus T3D. Here we studied reovirus infection in U-118 MG cells 
grown in spheroid cultures with the premise that cells in such cultures resemble 
cells in tumours more than those grown under standard adherent cell culture 
 conditions on a plastic surface. Although the U-118 MG cells in spheroids do not 
 express JAM-A, they are susceptible to reovirus T3D infection. We show that this 
can be attributed to factors secreted by cells in the spheroids. The concentration of 
active extracellular proteases cathepsin B and L in the medium of spheroid 
 cultures was increased 19- and 24-fold, respectively, as compared with SCCC. 
These enzymes can convert the reovirus particles into a form that can infect the 
U-118 MG cells independent of JAM-A. Taken together, these data demonstrate 
that  infection of tumour cells by wild-type reovirus T3D is not strictly dependent 
on the expression of JAM-A on the cell surface.
3.2 Introduction
The mammalian orthoreovirus Type 3 Dearing (T3D) is a promising oncolytic 
agent. Currently, its use as anti-cancer therapeutic, either in stand-alone treatment 
or in combination with existing medication, is explored in a variety of clinical 
 trials. Reovirus T3D has been well tolerated and no dose-limiting toxicity has been 
reported so far. Anecdotal evidence of antitumour efficacy exists in stand-alone 
treatment and in combination therapies [1]. The reovirus T3D is a member of the 
Reoviridae family, which is characterized by a segmented double-stranded RNA 
genome. The non-enveloped virus contains two icosahedral protein shells. Reo-
virus has been long known to induce cell death preferentially in tumour cells, and 
much less in non-transformed diploid cells [2]. Various determinants underlie the 
virus’ preferences for killing cancer cells of which active Ras signalling [3, 4], 
 receptor availability [5], viral uncoating [6], and endosomal trafficking [7] appear 
the most important. 
Reovirus attachment protein σ1 is considered as the main determinant of the 
virus’ tropism. Attachment of the virus to the host cell is a three-step process. The 
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virus first scans the cell surface by high avidity binding to sialic acids with 
 residues in the shaft domain of the spike protein [8]. This leads to the engagement 
of the high-affinity reovirus receptor Junction Adhesion Molecule-A (JAM-A, also 
named JAM-1) by a defined region in the head domain of σ1 [9]. JAM-A is a trans-
membrane protein with two extracellular immunoglobulin domains and a short 
cytoplasmic tail. The protein is concentrated at the apical region of intercellular 
tight junctions of epithelial and endothelial cells [10]. Following JAM-A binding, 
β1 integrins guide internalization of the virus, most likely by clathrin-mediated 
endocytosis [11]. In the endosome the virus is partially uncoated by proteolytic 
 disassembly by the host proteases such as cathepsin B and L [12].This process is 
characterized by structural changes in σ1, removal of the outer-capsid protein σ3 
and conformational rearrangements in outer-capsid protein μ1. In this stage the 
particles are designated as intermediate subviral particles (ISVPs) (reviewed by 
Danthi et al. [13]). ISVPs are able to escape the endosome, thereby delivering 
 transcriptionally active cores into the cytoplasm [14]. In the intestines and the 
lungs, the initial sites of reovirus infection in vivo, disassembly of the virion by 
host proteases can take place extracellularly and the resulting ISVPs can enter 
cells independent of JAM-A directly at the cell membrane [15-18].
Under standard cell culture conditions, infection of glioma cells by reovirus 
T3D strictly depends on expression of JAM-A. We and others demonstrated that 
the reovirus-resistance of the glioblastoma cell line U-118 MG, upon its growth in 
standard cell culture conditions, can be overcome by heterologous expression of 
the JAM-A receptor or its extracellular domain coupled to a heterologous trans-
membrane domain [19, 20]. Remarkably, however, various JAM-A negative 
 primary glioma cell cultures, that had been isolated from tumour resection mate-
rial and were grown as spheroid cultures, were found to be sensitive to reovirus 
T3D infection [21]. These paradoxical results question the importance of JAM-A in 
reovirus infection. Therefore we decided to study the role of JAM-A in more detail 
in two in vitro cell culture models. These are the standard cell cultures condition 
(SCCC) cultures adherent to a polystyrene surface, and the three-dimensional 
 tumour-cell spheroids.
The spheroid cell culture models are being used in cancer research since the 
1970s [22] but gained renewed interest when the limitations of two-dimensional 
culture methods became apparent (reviewed by Achilli et al. [23]). Spheroids 
 resemble the architecture of an in vivo tumour (including its micro environment) 
more closely than SCCC cultures. As an example, spheroids establish gradients of 
products that are secreted or taken up by cells. Also, cell-cell and cell-matrix inter-
actions in spheroids better mimic tumours [24]. This also became evident from 
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glioma material; spheroids more closely resemble the genetic characteristics of the 
parental tumour [25].
Here we grew U-118 MG glioblastoma cells as SCCC cultures and as multi-
cellular spheroids to compare the susceptibility to reovirus in these two models. 
We show that, while U-118 MG cells grown in spheroid cultures are JAM-A 
 deficient, they are highly susceptible to reovirus infection. This can be attributed 
to proteolytic activation of the reoviruses by proteases secreted by the cells in the 
spheroid cultures. This demonstrates that factors secreted by cells in the three- 
dimensional cultures can proteolytically activate the reoviruses which  results in 
infection independent of JAM-A expression.
3.3 Results
Growth of U-118 MG cells in SCCC and spheroid cultures
To study the effects of the culture system on the growth rates of U-118 MG 
cells, the cell numbers were counted at various time points after initiation of the 
SCCC and spheroid cultures. Both cultures started with 5,000 cells per well and 
cell numbers were counted regularly during five days (Figure 1A). As expected, 
cells in SCCC cultures divide more frequently than in spheroid cultures. In five 
days after initiation, the cell numbers in adherent SCCC cultures increased almost 
ten-fold, whereas the cell number in the spheroid cultures increased only three-
fold. The diameter of the spheroids increased linearly during time (Figure 1B). 
Ki-67 protein staining on microtome sections of spheroids revealed the presence 
of proliferating cells throughout the spheroid (Figure 1C). These data confirm the 
presence of viable cells within the spheroid. Analysis by Transmission Electron 
Microscopy (TEM) of a section of a spheroid (Figure 1D) revealed the presence of 
extracellular matrix (ECM). No evidence was obtained on the appearance of a 
 necrotic centre, which is often observed in multicellular spheroids [24].
U-118 MG spheroids do not express Junction Adhesion Molecule-A
Cell-cell interactions of cells in spheroids inevitably differ from cells in SCCC 
cultures. U-118 MG cells in SCCC cultures do not express reovirus’ primary cellu-
lar receptor, JAM-A [19]. To study whether JAM-A expression is induced by 
growth in spheroid cultures, we investigated the JAM-A expression status. As a 
positive control, U-118HA-JAM cells were used which were generated by trans-
duction of U-118 MG cells with a lentiviral vector encoding JAM-A [19]. Flow-
cytometry analyses showed that U-118 MG cells retrieved from spheroid cultures 




Growth of U-118 MG SCCC and 
 spheroid cultures.
A. Growth curves of U-118 MG cells 
in SCCC and spheroid cultures, 
showing the number of cells per 
culture, which were initiated with 
5000 cells per culture.
B. The diameter of U-118 MG 
 spheroids was measured at five 
consecutive days. 
C. Viability assay by Ki-67 protein staining in cross-sections of U-118 MG spheroids,  
2 days after preparation. The right panel is an enlargement of the lower right spheroid. 
 Examples of Ki-67-positive cells are indicated by an arrow. To enhance the visibility of 
weak signals, no counterstain was applied in these sections. 
D. Electron microscopy image of a U-118 MG spheroid, 2 days after preparation. The boxed 
sections are enlarged in the right, lower panel. The  extracellular matrix (ECM)  between 
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 spheroids were clearly JAM-A positive (Figure 2A). The absence of JAM-A expres-
sion in both U-118 MG SCCC cells and spheroids was confirmed by reverse tran-
scription polymerase chain reaction (RT-PCR) on total cellular RNA (Figure 2B). 
U-118 MG cells in spheroids are more susceptible to reovirus 
 infection than U-118 MG SCCC cultures 
Results from our previous study suggested that JAM-A expression is not a 
prime determinant of the sensitivity of human glioma cells to reovirus infection 
and that significant reovirus infection can occur in cells that have only very low 
amounts of JAM-A at their surface [21]. Therefore, we studied the difference in 
sensitivity to reovirus infection of U-118 MG cells grown as SCCC and as spheroid 
cultures. Spheroid cultures (consisting of 5000 cells) were prepared using methyl-
cellulose-containing culture medium in non-adherent U-bottom plates [26]. As 
controls, SCCC cultures were prepared with the same number of cells. We 
exposed the cells in both cultures to wild-type reoviruses at varying multiplicities 
FIGURE 2. 
JAM-A expression in U-118 MG cells.
A. Flow cytometry analysis of JAM-A expression on U-118 MG and U-118HA-JAM SCCC 
cells and U-118 MG spheroid cells using a JAM-A specific antibody.
B. RT–PCR assay on total  cellular RNA of U-118 MG and U-118HA-JAM SCCC and 
 spheroid cultures using JAM-A-specific primers. Beta-actin analysis was performed to 





of infection (MOI911), ranging from 0 to 100 PFU911 per cell. Three-days post infec-
tion, the presence of the reovirus protein σ3 was visualized by immunocyto-
chemistry. This revealed only few positive cells at both MOI911 10 and 100 in the 
SCCC cultures, while the outer rim of the spheroids was almost completely 
infected at MOI911 10. Virus infection deep into the spheroid was clearly visible at 
MOI911 100 (Figure 3A). The number of infected cells was quantified by flow 
 cytometry by staining for the reovirus protein σ3 with a fluorochrome R-Phyco-
erythrin (PE)-coupled antibody. In SCCC cultures only 0.3 % and 2.4 % of the cells 
were positive for σ3 upon exposure to MOI911 of 10 and 100, respectively. The 
cells in the spheroids cultures were more efficiently infected, with 13.0 % and 39.0 
% of the cells positive for σ3 expression upon exposure to MOI911 of 10 and 100, 
respectively (Figure 3B). Finally, the viability of SCCC cells and spheroids after 
reovirus infection was assessed eight days post infection (Figure 3C). While the 
viability of SCCC cultures only slightly decreased at increasing virus titer, 
FIGURE 3. 
Reovirus infection of U-118 MG SCCC and spheroid cultures.
A. Detection of reo virus protein σ3 by DAB staining in reovirus-infected U-118 MG SCCC 
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 spheroids showed a distinct decrease in viability especially at MOI911 10 and 100. 
We considered the possibility that the methylcellulose used in formation of the 
cultures may increase the sensitivity of the cells to reovirus infection. To investi-
gate this, we compared the viability of reovirus infected spheroids generated in 
culture medium containing methylcellulose or made on a solid agarose matrix. In 
both spheroids systems the cells were equally susceptible to reovirus (data not 
shown), demonstrating that the methylcellulose treatment does not increase the 
cells’ susceptibility to reovirus infection. 
As compared to cells in monolayer cultures, cells in a spheroid grow at higher 
concentrations. This allows the cells of a spheroid to affect their local environment 
FIGURE 3. 
Reovirus infection of U-118 MG SCCC and spheroid cultures.
B. Flow cytometry  analysis of reovirus-infected U-118 MG SCCC and spheroid cells by 





to a greater extent than cells in monolayer cultures. To test whether a high local 
concentration of cells in SCCC cultures can mimic the spheroid environment and 
stimulated JAM-A-independent transduction, we generated SCCC cultures at low, 
normal, and high density and exposed them to reovirus at MOI911 100. This assay 
revealed higher infection efficiency (as concluded from σ3 protein staining) for the 
high density cultures (Figure 4A). This was confirmed by flow cytometry to 
 quantify the number of infected cells. Cell cultures with low and normal density 
exhibited only 0.9 % and 3.3 % reovirus-infected cells, respectively, while 20.8 % 
of cells in the high density culture were infected (Figure 4B). These results 
 demonstrate that, as in spheroid cultures, JAM-A is dispensable for reovirus 
 infection in dense SCCC cultures. 
Secreted products enhance reovirus infection of JAM-A negative 
cells
Our data show that U-118 MG cells in spheroid cultures are more susceptible 
to reovirus infection than their counterparts in SCCC cultures, despite the absence 
of JAM-A. Since tumours are known to secrete proteases into their microenviron-
ment [27], which may result in reovirus disassembly outside the cell, we specu-
lated that a similar process may occur in the medium surrounding the U-118 MG 
cells in spheroid cultures. To test this hypothesis, we collected medium from 
U-118 MG cells in SCCC and in spheroid cultures five days after establishing 
FIGURE 3. 
Reovirus infection of U-118 MG SCCC and spheroid cultures.
C. Viability assay of reovirus -infected U-118 MG SCCC and spheroid cultures, at 8 days 
post infection. The viability of uninfected samples is set to 100%. The error bars  represent 
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these cultures. Reoviruses were added to the collected media, which was sub-
sequently exposed to semi-confluent U-118 MG SCCC cultures at MOI911 of 100. 
Three days post infection, the number of infected cells was analysed by flow 
 cytometry. While U-118 MG cells infected with reovirus in presence of fresh 
 medium or medium from adherent cells show only 2.8 % and 2.3 % infected cells, 
respectively, the spheroid medium with reovirus yielded an infection in 16.2 % of 
the cells (Figure 5A). This increase in infection was supported by a viability assay 
on  semi-confluent U-118 MG cells. As semi-confluent U-118 MG cells do not read-
ily exhibit a cytopathic effect upon reovirus infection, cells were replated in fresh 
 medium three days post infection and allowed to attach and proliferate. The next 
day the cells’ viability was assessed. While infection (at MOI911 of 10) in the 
 context of fresh medium or SCCC-derived medium showed a marginal decrease 
in viability, the viability was reduced to 70% after infection in the context of 
 spheroid-derived medium (Figure 5B). At MOI911 of 100, a more pronounced 
decrease in viability was observed for cells infected in presence of fresh medium 
FIGURE 4. 
Reovirus infection of U-118 MG SCCC cultures at different densities.
A. Detection of reovirus protein σ3 by DAB staining in SCCC cultures at different  densities 
infected with reovirus at MOI911 2.5 of 100, at 4 days post infection.
B. Flow cytometry analyses of reovirus-infected (MOI911 of 100) SCCC cultures  











































































or SCCC cell medium. However, the viability of cells infected in spheroid-derived 
medium decreased even more, up to 40%. 
We next investigated whether the medium derived from spheroid cultures 
 indeed has a direct effect on the virions, thereby promoting the infection of 
JAM-A-deficient cells. We dissolved reovirus into medium from SCCC cells, 
 medium from spheroids, and non-conditioned control medium, and subsequently 
purified the virus by CsCl banding. Infection of semi-confluent U-118 MG cells in 
monolayer cultures revealed that the virus particles incubated with SCCC-derived 
FIGURE 5. 
Assessment of the effects of culture-derived factors on reovirus infection  efficiency.
A. Flow cytometry assay on reovirus- infected U-118 MG cells (MOI911 of 100) in the 
 presence of medium derived from U-118 MG SCCC cultures, U-118 MG spheroid cultures 
or fresh medium, at 3 days post infection. Error bars indicate the s.d. (n = 3), *P < 2.5E−4. 
B. Viability analysis of U-118 MG cells exposed to reovirus at MOI911 of 100 in the presence 
of medium derived from U-118 MG SCCC cultures,  spheroid cultures or fresh medium. 
Error bars represent the s.e.m. (n=12), *P < 3.6E−3, **P < 1.2E−6. 
C. Flow cytometry analyses of U-118 MG cells infected with reovirus that were previously 
incubated with  medium derived from U-118 MG SCCC cultures, spheroid cultures or 













Tweaking Reovirus T3D to Boost the Oncolytic Potency
medium do not enhance transduction of U-118 MG cells (Figure 5C). In contrast, 
infection with virus that had been pre-exposed with spheroid-derived medium 
was significantly increased. These data demonstrate that one or more factors 
 secreted by the U-118 MG cells in spheroid cultures enhance the reovirus infection 
of JAM-A negative cells. 
Cathepsin B and L secretion of spheroids is upregulated and 
 enhances reovirus infection of cells
Many tumours produce high amounts of cathepsins that are secreted into the 
extracellular microenvironment [27, 28]. Cathepsin B and L are known to be 
involved in reovirus disassembly in the endosome [12]. To test whether cathepsin 
B and L are secreted by U-118 MG spheroids and could activate the reovirus 
entry, we examined the cathepsin B and L activity in cells and medium of U-118 
MG SCCC and spheroid cultures. This demonstrated a two-fold increase in intra-
cellular  cathepsin B and L activity in the U-118 MG spheroid cultures compared to 
SCCC cultures (Figure 6A). In the media, this difference was even more pro-
nounced, with a 19 and 24-fold increase, respectively. To investigate whether 
cathepsin B and L can modify reovirus particles and enhance infection of 
semi-confluent SCCC cultures of U-118 MG cells, we incubated reovirus stocks 
with either  cathepsin B or L. After virus purification, semi-confluent SCCC cul-
tures of U-118 MG cells were exposed to these particles and analysed three-days 
post infection by flow cytometry. This revealed a five-fold increase in the percent-
age of infected cells incubated with cathepsin B-treated virus, as compared to 
virus incubated in the cleavage buffer alone. Cathepsin L treatment rendered the 
virus two-fold more infectious in U-118 MG cells (Figure 6B). These data demon-
strate that  cathepsins secreted by U-118 MG cells grown in spheroid cultures can 
modify reovirus particles allowing them to infect JAM-A deficient U-118 MG 
 glioma cells. 
3.4 Discussion
Based on in vitro studies, JAM-A has originally been characterized as the major 
cellular receptor of reovirus [9]. The function of JAM-A in reovirus T3D infection 
in vivo became evident by studies using JAM-A-deficient animals [29]. While the 
virus’ distribution towards the central nervous system, which is the major tropism 
in mice, can occur via both neural- and bloodstream routing, only the bloodstream 
routing appears to be JAM-A dependent [29]. Also, JAM-A is not required for the 
initial in vivo infection with reovirus T3D in the intestines [15, 16] and in the lungs 
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[17]. Here the reovirus can infect as ISVPs upon proteolytic conversion by extracel-
lular proteases. 
For reovirus’ use as oncolytic agent, the importance of JAM-A is unclear. 
Whereas reovirus is able to induce apoptosis after JAM-A independent cell entry 
[30], the presence of JAM-A on the cell membrane of tumour cell lines has been 
reported to be important for the cells’ susceptibility to reovirus infection in vitro 
[31, 32]. JAM-A positive tumours in vivo are generally well infected by reovirus 
[32, 33] and resistance to reovirus is observed when JAM-A is absent, or not 
located on the  tumour cell surface [5, 32]. Remarkably, some cell lines that are 
FIGURE 6.
Cathepsin B and L activity in U-118 MG cultures and culture medium, and its effect on 
 reovirus infection.
A. Cathepsin B and L activity in the cells and conditioned media of U-118 MG SCCC 
 cultures and spheroids. Error bars indicate the s.d. (n = 3), *P < 2.0E−6 **P < 9.0E−10. 
B. Increase in reovirus infectivity in  semi-confluent SCCC cultures of U-118 MG cells upon 
exposure of the virus to Cathepsin B, Cathepsin L or buffer. After treatment, the virus 
preparations were purified by CsCl centrifugation before the infectivity assay. The 
 number of  infected cells was assayed by flow  cytometry at 3 days post infection.  
The graph shows the fold increase in  infectivity over buffer-treated virus. The error bars 
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JAM-A negative in vitro, can form reovirus susceptible tumours upon implanta-
tion as xenografts in mice. Alain et al. demonstrated that U-118 MG tumours in 
mice are susceptible to reovirus infection, in marked contrast to the reovirus 
resistance of U-118 MG cells grown in adherent cell monolayer cultures [6]. Here 
we demonstrated that also in vitro JAM-A can be dispensable for reovirus infec-
tion. Despite high resistance to reovirus of U-118 MG cells in monolayer cultures, 
U-118 MG  spheroids can be readily infected and killed. Similar observations have 
been made in glioblastoma stem-like cell (GSC) cultures, isolated from tumour 
resections of glioma patients [21].
We demonstrate that the increased sensitivity to reovirus infection of U-118 
MG cells in spheroid cultures is mediated by components secreted into the 
 medium. Infection of JAM-A deficient adherent cells in presence of conditioned 
medium from spheroid cultures significantly enhances the capacity of the reo-
virus to infect these cells. In many tumour types, such as mammary-carcinoma, 
prostate cancer and glioma, the secretion of proteases is upregulated [27, 28]. In a 
tumour and its microenvironment these proteases are part of complex, multidirec-
tional pathways interacting to modulate key processes as angiogenesis, metastasis 
and ECM composition, ultimately promoting tumour progression [27, 34]. The 
main players in this network are cathepsins (predominantly cathepsin B), metallo-
proteinases (MMPs) and urokinase plasminogen activator [27, 28, 35]. For the reo-
virus infectious pathway, cathepsins B, L and S are important in the disassembly 
process of the virion [12, 36, 37], creating ISVPs that are able to escape the endo-
some. In the acidic environment of tumours and spheroids [24, 38, 39], reovirus 
ISVPs may be generated extracellularly. This could provide the reoviruses with a 
mechanism that bypasses JAM-A for cell entry [14]. There is evidence that 
 cathepsin B expression is upregulated in U251N glioma spheroids compared to 
monolayer cells [40] and that cathepsin B and L expression is higher in reovirus 
sensitive U-118 MG tumours in mice than in resistant adherent cells [6]. We extend 
these  observations and show that cathepsin B and L expression and secretion is 
strongly enhanced in U-118 MG cells grown in spheroids compared to cells in 
 adherent monolayer cultures. Approximately 20-25 fold enhanced secretion of 
 active  cathepsins B and L were found in the medium of spheroids, reminiscent of 
the  enhanced secretion of cathepsins by tumours in vivo. The cathepsins may be 
involved in the deposition and organisation of ECM components, such as 
fibronectin and proteoglycans, as observed in U-118 MG and other glioma sphe-
roids [41]. The depositions of ECM in our spheroid cultures, as readily observed 
by EM  analysis, may have been the result of increased cathepsin secretion.
We also demonstrated that the infectivity of reovirus particles in U-118 MG 
cells can be affected by components in the spheroid-conditioned medium. The 
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amount of activating proteases is limiting activation, as is evident from the obser-
vation that five- and 25-fold dilutions of the conditioned media in fresh medium 
were incapable of generating reoviruses capable of infecting U118MG cell in 
SCCC cultures (data not shown). It should be noted however, that the effective 
concentrations of activating proteases at the cell surface may be higher than the 
amounts that are present in the conditioned media. Purified cathepsins could 
 convert reoviruses to particles that are infections for U118 cells in SCCC cultures. 
Moreover, we demonstrated that JAM-A independent infection by reoviruses 
could be enhanced when the U-118 MG cells were grown at very high densities 
(Figure 4A). These conditions may mimic the high cell density seen in spheroid 
cultures. 
There may be other cellular processes or components that enhance reovirus 
 infection in our spheroid model. Our data do not exclude the potential involve-
ment of other secreted proteases such as MMPs. MMP expression is upregulated 
in many gliomas [27] and MMPs have been shown to enhance the intratumoral 
spread of herpes simplex viruses and adenoviruses by remodelling the ECM [42, 
43]. A similar mechanism might also augment reovirus spread in spheroids and 
tumours. It may therefore be useful to study the production of proteases by cellu-
lar explants from solid tumors that will subjected to oncolytic reoviruses therapy.
By showing that spheroids can upregulate the secretion of proteases, and con-
sequently display an enhanced susceptibility to reovirus, we demonstrated that 
spheroids are a valuable in vitro model, better resembling the in vivo situation than 
SCCC cultures. The spheroid model should therefore be considered as alternative 
for monolayer tumour cell cultures. It could be implemented in studies for new 
therapeutics prior to experiments in tumour-bearing animals. It could provide 
 information about the anticancer agent’s efficacy that may be more faithfully 
 mimicking the in vivo effects than adherent cell monolayer cultures.
3.5 Materials and methods
Cell lines
The human cell lines U-118 MG (glioblastoma) and 911 (adenovirus type 5 
early region 1 transformed human embryonic retinoblasts [44]) were maintained 
at 37°C in a humidified atmosphere of 5% CO2, in high glucose Dulbecco’s modi-
fied Eagle’s medium (DMEM, Gibco-BRL, Breda, The Netherlands) supplemented 
with 8% fetal bovine serum (FBS) (Gibco-BRL) and penicillin-streptomycin (pen-
strep). The generation of U-118HA-JAM cells by transducing U-118 MG cells with 
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previously [19]. These cells were cultured in DMEM high glucose, supplemented 
with 8% FBS, penicillin, streptomycin, and 200 μg/ml G418 (Life Technologies, 
Carlsbad, CA, USA).
Reovirus production and purification
The wild-type T3D reovirus strain R124 (here referred to as reovirus) was 
 isolated previously from a reovirus T3D stock (stock VR-824) obtained from the 
American Type Culture Collection (ATCC) by two rounds of plaque purification 
using 911 cells. Large-scale virus production was performed by infecting 911 cells 
with a multiplicity of infection (MOI) of 1 to 3 plaque forming units (PFU911), 
 followed by medium replacement at three hours post infection, and harvesting of 
cells and medium at 72 hours post infection. Cells and medium were separated by 
centrifugation for 15 minutes at 3000 x g. The pellet was resuspended in 2 ml of 
the medium fraction and subjected to three cycles of freezing and thawing. The 
sample was cleared by centrifugation for 10 minutes at 3000 x g and the super-
natant was mixed with the medium fraction. From this suspension, the virus was 
 further purified by a double discontinuous caesium chloride (CsCl) gradient 
 protocol. Hereby, the virus suspension was layered onto a double-layered (1.45 
and 1.20 g/cm3) CsCl cushion in phosphate buffered saline (PBS) and centrifuged 
in a SW28 rotor at 95,000 x g for 3 hours at 16°C. After the first centrifugation step 
the lowest of the two virus bands (containing the infectious virions) was isolated 
with a syringe, and loaded onto a new CsCl gradient and centrifuged as before. 
After isolation the virus particles were desalted in an Amicon Ultra-15 Centrifugal 
Filter Device (molecular weight limit of 100 kDa, Millipore, Billerica, MA, USA). 
The virus was stored in reovirus storage buffer (10 mM Tris pH 7.5, 150 mM 
NaCl, 10mM MgCl2·6 H2O, 5% sucrose) at -80°C. The infectious titer of the virus 
was  determined by plaque assay on 911 cells.
Preparation and infection of SCCC cultures and spheroid cultures
To grow U-118 MG and U-118HA-JAM cells in standard cell cultures condi-
tions (SCCC) (adherent to a plastic surface) and as spheroid cultures, the cells 
were harvested from semi-confluent monolayers by trypsin treatment, counted 
and  resuspended in medium containing 2.4 mg/ml methylcellulose (Sigma 
Aldrich Chemie, Zwijndrecht, The Netherlands) at the concentration of 50,000 
cells/ml  (described in [26]). Of these suspensions, 100 μl was added into each well 
of a flat-bottom (for SCCC cultures) or U-bottom (for spheroids) 96-well-plate. 
Cells were re-inserted in the incubator for 24 hours to allow their adherence or 
establishment as spheroid (one spheroid per well (5,000 cells/well)). Methylcellu-
lose was removed by repeated washes with medium. Reovirus infection was done 
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with an MOI911 ranging from 0 to 100 PFU per cell. Unless stated otherwise, the 
virus  concentrations (PFU/μl) were kept equal for SCCC cultures and spheroids. 
As the number of cells per well differed between the two cell culture methods, the 
 culture medium volume in the wells was adjusted to obtain the desired titer in 
PFU per cell. To count the number of cells per well, cells were dissociated using 
TrypLe Select (Gibco-BRL) and counted using a hemocytometer. The diameter of 
the spheroids was measured on an Olympus CK40 microscope, using an Olympus 
Camedia Digital Camera C-3030 and Olympus software; Olympus DP-soft.
Immunocytochemistry analysis
SCCC cultures
For immunocytochemistry analysis, SCCC cultures were grown on glass cover-
slips, fixed in 4% formaldehyde for 15 minutes at room temperature (RT), washed 
with PBS and further permeabilized in PBS containing 0.1% triton for 15 minutes. 
After exposure to blocking solution (10% goat serum in PBS) for 1 hour at RT, cells 
were incubated for 3 hours at RT with antibody 4F2 directed against reovirus σ3 
protein (monoclonal antibody [45], obtained from the Developmental Studies 
 Hybridoma Bank, maintained by The University of Iowa, Department of Biology, 
Iowa City, IA 52242), 1:200 diluted in blocking solution. After washing in PBS, the 
samples were incubated with polyclonal goat anti-mouse antibody conjugated 
with horseradish peroxidase (HRP) (P0447, Dako, Glostrup, Denmark), 1:50 in 
blocking solution, for 30 minutes at RT. After extensive washing, the cells were 
stained with a filtered 3,3’-diaminobenzidine (DAB) solution (10mg DAB dis-
solved in 10 ml PBS and mixed with 10 ml H2O and 10 μl 30% H2O2) under the 
 microscope and immersed in H2O after appearance of the brown colour. After 
 dehydration by incubation in increasing concentrations of ethanol (50-100%), the 
samples were briefly exposed to xylene and mounted in Pertex (Pertex Mounting 
Medium, Leica Biosystems, Wetzlar, Germany).
Spheroids
Spheroids were fixed overnight in 4% formaldehyde at 4°C, dehydrated and 
stained in an eosin solution (1% eosin in ethanol) for 10 minutes. After removing 
the excess of eosin by washing with 100% ethanol, spheroids were incubated 
twice in xylene for 15 minutes and embedded in paraffin. The paraffin blocks 
were sectioned in 6 μm thick slices on a microtome and after paraffin stretching in 
a 40°C water bath, transferred to Superfrost Plus slides (Thermo Fisher Scientific, 
Waltham, MA, USA) and allowed to dry. The slides were deparaffinised in 
 xylene, before rehydration of the samples by immersion in decreasing concentra-
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mM sodium citrate buffer (0.19 g citric acid monohydrate and 1.2 g trisodium 
 citrate dehydrate in 500 ml H2O) and maintaining the temperature just below the 
boiling point for 6 minutes. Samples were allowed to cool, washed twice in H2O 
and incubated in 0.3% H2O2 for 10 minutes. After a brief wash in H2O and PBS, 
samples were blocked and further processed as described above for the SCCC 
samples. Ki-67 protein staining was performed to detect proliferating cells. For 
this, uninfected spheroids were treated as outlined above, though incubated with 
a primary purified mouse antibody against human Ki-67 (BD Biosciences), 1:100 
diluted in blocking solution.
Electron microscopy analysis of the spheroids
Spheroids were fixed in 1.5% glutaraldehyde, postfixed in 1% osmium 
 tetroxide and subsequently en-block stained in 1% aqueous uranyl acetate. After 
dehydration in ethanol, the samples were embedded in Epoxy resin LX-112 (Ladd 
Research). Ultrathin 100-nm sections were prepared and post-stained with uranyl 
acetate and lead citrate for ultrastructural analysis. Electron microscopy images 
were obtained in an FEI Tecnai 12 BioTwin operated at 120 kV and equipped with 
an Eagle cooled slow-scan charge-couple device (CCD) camera (FEI Company, 
USA). A total of 3545 overlapping images were collected at a magnification of x 
6800 and binning 2 (pixel size of 3.2 nm at the specimen level) and stitched 
 together into a single virtual slide as previously described [46].
Flow cytometry analysis
Anti-JAM immunostaining
Adherent cell cultures of U-118 MG and U-118HA-JAM cells and spheroids of 
U-118 MG cells were prepared as described before. Three days post preparation of 
spheroids or SCCC cultures, cells were harvested by dissociating the cells using 
TrypLe Select. Cells originating from 24 wells were pooled and fixed by incuba-
tion in 4% formaldehyde for 15 minutes at RT. After washing cells in staining 
buffer (1% FBS, 0.09% w/v sodium azide in PBS, pH 7.5, filtered), cells were incu-
bated for 1 hour at RT with a 1:200 dilution of mouse monoclonal anti-JAM-A 
antibody (clone M.Ab.F11, Abcam, Cambridge, UK) in staining buffer. After 
washing, the cells were exposed to R-phycoerythrin (PE) fluorochrome-conju-
gated rat anti-mouse immunoglobulins (IgG1, BD Biosciences) for 30 minutes at 
RT in the dark, 1:100 diluted in staining buffer. Subsequently, the cells were 
washed extensively, resuspended in FACS buffer (0.5% BSA, 2mM EDTA in PBS) 
and  assayed on a BD LSRII flow cytometer, 10,000 events per sample. Data were 




To analyze the susceptibility to a reovirus infection, SCCC cultures and sphe-
roids of U-118 MG cells were prepared and infected with MOI911 of 10 or 100 PFU 
per cell. Three days post infection cells were dissociated, pooled and fixed as 
above, washed in staining buffer. After permeabilizing the samples in Perm/Wash 
Buffer (BD Biosciences, San Jose, CA, USA) for 15 minutes at RT, they were incu-
bated with primary antibody against reovirus σ3 protein, 1:200 diluted in Perm/
Wash Buffer for 1 hour at RT. Subsequently cells were washed and exposed to PE 
fluorochrome-conjugated rat anti-mouse antibody (IgG2a+b, BD Biosciences) for 30 
minutes at RT in the dark, 1:100 diluted in Perm/Wash buffer. After extensive 
washing, the samples were resuspended in FACS buffer and analyzed on the flow 
cytometer as described above.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA from SCCC cultures or spheroids of U-118 MG and U-118HA-JAM 
cells was extracted using the Absolutely RNA miniprep kit (Stratagene, La Jolla, 
CA, USA) according to the manufacturer’s protocol, upon sonification at 4°C of 
the spheroids. First-strand cDNA was generated with 100 ng total RNA using 
 SuperScript II reverse transcriptase (Life Technologies - Invitrogen, Carlsbad, CA, 
USA) and oligonucleotide hJAM_RT Rev (5’-CACCAGGAATGACGAGGTC-3’). 
The resulting cDNA was amplified in 30 cycli using oligonucleotide hJAM_RT 
Rev and hJAM For (5’-ATGGGGACAAAGGCGCAAGTC-3’) employing PFU 
DNA polymerase (Thermo Fisher Scientific – Fermentas) and visualized with gel 
 electrophoresis on a 1% agarose matrix together with plasmid pcDNA-HA-JAM 
as a positive control. As a loading control, 25 ng of total RNA was used to gener-
ate cDNA with oligonucleotide Hum_β-actin Rev (5’-TCCTTCTGCATCCTGTCG-
GGCA-3’). Amplification was performed using oligonucleotides Hum_β-actin For 
(5’-CAAGAGATGGCCACGGCTGCT-3’) and Hum_β-actin Rev.
Cell viability assay
Eight days post infection of SCCC cultures or spheroids the cell viability was 
assessed by replacing the culture medium by fresh medium containing 10% 
WST-1 reagent (Roche, Penzburg, Germany) in 12 wells per condition. After 1 
hour (for SCCC cultures) or overnight (for spheroids) the absorbance was meas-
ured in a microplate reader (Bio-Rad model 550, Bio-Rad, Hercules, CA, USA) at a 
wavelength of 450 nm. The viability measurements were normalized to the viabil-
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Analyzing high and low confluent adherent cells cultures
MG cells in low (split ratio 1 to 25), normal (1 to 10) or high (1 to 2.5) conflu-
ence in 6 well (high and normal confluence) or 24 well (low confluence) plates. 
Two days post preparation the cells were counted and infected as described 
 before Four days post infection the cells were harvested, fixed and assayed for 
reovirus expression on the flow cytometer or stained for immunocytochemistry 
analysis as described before.
Analyzing secretion products of spheroids
Semi confluent U-118 MG monolayers were grown in 6 well plates (flowcytom-
etry assay) or 96 well plates (viability assay) and infected with reovirus with an 
MOI ranging from 0 – 100 PFU per cell in fresh culture medium or culture-derived 
medium (isolated from SCCC cultures or spheroid cultures after 5 days of incuba-
tion). The percentage of reovirus infected cells was analyzed on the flow cytome-
ter. For viability analysis, cells were dissociated, at four days post infection, using 
TrypLe Select and seeded in 48 well plates using fresh medium. The next day, the 
viability of the cells was examined by WST-1 assay.
Reovirus incubation with conditioned medium or cathepsins
The effect of secretion products of spheroids on the virus was studied by incu-
bating 109 PFU reovirus with 1.5 ml fresh medium, or 5-day-old conditioned 
 medium from adherent cells or spheroids at 37°C. At 24 and 48 hours post incuba-
tion, 1 ml fresh or conditioned medium was added to the incubation, to ensure the 
presence of active secretion products. For determining the effect of cathepsins on 
the virus, 109 PFU reovirus was incubated with 12.5 μg cathepsin B or L in 
 cathepsin cleavage buffer (100 mM NaCl, 15 mM MgCl2, 50 mM sodiumacetate 
(pH 5.0) [47]. After 72 hours incubation, the solutions were loaded on a CsCl gra-
dient (1.55, 1.45 and 1.20 g/cm3 in PBS) and centrifuged as described before. The 
virus band was isolated and the CsCl was removed by Amicon filter purification. 
In the purification the volumes and conditions were standardized for all samples. 
The purified virus was added to semi-confluent cultures of U-118 MG cells at con-
centrations of 10 and 100 PFU/cell. Three days post-infection the percentage of 
reovirus-infected cells was analyzed by flow-cytometetry.
Measurement of cathepsin L and B activity
Enzymatic cathepsin L and B activity was examined in conditioned medium 
and cell lysates of SCCC and spheroid cultures with a Cathepsin B or Cathepsin L 
Activity Assay Kit (Abcam). After five days of culturing, cells and medium were 
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separated, medium was stored at 4°C and cells were counted. Cells were lysed in 
the kit’s lysis buffer and the lysate from two 96 well plates was pooled, centri-
fuged and protein content was measured using a BCA protein assay (Pierce, 
 Etten-Leur, The Netherlands). 50 μl of cell lysate or medium was assayed for 
 cathepsin B or L activity according to the manufacturer’s protocol.
Statistical analysis
The statistical significance of key data was assessed using GraphPad Prism V6 
by performing a the Student’s t Test. P-values below 0.05 were considered signifi-
cant.
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Tweaking Reovirus T3D to Boost the Oncolytic Potency
4.1 Abstract
Human Orthoreovirus Type 3 Dearing is not pathogenic to humans and has 
been evaluated clinically as oncolytic agent. Its transduction efficiency and the 
 tumor cell selectivity may be enhanced by incorporating ligands for alternative 
 receptors. However, genetic modification of reoviruses has been difficult and 
 genetic targeting of reoviruses has not been reported so far. Here we describe a 
technique for generating genetically targeted reoviruses. Propagation of wild-type 
reoviruses on cells expressing a modified σ1-encoding segment embedded in a 
conventional RNA-polymerase-II transcript leads to substitution of the wild-type 
genome segment by the modified version. This technique was used for generating 
reoviruses which are genetically targeted to an artificial receptor expressed on 
U118MG cells. These cells lack the Junction Adhesion Molecule-1 and therefore 
 resist infection by wild-type reoviruses. The targeted reoviruses were engineered 
to carry the ligand for this receptor at the C-terminus of the σ1 spike protein. This 
demonstrates that the C-terminus of the σ1 protein is a suitable locale for the 
 insertion of oligopeptides ligands and that targeting of reoviruses is feasible. The 
genetically targeted viruses can be propagated using the modified U118MG cells 
as helper cells. This technique may be applicable for the improvement of human 
reoviruses as oncolytic agent.
4.2 Introduction
Orthoreovirus Type 3 Dearing (T3D) has been evaluated clinically as oncolytic 
agent [1, 2]. The impetus for these studies has been the observation that reovirus 
T3D preferentially lyses tumor cells, especially those with an activated Ras-signal-
ing pathway [3-7]. The Reoviridae (Respiratory Enteric Orphan viruses) constitute 
a family of non-enveloped viruses with segmented double-strand (ds)RNA 
 genomes. The three types of human reoviruses have 10 genome segments and are 
classified in the genus Orthoreovirus. These viruses are not associated with 
 disease in humans. In newborn mice, however, these viruses can cause lethal 
 infections [8]. The Orthoreovirus Type 3 Dearing (T3D) is often studied and serves 
as a model for the family. Reovirus T3D enters the host cell through the interac-
tion of the spike protein 1 with its cognate receptor, the Junction Adhesion Mole-
cule (JAM-1). In addition, sialic-acid groups at the cell surface can act as receptors 
[9-13]. The JAM-1-binding amino acids are located in the C-terminal head domain 
of σ1 [11, 14-16]. After cell attachment, integrin-binding motifs in the capsid 
 protein λ2, which forms the structural base for σ1, bind β1 integrins and mediate 
96
CHAPTER 4
endocytosis [17]. Following endosomal escape viral replication ensues. Capped 
plus-strand RNA molecules are formed by transcription of the genome segments 
by the viral RNA-dependent RNA-polymerase. Plus-strand RNA molecules are 
used for translation and also associates with viral core proteins in special virus- 
induced cellular compartments, the so-called “viral factories” [18]. The packaging 
of the 10 genomic segments must be well orchestrated since each viral core must 
contain a single copy of each of the plus-strand transcripts. Recent studies suggest 
that sequences contained within the 130 nucleotides (nt) at the 5’ terminus serve 
as identity label for each of the segments [19]. Negative-strand synthesis takes 
place within the newly-formed core, yielding dsRNA segments. These can be 
 further transcribed, or included in maturing virions to be released by the infected 
cell [20-22]. The plus-strand RNAs contain the tetranucleotide sequence ‘GCUA’ 
at the 5’ end and the pentanucleotide sequence ‘UCAUC’ at the 3’ end, which may 
have a role in the encapsidation process [23]. 
The efficiency of reovirus-based oncolytic therapies is likely compromised by 
the scarcity of reovirus receptors on the surface of tumor cells. Freshly isolated 
 colorectal tumor cells resist T3D infection, probably due a lack of JAM-1 on their 
surface [24]. The transduction efficiency and the tumor cell selectivity of oncolytic 
viruses, such as adenoviruses, has been enhanced by genetically incorporating 
 ligands for alternative receptors [25]. However, genetic modification of reoviruses 
has been notoriously difficult. A few reports have been published on the genetic 
modification of member of the Reoviridae family [21, 26]. However, these systems 
are arduous and rather inefficient. Recently, a reverse genetics method has been 
described that relies on transfection of 10 different expression plasmids encoding 
all of the viral segments [27]. With this method a heterologous transgene was 
engineered into one of the genome segments. However, the genetic modification 
of capsid components to amend viral tropism was not reported.
Here we describe a new technique for genetically modifying reoviruses. The 
technique was used for generating targeted T3D variants carrying (His)6 tags at 
exposed positions in the head domain of the σ1 spike. Reoviruses carrying the 
1-(His)6 spikes, but not wild-type T3D, can infect genetically engineered U118MG 
glioblastoma cells displaying a single-chain antibody fragment (scFv-His) recog-
nizing the (His)6 tag as an artificial receptor on their surface. The (His)6-tagged 
reoviruses, in combination with the scFv-His-expressing U118MG cells, can serve 
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4.3 Results
The efficacy and specificity of oncolytic-virus approaches can be enhanced by 
targeting infection to tumor cells. The development of targeted reoviruses has 
been hampered by the difficulties in applying reverse-genetics procedures to the 
segmented dsRNA genomes of these viruses. Therefore we set out to develop a 
novel technique for generating such genetically targeted reoviruses (Figure 1). A 
cell line was selected that supports reovirus replication but resists infection due to 
FIGURE 1. 
Schematic representation of the selection system for a targeted reovirus.
The lentivirus vector LV-S1His was used to transfer a reovirus S1-expression cassette into 
911 cells. The resulting 911S1His cells produce the σ1 protein carrying the (His)6 tag at its 
C-terminus. Upon infection of the 911S1His cells with wild-type T3D, the  progeny viruses 
may carry a mixture of σ1-His and σ1 spike proteins in their capsid.  
As a consequence, these viruses can infect the U118scFvHis cells that display an  
anti-His-tag single chain-antibody on their cell surface which can serve as an artificial 
receptor. Unmodified U118MG cells resist reovirus infection. Sequential passaging of virus 
in U118scFvHis cells selects for viruses in which the wild-type S1 segment has been 
replaced by the heterologous S1His segment during replication in the 911S1His cells.
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the absence of reovirus receptors. This cell line was endowed with a cell-surface 
protein that can function as an artificial receptor. The codons for the peptide 
 ligand were engineered in a suitable position in one of the reovirus capsid pro-
teins. Finally, the genomic segment encoding this modified capsid protein was 
 introduced in the reovirus genome. 
JAM-1 deficiency underlies U118MG resistance to reovirus 
 infection
A cell line lacking reovirus receptors and, as a result resistant to infection, is 
crucial in the development of genetically retargeted reoviruses. Based on 
 published data [28], the human glioblastoma cell line U118MG was selected as a 
candidate. To confirm its resistance to reovirus infection, cultures of U118MG cells 
were exposed to T3D and assayed for cell viability (Figure 2A). The viability of 
U118MG cells was not affected by T3D, up to a multiplicity of infection (MOI) of 
100. In contrast, survival of the control cell line 911 declined significantly after 
 infection at a MOI of 0.001. The viability of the cells as measured by WST-1 assay 
strongly correlated with the induction of CPE (data not shown).
To determine whether the resistance of U118MG cells to T3D is due to the 
 absence of the reovirus receptor JAM-1 [9, 29, 30], RNA isolated from U118MG 
cells and 911 cells was assayed for the presence of JAM-1 mRNA by reverse 
 transcriptase-polymerase chain reaction (RT-PCR) using a JAM-1-specific primer 
set. The RNA from U118MG cells yielded no detectable PCR product (Figure 2B), 
confirming the absence of JAM-1. This was further corroborated by immunofluo-
rescence microscopy with JAM-1-specific antisera (data not shown). In contrast, 
JAM-1 mRNA was readily detectable in 911 cell-derived RNA (Figure 2B).
To study whether the absence of JAM-1 is the sole factor contributing to the 
 resistance of U118MG cells to T3D infection, U118MG cells were transduced with 
a lentiviral vector encoding Hemagglutinin (HA)-tagged JAM-1 (Figure 3). In 
another vector (LV-JAM-ECD) the extracellular domain (ECD) of JAM-1 was 
linked to a heterologous transmembrane domain, to formally rule out JAM-1- 
mediated signaling (Figure 2C). Parental U118MG cells and HA-JAM- or JAM- 
ECD-expressing U118MG cells were exposed to T3D and metabolically labeled 
with [35S]-Methionine to assess reovirus-protein synthesis, as an indicator for viral 
replication. No synthesis of reovirus proteins was observed up to 7 days post 
infection in U118MG. In contrast, synthesis of the reovirus proteins was detectable 
in the  HA-JAM- and JAM-ECD-expressing U118MG derivatives (Figure 2D). Note 
that host-protein synthesis is not fully shut-off by reovirus in U118MG cells. 
Taken  together, these data show that the absence of JAM-1 on the surface of 
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Expression of an artificial receptor on the surface of U118MG cells
As an artificial receptor that could be utilized by targeted reoviruses, we 
 exploited a single-chain antibody fragment specific for stretch of 6 C-terminal 
 Histidine residues (scFv-His) [31] as an artificial receptor for the reovirus T3D. 
FIGURE 2. 
U118MG cells resist reovirus infection due to a lack of JAM-1 expression.
A. U118MG cells survive reovirus infection. The viability of cultures of U118MG cells (•) 
and cultures of 911 cells ( ) infected with increasing amounts of reovirus T3D was 
 measured two days post infection by WST-1 assay.
B. hJAM-1 RNA is absent in U118MG cells. RNA from U118MG cells (U118) and 911 cells 
was isolated and used for cDNA synthesis with primer hJAM_RT rev (See Table 1).  
As a  positive control (+), a small amount of the pCDNA-HA-JAM plasmid was included 
in a PCR reaction (product length see Table 1). A β-actin-specific RT-PCR assay was 
 performed to confirm the integrity of the RNA.
C. Schematic representation of the HA-JAM and JAM-ECD proteins displayed at the cell 
membrane. 
D. Display of JAM-1 or its extracellular domain sensitized U118MG cells to reovirus T3D. 
Reovirus T3D-infected cells and mock-infected cells were labeled with [35S]- methionine 
once CPE became apparent, and protein samples were analyzed by SDS-PAGE. The 
 positions of the reoviral σ, μ, and λ proteins are indicated. JAM-1, junction adhesion 







This scFv is expressed on the surface of mammalian cells if linked to a transmem-
brane domain and has been previously used as an artificial receptor for propaga-
tion of recombinant adenoviruses [32]. The codons for scFv-His, linked to the 
transmembrane domain of the human PDGF receptor and an HA tag, were 
inserted in the vector pLV-CMV-x-IRES-Neo (Figure 3) and the resulting vector 
was used to transduce U118MG cells. Immunochemical staining confirmed homo-
geneous expression of the artificial receptor in the transduced U118MG cell popu-
lation (data not shown).
Modification of σ1 by adding a (His)6-tag to its C terminus
To produce σ1-variants, we opted to using a trans-complementation approach 
in which reovirus was propagated on a cell line producing one of the capsid com-
ponents. The virus may incorporate the modified component in its capsid during 
virus generation. To generate reoviruses with modified σ1-variants in its capsid, 
FIGURE 3. 
Lentiviral vectors used in this study.
The scheme represents the integrated lentiviral vectors. The vectors are derived from a 
self-inactivating, third-generation HIV-1 vector. Upon integration, the  vector loses its 
capacity to produce mRNA other than the mRNA derived from the transgene-expression 
cassette. The positions of the Rev-responsive Element (RRE), the central polypurine tract 
(cPPT), and the posttranscriptional regulatory element (PRE) are indicated. The transgenes 
were inserted upstream of the internal ribosome entry site (IRES) and the neomycin 
 phosphotransferase (Neo) selection marker. JAM is the cDNA encoding human Junction 
Adhesion Molecule. JAM-ECD encodes the  extracellular domain of JAM-1 fused to the 
PDGF transmembrane domain. scFvHis  represents the single-chain antibody directed 
against the (His)6 tag. S1His is a  modified cDNA of the reovirus T3D S1 segment in which 
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911 cells were generated that stably express a modified S1 gene segments. The S1 
genome segment was cloned from wild-type reovirus T3D-infected 911 cells, 
using primers chosen on the basis of the published S1 sequence [33]. The deduced 
σ1 amino-acid sequence of the S1 genome segment cloned from the ATCC VR-824 
T3D reovirus batch was found to differ from the published S1 sequence at two 
 positions, Ile246 to Thr and Thr249 to Ile. These mutations are known to abolish a 
trypsin-sensitive site in the σ1 shaft [34]. 
The codons for (His)6 tag were inserted by mutation PCR downstream of the 
triplet encoding the C-terminal Thr of σ1. The resulting recombinant S1-genome 
segment encoding (His)6-tagged σ1 (S1His) was inserted into a lentiviral vector 
(Figure 3). This vector was used to generate 911 cells which stably express S1His. 
TABLE 1.
Primers used in this study.
Abbreviations: JAM-1, junction adhesion molecule-1; RT-PCR, reverse transcription-PCR. 
The primers used in this study and fragment lengths of the PCR products expected with the 
designated primer combination are shown. The restriction sites (primers 4 & 5) and the 
codons for the (His)6 tag (primer 6) are underlined.








 Detection hJAM For  1 5’-ATGGGGACAAAGGCGCAAGTC-3’
hJAM_RT Rev  2 5’-CACCAGGAATGACGAGGTC-3’ 1+2  928
S1 
 Cloning ReoS1 For  3
5’-CCAAGCTTGCTATTGGTCGGATG-
GATCCTCG-3’
ReoS1Rev  4 5’-ATTGCGGCCGCGAT-GAAATGCCCCAGTGCCG-3’ 3+4  1435
His-tag 





SigmaEnd Rev  6 5’-GATGAAATGCCCCAGTGCCGCG-GGGTGGTCTGATCCTCA-3’ 3+6  1442
S1His  
RT-PCR S1endR  7 5’-GATGAAATGCCCCAGTGC-3’ 3+7  1442




For  9 5’-CAAGAGATGGCCACGGCTGCT-3’
Hum_ β-actin 
Rev  10 5’-TCCTTCTGCATCCTGTCGGGCA-3’ 9+10  275
JAM-ECD 
 cloning JamDP For  11
5’-TGTACTGCAGTGCACTCTTCT-
GAACCTGAAGT-3’




Characterization of the 911S1His cell line.
A. Immunofluorescence assay demonstrating the presence of the -His protein in 911S1His 
cells. The mouse -His antibody and FITC-coupled Goat-anti-Mouse sera (green) were 
used to detect the 1-His protein in the LV-S1His-transduced 911 cells. The nucleus is 
stained with DAPI (Blue).
B. Schematic representation of S1His-expression cassette after lentivirus-mediated gene 
transfer. The region coding for 1 is indicated by the open box. The primers used in the 
PCR assay and the expected PCR products are indicted. H represents the position of the 
(His)6 tag (see Table 1 for the sequence of the primers).
The synthesis of the (His)6-tagged σ1 (σ1-His) in the polyclonal 911S1His cell lines 
was verified by immunofluorescence (Figure 4A), RT-PCR (Figure 4B-C, and 
Table 1), and Western-blot analysis (Figure 4D). The staining pattern of σ1-His 
(Figure 4A) is reminiscent of the morphology of the viral factory [8, 35]. These 
data led us to conclude that σ1-His protein was produced in the transduced cells.
Reovirus pseudotyping by modification of σ-1
To evaluate whether the σ1-His protein was incorporated in the capsid, the 
911S1His cells were infected with wild-type T3D, and the virus was passaged 
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 tropism. To test the tropism U118MG, U118HA-JAM and U118scFvHis cells were 
infected with either wild-type T3D or with T3D from the 3rd passage on 911S1His 
cells. T3D harvested from 911S1His cells, but not wild-type T3D virus, could 
 infect and lyse U118scFvHis cells (Figure 5A). The cell-viability assay confirmed 
that U118MG cells resist the σ1-His containing T3D, and showed survival of 10% 
of the U118HA-JAM cells at 3 days after exposure to the 911S1His-cell derived 
T3D. U118scFvHis cells exposed to the σ1-pseudotyped T3D showed a drop of 
55% in viability (Figure 5B). These data demonstrate that the 911S1His-derived 
reovirus can infect U118MG cells that express the scFvHis as an artificial receptor. 
From these results, we conclude that σ1-His is incorporated in the reovirus capsid, 
that the (His)6 tag is accessible to the artificial receptor, and that interaction of this 
tag with its receptor leads to productive infection. 
Selecting a genetically modified reovirus
Recent data suggest that the sequence motifs that facilitate assortment and 
packaging of the reovirus segments are contained within a 130 nt region at the 5’ 
end of reoviral RNAs [19]. This region is also present in the heterologous tran-
scripts produced in 911S1His cells. If the reoviral signals in the LV-S1His-derived 
σ1-His-encoding transcripts are functional, these transcripts should associate with 
newly formed cores and replace the wild-type S1 segment in the progeny virus. 
FIGURE 4. 
Characterization of the 911S1His cell line.
C. RT-PCR to detect S1 RNA in 911S1His cells. Reverse transcription of 911S1His and  
911-cell RNA was performed using primer S1endR. The plasmid pRT3S1His was used  
as a positive control for the PCR analysis which used the primers indicated in (B). 
 Positions of the primers in the S1 segment as well as the expected PCR products  
S1F-E and S1F-His are indicated in (B).
D. Western analysis demonstrating the presence of the 1-His protein in 911S1His cell 
lysates. 1-His protein was detected with the Penta-His antibody. DAPI, 4’,6-diamidi-




To test this hypothesis, we harvested the virus progeny from the U118scFvHis 
cells that were infected with 1-pseudotyped T3D. If the particles contain the S1His 
genome segment, it should be possible to propagate them on U118scFvHis cells. 
Indeed, a metabolic labeling experiment performed at three days post infection 
showed that the reovirus particles produced in U118scFvHis cells could again 
 infect U118scFvHis, in contrast to unmodified T3D (Figure 6A). The propagated 
virus, which was named T3D-S1His, was passaged 11 times and maintained the 
1-His protein as assayed by Western blotting (Figure 6B). The presence of the 
(His)6-tag was also confirmed by sequence analysis of cloned RT-PCR products 
(Figure 7). These data suggest that S1His segment is incorporated as a genome 
segment in T3D, and expanded its tropism. 
Selection for the (His)6-tag co-selects other alterations in genome 
segment S1
So far we demonstrated that the (His)6 tag of the S1 segment is incorporated in 
the reovirus. To test whether selection for the presence of the (His)6 tag could be 
used for selecting other mutations in the same segment, we repeated the selection 
experiment with the T3D laboratory strain R124. Because the nucleotide sequence 
FIGURE 5. 
Pseudotyping of T3D reovirus after propagation in 911S1His cells.
A. CPE induction in cultures of U118scFvHis and U118HA-JAM cells, but not U118MG cells, 
infected with reovirus T3D harvested from 911S1His cells. Photos of CPE were taken 
three days post infection.
B. Cell viability of U118MG, U118HA-JAM and U118scFvHis cells, as measured by WST-1 
assay, three days after infection with reovirus T3D harvested from 911S1His cells. The 
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of S1 from R124 differs in two nucleotides from that used to construct LV-S1His 
(Figure 7). This allows distinguishing the origin of the S1 sequences in the result-
ing T3D-S1His independent of the His tag sequences. After three passages of 
R124 on 911S1His cells, the virus was harvested and used to infect U118MG, 
U118HA-JAM, and U118scFvHis cells. CPE was observed in U118HA-JAM and 
U118sc FvHis cell cultures but not in the infected U118MG cultures. In contrast, 
non-pseudo-typed R124 only induced cell death in U118HA-JAM cells (data not 
shown). 
The virus produced in the U118scFvHis cells was passaged for 6 times on this 
cell line. The resulting virus, named R124-S1His, was used again to infect 
U118scFvHis cells. After confirming the presence of the (His)6-tagged σ1 (Figure 
FIGURE 6. 
Selection of genetically stable T3D-S1His reovirus stock on U118scFvHis cells.
A. U118scFvHis cells synthesize reovirus proteins upon infection with T3D-S1His.
 [35S]-Methionine-incorporation assay were performed three-days post infection on 
U118scFvHis and U118HA-JAM cells infected with wild-type reovirus T3D (wt),  
T3D-S1His 740 (SH) reoviruses, or mock-infected (m), respectively.
B. 1-His is present in S1His reovirus batches as evidenced by Western analysis of 
 reovirus-containing lysates. Western analyses were performed on different viral lysates 
for the presence of the (His)6-modified 1 using the anti His-tag serum. T3D depicts a 
lysate of the unmodified reovirus T3D. Sel9 -11 represents T3D reovirus  lysates 
 propagated for 9 to 11 passages on U118scFvHis cells. Loading controls using the 
 antibody 7F4 against reovirus λ2 are depicted in the upper panel. (His)6-tagged σ1 




8A), RNA was isolated from infected cells and the S1 segments were cloned after 
 RT-PCR amplification. Sequence analysis confirmed the presence of the (His)6-tag 
encoding sequence. All clones have a sequence identical to the cloned S1His, 
 rather than the R124-S1, at the positions which differ between isolates (Figure 8B 
and C). These data suggest that selection for the presence of the (His)6 tag leads to 
incorporation of the entire S1 segment into reovirus particles. A few additional 
changes were found in the 1 encoded by the S1 of R124-S1His (Figure 7). This can 
be attributed to the RNA-dependent RNA polymerase’s relative lack of fidelity 
[36]. Taken together, our data are consistent with a mechanism in which the  entire 
S1 genome segment is replaced by the S1His segment. 
Selective infection of cells in a mixed population by a targeted 
 reovirus
To verify that genetically targeted reoviruses could be used to selectively erad-
icate specific cells in a mixed population, U118scFvHis cells were plated with 
U118-eGFP cells to represent target and non-target cells, respectively. A number 
of these mixed cultures were exposed to the R124-S1His virus at an MOI of 1.5 at 
various time points after infection the relative number of eGFP-positive cells was 
determined by flow-cytometry (Figure 8D). The relative number of eGFP-positive 
cells increased more than 5.4-fold in comparison with mock-infected cultures at 96 
hrs post infection. These data demonstrate selective eradication of sensitized cells 
by a genetically-targeted reovirus. 
4.4 Discussion
Reverse genetics in RNA viruses with segmented genomes has been techni-
cally challenging. For Reoviridae, this is due, at least in part, to the difficulties in 
achieving sufficient quantities of non-poly-adenylated plus-strand reovirus 
RNA’s in the cytoplasm of mammalian cells. The previously described methods to 
FIGURE 7. 
Amino-acid sequence of different σ1 and σ1-His proteins.
The amino-acid sequence alignment of σ1 (455 aa) and σ1His (461 aa) is shown.  
The upper sequence (1[pub]) is the published sequence of σ1 (accession number 
gi|333742|gb|M10262.1). R124 is our lab strain of reovirus T3D. The isolate was purified 
from the VR-824 stock obtained from the ATCC by two rounds of plaque purification on 
911 cells. σ1His (cloned) is the sequence in pRT3S1His. σ1His RT1 and 2 are two RT-PCR 
 amplified clones from the ATCC-T3D-derived T3D-S1His viruses. σ1His RT3 and 4 are 
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manipulate reovirus genomes either involve transfection of RNA synthesized in 
vitro, or employ T7 polymerase-driven expression cassettes [21, 26, 27]. In these 
techniques, ribozymes generate transcripts with 3’ ends that are identical to nor-
mal segment termini. In general, such transcripts are unstable since they lack a 
 poly-A tract [21, 26, 27]. Here we show that also polyadenylated transcripts gener-
ated with a conventional RNA polymerase II expression cassette can be used to 
replace a genome segment. A transcript containing a modified copy of the reo-
virus T3D S1 segment, encoding a (His)6-tagged version of the spike protein σ1, 
was stably expressed. This protein was capable of binding a single-chain antibody 
fragment for oligo (His) tags. Propagation of wild-type T3D on cells producing 
1-His led to its incorporation into reovirus capsids. A similar strategy has been 
previously used for other capsid proteins of reoviruses [37] and other non-envel-
oped viruses such as adenoviruses [38, 39]. However, if the genetic sequences 
encoding the modified capsid protein are not encapsidated, the altered targeting 
specificity would be lost after a single round of replication. 
The transcripts encoded by the lentivirus vector LV-S1HIS contain all genetic 
information and most likely also the structural information contained within the 
S1 segment, e.g. the motifs regulating plus- and minus-strand synthesis. We 
hypothesized that these transcripts would be targeted to the “viral factories” and 
here associate with newly-formed viral cores. Furthermore, if the signals for 
FIGURE 8. Selection of R124-S1His reoviruses on U118scFvHis cells.
A. The 1-His protein is present in lysates of R124-S1His reoviruses serially passaged on 
U118scFvHis cells. R124 is a lysate of the plaque-purified T3D reovirus. Sel 4-6 depict 
R124-S1His reovirus lysates isolated after the indicated number of passages on 
U118scFvHis cells. Upper panel: Western blot analysis for 2. The presence of λ2 was 
 confirmed by western blotting using the 7F4 specific for λ2. Lower panel: Western 
 blotting demonstrates the presence of (His)6-tagged σ1 with the Penta-His antibody  
in the R124-S1His virus.
B. Nucleotide differences distinguish the cloned S1His sequence and the R124 S1  sequence. 
The amino acids coded by codons at positions 749 and 758 of the R124-S1 create a 











Tweaking Reovirus T3D to Boost the Oncolytic Potency
minus -strand synthesis [22, 40] are functional, the S1 part of the lentiviral tran-
script should be converted in dsRNA. Secondary transcription of this dsRNA 
would lead to S1 segments with authentic termini. Our results propagating the 
T3D-S1His variant support these hypotheses. 
Based on our hypothesis, we anticipated that the entire LV-S1His-derived 
 genome segment, rather than only the region encoding the (His)6 tag, would 
 become incorporated into the virion. This was confirmed using the R124 strain in 
the selection. The reovirus selected after infection of the U118scFvHis with the 
R124 strain propagated in 911S1His cells contained the sequence of the (His)6-
FIGURE 8. Selection of R124-S1His reoviruses on U118scFvHis cells.
C. Sequence analyses depict the differences at nucleotides 747-760 of RT-PCR clone 
 R124-S1His RT4 and R124. Arrows represent the nucleotide differences at position  
749 and 758.
D. The R124-S1His reovirus specifically eradicates the U118scFvHis cells from a mixed 
 population. A mixture of U118scFvHis and U118-eGFP cells were infected with  
R124-S1His reovirus at an MOI of 2, and samples were taken for flow-cytometric  
analyses at the indicated times after the infection. Represented is relative frequency  
of GFP-positive cells in the virus-infected cultures relative to mock-infected  cultures. 
These data show that the relative frequency of the R124-S1His-resitant eGFP- positive 
cells increased more than 10-fold upon selective eradication of the cells which are 
 sensitive to the targeted reovirus. GFP, green fluorescent protein; MOI, multiplicity of 




tagged-1 encoding segment instead of the S1 from R124 at the isolate-specific posi-
tions. These findings are consistent with the model that the entire S1His segment 
is derived from the transcript specified by LV-S1His. 
This approach may prove useful for improving reoviruses as oncolytic agents. 
To date, only wild-type T3D has been used in clinical trials [1, 6, 41]. The results of 
this approach are encouraging and the procedure is well tolerated. However, the 
scarcity or inaccessibility of reovirus receptors on the surface of tumor cells may 
limit the efficacy of wild-type reoviruses as oncolytic agents. We recently reported 
that cultures of colorectal tumor cells isolated from resected tumor material resist 
reovirus infection, despite the presence of JAM-A [24]. This is likely attributable to 
the insufficient expression of reovirus receptors at their plasma membranes since 
T3D-derived infectious sub-viral particles, which are known to enter cells inde-
pendent of JAM-1 and sialic acid, efficiently infect and lyse these cells. Further 
 development of the approach presented here should allow modification of reo-
viruses to enhance tumor cell transduction and reduce the infection of non-target 
cells. This will increased the safety and efficacy of anticancer strategies using reo-
viruses as oncolytic agents.
We have developed a simple technique to genetically-modify reoviruses, and 
identified the C-terminus of σ1 as a good location for insertion of a targeting 
oligo peptides. Moreover, the (His)6 tag at the C-terminus of σ1, in combination 
with the U118scFvHis cells allowed the construction of reoviruses that do not 
depend on JAM-1 for attachment and cell entry. Furthermore the development of 
 tumor-targeted reoviruses can benefit from the experience with targeted adeno-
viruses, especially since the spatial structure of the reovirus spike is remarkably 
similar to the adenovirus fiber [42].
This reovirus genetic-modification technique developed in this study may be 
widely applicable. It may be adapted for other reovirus genome segments [43]. 
This would allow generation of defined mutants for gaining insight in the intri-
cate interactions between the reoviruses and their hosts, and to address questions 
about virus structure, function, and pathogenesis. The strategy may be amendable 
for use in other Reoviridae. Although from the family name one may get the 
 impression that all its members are “orphan” viruses, some of them cause severe 
diseases and have considerable economic impact. Members of its genera Orbivirus 
and Coltivirus cause diseases of humans, e.g. Colorado tick fever, and of domestic 
livestock, e.g. African horse sickness, and bluetongue disease [44]. Moreover, 
members of the genus Rotaviruses are the major etiologic agents of serious diar-
rhea in children under 2 years of age [45]. In these genera, too, this reverse genet-
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4.5 Materials and methods
Cell lines 
911 cells are adenovirus type 5 early region 1-transformed human embryonic 
retinoblasts [46]. U118MG human glioblastoma cells were obtained from Dr. B. de 
Leeuw (Erasmus Medical Center, Rotterdam, The Netherlands). All cell lines were 
cultured in Dulbecco modified Eagle medium (DMEM; Invitrogen, Breda, The 
Netherlands) supplemented with penicillin, streptomycin, glucose, and 8% Fetal 
Bovine Serum (FBS; Invitrogen), unless otherwise specified. Cells were cultured in 
a 5% CO2 atmosphere at 37°C. 
Reovirus propagation
911 cells were used to propagate wild-type T3D (American Type Culture Col-
lection, VR-824) as described previously [47]. Briefly, cells were exposed to reo-
virus in DMEM/2% FBS for 2 hours at 37C, 5% CO2. Subsequently, the inoculum 
was replaced by DMEM containing 8% FBS. The virus was harvested 48 hours 
post infection by resuspending the cells in phosphate-buffered saline (PBS) with 
2% FBS and subjecting the suspension to three cycles of freezing and thawing. The 
sample was cleared by centrifugation for 10 minutes at 800x g. Where indicated, 
the virus was further purified by CsCl equilibrium centrifugation essentially as 
described [46]. In some experiments the R124 clonal isolate was used. This isolate 
was purified from the VR-824 stock obtained from the ATCC by two rounds of 
plaque purification on 911 cells. The infectious reovirus titer was determined by 
plaque assay on 911 cells.
Cell viability assay
WST-1 reagent (Roche, Woerden, The Netherlands) was used to assay the 
 viability of cells after reovirus infections. Cells were infected with different 
amounts of reovirus in 96-well plates and WST-1 reagent was added, according to 
the manufacturer’s instructions, at various time points post infection. 
Cloning of T3D S1 from infected 911 cells
911 cultures were infected with to wild-type reovirus T3D at an MOI of ~2 
plaque-forming units (PFU)/cell. Total cellular RNA was extracted 24 hours 
post-infection using the Absolutely RNA miniprep kit (Stratagene, Huissen, The 
Netherlands). First-strand cDNA synthesis employed the ReoS1 Rev primer, using 
SuperScript II reverse transcriptase (Invitrogen). PFU polymerase (Promega, 
 Leiden, The Netherlands) was used for template amplification. See Table 1 for 
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 details about the primers and the PCR fragments. The PCR product was purified 
from a 1% agarose gel using the JetSorb kit (Genomed, ITK Diagnostics, Uithoorn, 
The Netherlands). The product was digested using Hind III and Not I, and cloned 
into the plasmid pCDNA3.1+ (Invitrogen) digested with the same enzymes, 
 yielding plasmid pRT3S1. The sequence of the insert was verified at the Leiden 
 Genome Technology Center.
To insert the codons for the (His)6-tag at the C-terminus of σ1, the σ1-coding 
region was PCR amplified with primers HisReoS1_Rev and ReoS1_For (Table 1). 
The PCR product was digested with HindIII and ligated to HindIII-and EcoRV- 
digested pCDNA3.1+. The resulting plasmid was used as template for PCR ampli-
fication with primers SigmaEnd_Rev and ReoS1_For and, after digestion with 
HindIII, ligated into Hind III and EcoRV-digested plasmid pCDNA3.1+, generat-
ing plasmid pRT3S1His. 
The sequences of all the constructs described in this study are available on 
 request.
RT-PCR
Primers used for the RT-PCR procedures are listed in Table 1. For the detec-
tion of human JAM-1 RNA , 911 cells and U118MG cells were seeded on 5 cm 
dishes and total cellular RNA was isolated using the Absolutely RNA miniprep 
kit (Stratagene). In all cases, SuperScript II was used to generate first-strand 
cDNA. For the characterization of the 911S1His cell line, total cellular RNA was 
extracted from confluent cultures of 911 and 911S1His cells, as described above. 
For the  detection of S1His in reovirus batches, infections of 911 cells were 
 performed. RNA was isolated 24 hours after infection and used for RT-PCR 
amplification. The resulting PCR products were cloned into plasmid pTOPO-TA 
(Invitrogen) and their DNA sequences were determined.
Production of lentiviral vectors
All lentiviral constructs used in this study were based on the pLV-CMV-x-
IRES-Neo vector [48] (see Figure 3). The S1His region of plasmid pRT3S1His was 
released by Eco105I and XbaI digestion and inserted in the same restriction sites of 
pLV-CMV-x-IRES-Neo. To generate the HA-JAM lentiviral expression vector, 
plasmid pCDNA-HA-JAM [49] (kindly provided by Dr. U.P Naik, Delaware, 
 Newark) was digested with Eco105I and XbaI and inserted in pLV-CMV-BC-Neo. 
Plasmid pLV-JAM-ECD-IRES-Neo was made by first inserting the codons for the 
extracellular domain of JAM into pDisplay (Invitrogen) and cloning the Eco105I - 
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as template to amplify the JAM-ECD (see Table 1). To generate pLV-scFvHis-
IRES-Neo, encoding the anti-His tag single-chain antibody fragment, pHissFv.rec 
[32] (a kind gift from Dr. D.T. Curiel, Univ. of Alabama) was digested with 
Eco105I and XhoI and inserted in the pLV vector. Production of the lentiviral 
 vectors and transduction of the cells were performed as described previously [48, 
50]. The LV-S1His vector was used for transducing cultures of 911 cells at an 
 estimated MOI of 0.5. The polyclonal, G418-restistant cell population, referred to 
as 911S1His cells were used for further studies.
Generation of modified reoviruses carrying the S1His segment
Wild-type reoviruses were used to infect 911S1His cells according to routine 
procedures. After three rounds of propagation, the resulting σ1-His containing 
 viruses were harvested by freeze thawing and used to infect U118scFvHis cells. 
The virus produced in U118scFvHis cells was harvested at the first signs of CPE, 
and serially passaged several times in U118scFvHis cells.
[35S]-Methionine labeling
Infected or mock-infected cells were incubated with Redivue [35S]-Methionine 
Pro-mix (200 μCi/ml; Amersham, Roosendaal, the Netherlands) for 4 hours at 
 various time points post infection. Cells were washed once with PBS and lysed in 
Giordano Lysis Buffer (50 mM Tris-Cl [pH=7.4], 250 mM NaCl, 0.1% Triton, 5 mM 
EDTA) containing protease inhibitors (Complete mini tablets, Roche Diagnostics, 
Almere, The Netherlands). All labeling assays were performed in 24-wells plates 
with 5 μl Pro-mix per well. The cells were lysed with 100 μl lysis buffer per well. 
Fifty μl of the lysates was loaded on a 10% SDS-Polyacrylamide gel after addition 
of sample buffer. Gels were dried and exposed to a radiographic film to visualize 
the labeled proteins. 
Immunofluorescence assay
For immunofluorescence assays, cells were grown on round glass cover slips in 
24-well plates, fixed with methanol, washed with PBS containing 0.05% Tween-20, 
and incubated with a primary antibody against the oligo (His) tag primary anti-
body (Sigma Aldrich, Zwijndrecht, The Netherlands). The coverslips were washed 
and incubated with secondary fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse serum for 30 minutes at room temperature. The mounting solution 
consisted of glycerol containing 0.02 M Tris-HCl [pH=8.0], 2.3% 1,4-diazabicyclo -





Cell lysates were made in Giordano lysis buffer (50 mM Tris-HCl pH 7.4, 250 
mM NaCl, 0.1% Triton, 5 mM EDTA) supplemented with protease inhibitors. Reo-
virus lysates were prepared by adding 15 l of cleared reovirus to 5 l of Western 
sample buffer (final concentrations: 10% glycerol, 2% SDS, 60 mM Tris-Cl [pH 
6.7], 2.5% -mercaptoethanol, and 2.5% bromophenol blue). After incubation for 3 
min at 100C, the samples were analyzed on SDS 10% polyacrylamide gels. The 
proteins were transferred to Immobilon-P (Millipore, Etten-Leur, The Nether-
lands) and visualized using standard protocols. Primary antibodies used were the 
Penta-His antibody (Qiagen, The Netherlands) for detection of the (His)6 tag, 7F4 
directed against reovirus protein λ2 [51] (kindly provide by Dr. K. Tyler, Univer-
sity of Colorado Health Science Center, Denver, Colorado). The secondary anti-
body used was HRP-conjugated Goat anti-Mouse IgG (Santa Cruz Biotechnology, 
Santa Cruz, USA). 
Selective eradication assay
U118MG cells were transduced with a lentiviral vector encoding the eGFP 
gene [50]. The resulting U118eGFP cells were mixed with U118scFvHis cells and 
seeded in 6-well plates. The mixed cultures were either mock infected, or infected 
with R124-S1His (MOI of ~ 1 PFU/cell). At the indicated time points after the 
 infection, the co-cultures were trypsinized and the cells were collected in PBS. 
These cell suspensions were analyzed for eGFP activity using a BD LSRII flow 
 cytometer and BD FACSDiva software (BD Bioscience, Breda, The Netherlands).
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5.1 Abstract
The capacity to modify the reovirus genome facilitates generation of new 
 therapeutic reoviruses. We describe a method for generating replication-compe-
tent reoviruses carrying an heterologous transgene. The strategy is based on the 
expanded-tropism reovirus mutant jin-3, which can infect cells independent of the 
reovirus receptor JAM-A. Jin-3 harbors a mutation in the S1 segment resulting in a 
G196R substitution in the tail of the spike protein σ1. The use of the jin-3 tail- 
encoding S1 segment allows replacing the codons for the JAM-A-binding head 
domain by up to 522 nt of foreign sequences, without exceeding the size of the 
wild-type S1 segment. We inserted the codons for the porcine teschovirus-1 2A 
element fused with those encoding the fluorescent protein iLOV. Replicating 
rS1His-2A-iLOV reoviruses were generated by co-transfection of expression 
 plasmids for all reovirus segments. These reoviruses contain the S1His-2A-iLOV 
segment in  absence of the wild-type S1 segment. Density-gradient centrifugation 
confirmed the association of the σ1-tail fragment with the capsid. Both JAM-A 
positive and JAM-A negative cells exposed to the rS1His-2A-iLOV reoviruses 
exhibited iLOV fluorescence, confirming the jin-3 derived expanded-tropism 
 phenotype. These data demonstrated the feasibility of generating decapitated rep-
lication-competent T3D reoviruses carrying a heterologous transgene.
5.2 Introduction
Mammalian orthoreoviruses are non-enveloped viruses with a segmented 
 double-stranded RNA (dsRNA) genome. The name Reovirus is an acronym of 
 Respiratory and Enteric Orphan virus. So far the virus has not been associated 
with severe pathology in humans, hence its designation as an orphan virus. In cell 
culture reovirus infection initiates a lytic replication cycle. The reovirus preferen-
tially infects and lyses transformed cells. This has been attributed to the stimulat-
ing effects of the active RAS-signaling on virus uncoating, replication, egress, and 
the induction of apoptosis [1-4]. The reovirus’ preference for transformed cells 
and the absence of pathology in humans have led to the development of reovirus 
Type 3 Dearing as a viral oncolytic agent for clinical use in a number of cancer 
types [5, 6]. The results of the clinical trials published so far demonstrate that the 
reovirus- administrations are well tolerated. Moreover, evidence of anti-tumor effi-
cacy has been acquired. Nonetheless, the antitumor efficacy could be improved. 
This may be accomplished by increasing the infection efficiency in tumor cells and 
by increasing the oncolytic potency of the virus. Here we describe an approach to 




The mammalian reovirus genome consists of ten double stranded RNA 
 segments, making genetic modification of the reovirus genome especially difficult. 
The development of plasmid-based reverse genetic systems for mammalian reo-
viruses facilitated the development of reverse genetics approaches [7]. However, 
there is limited information available regarding locations in the genome that 
could accommodate the insertion of new protein coding genes without compro-
mising the virus’ capacity for autonomous replication. So far, small exogenous 
 sequences have been successfully added to the genome segments S1, S3, M1 and 
L1 [8-10]. Insertion in these locations increases the size of the genome segments 
and this may compromise the genomic stability of the modified reoviruses. Others 
report the replacement of the open reading frame (ORF) from some of the seg-
ments by heterologous genes, but this yields replication-incompetent reoviruses 
that require trans-complementation of the deleted functions for propagation in 
helper cells [7, 11]. Here, we present the generation of replication-competent reo-
viruses carrying the sequence encoding the fluorescent protein iLOV within the S1 
segment.
In our approach we employed a feature of the jin mutants of the Type 3 Dear-
ing reovirus. The jin mutants were obtained upon serial passaging of the T3D reo-
virus on glioblastoma cells that lack expression of the high-affinity reovirus 
 receptor Junction-Adhesion Molecule A (JAM-A) [12]. The absence of JAM-A 
 expression makes these cells non-permissive for wt reovirus infection in mono-
layer cultures [13]. The jin mutants could productively infect a variety of JAM-A 
negative cells. All jin mutants harbor mutations in the S1 segment close to the 
 region previously identified as the sialic acid-binding domain in the tail of the 
 trimeric spike protein σ1 [14, 15]. This suggests that the jin mutants do not require 
the presence of the head domain for cell entry. 
We used the S1 segment of reovirus jin-3, which harbors only one point muta-
tion that results in a G196R change in the tail of the σ1-spike. To reduce the size of 
the S1 segment, the σ1 protein was truncated after amino acid 252. This allows 
inserting transgenes up to a length of 470 nt without exceeding the length of the 
wild-type S1 segment. The ORF of the nonstructural protein σ1s, which entirely 
overlaps the σ1 ORF, but is read from another reading frame, is left intact. 
 Although in different field isolates of T3 reoviruses the amino acid sequence of 
the σ1s is more heterogeneous than that of σ1, some regions are conserved [16]. 
The role of σ1s in the reovirus replication cycle has not yet been fully elucidated, 
but evidence suggests that it is involved in virulence and apoptosis [17] and is 
 required for induction of G2/M cell cycle arrest in some cell lines [18, 19]. 
In our study we have used the small fluorescent protein iLOV as the reporter 
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 sensing domain of the blue-light receptor phototropin 2 of Arabidopsis thaliana. 
The protein contains the flavin mononucleotide (FMN) as chromophore. The 
small size (~330 nt) of the synthetic codon-optimized gene encoding the iLOV 
 fluorescent protein makes it a suitable reporter for our approach. 
Here we show how a synthetic transgene-containing segment can be incorpo-
rated in the genome of a mammalian reovirus without compromising the replica-
tive capacity of the resulting recombinant virus. Furthermore we demonstrate that 
the codons of the head domain of the spike protein σ1 can be replaced by a small 
transgene, and that the transgene is expressed. The reoviruses carrying the σ1-tail 
of jin-3 and the transgene on the S1 segment retained their capacity to infect 
JAM-A deficient cells. This technique may facilitate the development of new repli-
cation competent-recombinant reoviruses armed with a therapeutic transgene for 
oncolytic virus therapy. In addition this approach may be exploited for the gener-
ation of new reovirus-based life-virus vaccines.
5.3 Results
Generation of the rS1His-2A-iLOV reoviruses
The jin reoviruses infect cells through an interaction between the tail domain of 
the reovirus spike protein and sialic-acid residues at the cell surface. This observa-
tion, together with the notion that the head domain is not essential for trimeriza-
tion of σ1 molecules [21], led us to postulate that in jin viruses the head domain of 
the spike protein could be replaced by transgene sequences. To test this hypothe-
sis, the codons for the head domain of σ1 were replaced by the iLOV-coding 
 region in the S1 segment of jin-3. The trypsin cleavage site, which is present in the 
tail domain of the σ1 protein of the wtT3D reovirus was retained in our modified 
variant (Figure 1). Trypsin cleavage occurs after the arginine residue at position 
245 of the T3D-σ1 protein [22]. This cleavage is important in the formation of 
Infectious Subvirion Particles (ISVP’s) and can be of importance during the prote-
olytic disassembly [23].
The modified S1 segment encodes only the tail of σ1 (amino acids 1 - 252), 
 followed by a 6xHis tag, the porcine teschovirus-1 2A sequence (2A), and the 
iLOV coding sequence. The ORF is 1176 nt long (ORF of S1-wt is 1377 nt) and is 
followed by 198 nt of the 3’ region of S1. The latter region contains sequences 
reported to be involved in encapsidation [24]. Translation of the modified S1 ORF 
generates two distinct proteins that are separated upon the ribosome skipping 
 induced by the 2A peptide: the σ1-His protein and the iLOV fluorescent reporter 
protein (Figure 1). 
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CHAPTER 5
To generate the recombinant reovirus, plasmid pBT7-S1His-2A-iLOV encom-
passing the modified S1 segment, preceded by a T7 RNA polymerase dependent 
promoter and tailed by the hepatitis delta virus ribozyme, was transfected into 
BSR-T7 cells together with four plasmids encoding the other nine segments, essen-
tially as described [25]. Virus was harvested at 48 hours post-transfection (P0). 
FIGURE 1. 
Schematic representation of S1-wt and S1His-2A-iLOV RNA. The length of the  
S1His-2A-iLOV and the wt-S1 segment is 1386 nucleotides and 1416 nucleotides, 
 respectively. Two proteins are synthesized from the S1His-2A-iLOV ORF: 1) the σ1-His th at 
contains some additional amino acids derived from the 2A peptide, and 2) the iLOV protein 
that  contains an additional proline at the N-terminus as result of  processing of the 2A 
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Part of the yield was used to infect 911scFvHis cells (P1). The presence of the 
6xHis tag in the capsid allows the modified virus to use the membrane-bound 
 single-chain Fv recognising the His tag (scFVHis) as an artificial receptor [8]. Clear 
cytopathic effects (CPE) became apparent at 10-days post infection, suggesting the 
presence of infectious viruses (Figure 2A). Upon harvesting, the virus was used to 
infect cultures of 911 cells in a plaque assay experiment. The plaques formed by 
rS1His-2A-iLOV viruses were smaller than those of wt reoviruses, and the borders 
are not clearly defined. The plaque morphology was similar to those of the jin-3 
viruses (data not shown). To determine the titers of the freeze-thaw batches of 
rS1His-2A-iLOV viruses we used the TCID50 method on 911 cells. On average the 
yields are lower compared to the wtT3D reovirus and around 4*106 Infection 
Units per ml (IU911/ml). For the rS1His-2A-iLOV viruses the yields per cell in three 
FIGURE 2.
The recombinant S1His-2A-iLOV reovirus replicates in cells and is infectious. 
A. Morphological appearance of mock infected 911scFvHis cells and 911scFvHis cells 
infected with an early passage of rS1His-2A-iLOV. 
B. Detection of iLOV positive 911scFvHis cells infected with an early passage  
rS1His-2A-iLOV virus (MOI911 ~ 0.3). Bright-field and fluorescence photographs were 
taken using an Olympus CKX41 microscope. 
C. Detection of iLOV-positive 911scFvHis cells infected with rS1His-2A-iLOV by flow 
 cytometry at 72 hours post infection. 911scFvHis cells were either mock infected  
or infected with an early passage of rS1His-2A-iLOV (MOI911 ~ 0.4). The iLOV signal  






independent CsCl-density gradient purified virus batches ranged between 5.2 x 
103 and 1.0 x 104 physical particles per cell, which is 10 – 30 fold lower than the 
yields  obtained for wt and jin-1 viruses. The iLOV-derived fluorescent signal was 
detectable by fluorescence microscopy (Figure 2B). The fluorescence was quanti-
fied by flow cytometry. For this, 911scFvHis cells were either mock infected or 
infected with an early passage (P2) rS1His-2A-iLOV at a multiplicity of infection 
(MOI911) of 0.4 IU911/cell. Fluorescence was analysed by flow cytometry at 72 
hours post- infection (Figure 2C). In the rS1His-2A-iLOV infected cultures, 57% of 
the cells exhibited the iLOV fluorescence. These data demonstrate that the 
replacement of the codons for the head domain of the reovirus spike protein σ1 by 
an iLOV  coding fragment yields infectious and replicating reoviruses.
S1His-2A-iLOV RNA is present in the recombinant reoviruses
To confirm the presence of the modified S1His-2A-iLOV segment in the recom-
binant reoviruses, RT-PCR was performed using total RNA isolated from 
 rS1His-2A-iLOV-infected 911scFvHis cells at 24 and 48 hours post-infection. A 
schematic overview of the primers and their binding sites is represented in Figure 
3A. The S1 primer pair amplified the wt S1 segment as well as the iLOV-contain-
ing  segment. The length of the PCR product of the iLOV-containing S1 segment 
 almost equals the length of the wtT3D-S1 segment (Figure 3B) and the segment is 
present in both isolations (24 and 48 hour). The iLOV-specific PCR product is 
 detectable in both isolates but not in the wtT3D reovirus sample. As expected the 
PCR primers used to detect the region encoding the head domain of σ1 only 
 amplified a fragment in the RNA isolated from wt reovirus infected cells but not 
in the samples from rS1His-2A-iLOV virus infected cells. Sequence analysis of the 
amplified S1His-2A-iLOV PCR product showed no additional mutations within 
the segment (data not shown). 
To further confirm the presence of replicating reoviruses, total RNA was iso-
lated from cells infected with either wtT3D reovirus or with the rS1His-2A-iLOV 
reovirus, and used for poly-acrylamide gel electrophoresis (Figure 3C). The ten 
 individual segments could be detected, further confirming the presence of repli-
cating reoviruses. The modified S1 segment is slightly smaller than the wild-type 
S1 segment, resulting in a marginally increased electrophoretic mobility. From 
these data we conclude that the S1His-2A-iLOV segment is packaged in the reo-
virus particles and that the wt S1 segment is absent from these reovirus prepara-
tions. These data demonstrate that the rS1His-2A-iLOV reoviruses replicate 
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FIGURE 3.
Detection of S1His-2A-iLOV RNA in infected 911scFvHis cells. 
A. Schematic representation of binding sites for the primers used in the RT-PCR  procedure. 
The primer-binding sites are indicated by arrows. The crosses denote non-binding sites. 
PCR products formed with S1 primers (S1For and S1endR) are 1416 bp (S1 derived from 
wt Reovirus) or 1386 bp (S1 derived from rS1His-2A-iLOV) in length. The PCR product 
generated with iLOV primers (iLOVFor and iLOVRev) is 303 bp and with S1-wt primers 
(S1testFor and S1endR) is 354 bp. 
B. RT-PCR to detect S1 RNA, iLOV or absence of the S1 head domain in 911scFvHis cells 
 infected with passage 1 of the rS1His-2A-iLOV reovirus, at 24 and 48 hours post  infection 
(h.p.i). Controls are RNA isolated from either uninfected (mock;  negative) or wt reovirus 
infected 911scFvHis cells, resp. 48 or 24 hours post  infection. The positive DNA controls 
are plasmids pBACT7S1His-2A-iLOV in case of S1 and iLOV PCR and pBACT7S1T3D for 
the S1-wt PCR. Time post infection is not applicable (n.a.) for the PCR controls. 
C. RNA electrophoresis of wt reovirus and rS1His-2A-iLOV virus. RNA was isolated from 
infected 911scFvHis cells, analysed by 12% PAGE-SDS and detected with Sybr-Gold. L,  





The σ1-His protein is detectable in 911scFvHis cells infected with the recombi-
nant reovirus and is incorporated in the rS1His-2A-iLOV particles
To verify that the inclusion of the porcine teschovirus-1 2A sequence yields a 
truncated σ1 protein in the rS1His-2A-iLOV infected cells, 911scFvHis cells were 
exposed to rS1His-2A-iLOV virus at an MOI911 of 2. At 24 and 48 hours post 
infection the cells were harvested and protein lysates of the infected cells were 
analysed by western-blotting. The presence of truncated σ1 was detected by 
immunoblotting using the polyclonal rabbit antibody S1R3 directed against a 
σ1-derived synthetic peptide. The σ1-His protein is detectable already 24 hours 
after infection. A specific band of approximately 30 kDa is seen only in lysates 
prepared from the rS1His-2A-iLOV infected cells. This is in agreement with the 
calculated molecular mass of the truncated σ1-His protein. In contrast, in the 
FIGURE 4. 
Detection of σ1-His in infected 911scFvHis cells and CsCl purified particles. 
A. 911scFvHis cells were infected with early passage rS1His-2A-iLOV. Lysates of infected 
cells were made 24 hr or 48 hr post infection (h.p.i) and analysed by Western  blotting. As 
a positive control for σ1His protein, cells transfected with pCMVS1His-2A-iLOV are used 
and lysates were made 48 hr post transfection. Cells infected with wt-reovirus (24 h.p.i) 
are taken along to visualize the difference in size; predicted size of wt σ1 is about 49 kDa 
and σ1-His after P2A processing is about 30 kDa. σ1 is  detected with S1R3, polyclonal 
rabbit antibody directed against N-term of σ1. As a loading control a β-actin antibody  
is used. 
B. Approximately 5*109 particles of CsCl purified wt-reovirus or σ1-His containing  
rS1His-2A-iLOV reovirus was loaded onto 12% SDS-PAGE gels. S1R3 polyclonal 
 antibody against N-term of σ1 was used for detection of both, the wt-σ1 and the σ1-His 
protein (arrow). The smaller σ1-His protein is also detected with an antibody directed 
against the P2A peptide. The dot indicates a background band, probably cross reactivity 
with σ3. As an indication of the amount of particles that are  loaded on gel, σ3 is detected 
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 lysates from the cells infected with the wt reovirus show a band that corresponds 
to the calculated molecular mass of wt-σ1 (approximately 49 kDa) (Figure 4A). 
To confirm the presence of the truncated σ1-His protein in the virus capsid, 
rS1His-2A-iLOV particles were produced and purified by CsCl density gradient 
centrifugation. Protein lysates from these purified particles were used for western 
blot analysis. As a control, purified wtT3D reovirus was included. Again a band 
was detected migrating at an apparent molecular mass of 30 kDa only in the 
rS1His-2A-iLOV particles (Figure 4B) and this band was also detected with the 
antibody directed against the 2A peptide. The σ3 is used as a loading control. 
Taken together, our data demonstrate that the 2A sequence yields separate σ1 and 
iLOV proteins. In addition, our data show that at least part of the truncated σ1 
protein is associated with the reovirus capsid. 
rS1His-2A-iLOV virus can infect cells independently of the 
 artificial scFvHis receptor and the natural JAM-A receptor
So far, the rS1His-2A-iLOV reovirus was propagated in cells that contain the 
scFvHis as an artificial receptor for the modified virus. To test whether the rS1H-
is-2A-iLOV virus can infect cells independently of this scFvHis receptor,  cultures 
of 911 cells were exposed to the rS1His-2A-iLOV virus at an MOI911 of 0.4 and 
analyzed by flow cytometry for iLOV expression at 72 hours post infection (Fig-
ure 5A). Approximately 46% of the 911 cells exhibited iLOV fluorescence. This 
demonstrates that the rS1His-2A-iLOV recombinant reovirus can also infect cells 
in absence of the artificial scFvHis receptor. To further test if the infection is inde-
pendent of the reovirus receptor JAM-A, cultures of the JAM-A-deficient U118MG 
cells were exposed to rS1His-2A-iLOV at an MOI911 of 0.4 (Figure 5A). Approxi-
mately 21% of the U118MG cells exhibit iLOV fluorescence. This demonstrates 
that the rS1His-2A-iLOV virus does require neither expression of scFvHis nor 
JAM A as receptor for entry into cells. 
To test the cytolytic activity of the rS1His-2A-iLOV reovirus, monolayer cul-
tures of several cell lines that resist wtT3D reovirus infection were exposed to 
rS1His-2A-iLOV, or wtT3D reovirus at an MOI911 of 1, or mock infected. Four days 
post infection, cells were inspected visually for signs of CPE and micrographs 
were taken with an original magnification of 200x (Figure 5B). Subsequently the 
viability of the cultures was established on the same day (Figure 5C). In parallel, 
cultures of 911 cells were included to demonstrate that both wtT3D reovirus 
(wt-Reo) and the modified rS1His-2A-iLOV virus induce cell death in JAM-A 
 positive, permissive cells (Figures 5B and 5C). In monolayer cultures of JAM-A 
deficient U-118MG cells, only the rS1His-2A-iLOV reoviruses, but not wtT3D reo-




rS1His-2A-iLOV reovirus infection is independent of the scFvHis receptor and Junction 
Adhesion Molecule-A. 
A. 911 cells and U118MG cells were mock infected or infected with an early passage  
rS1His-2A-iLOV reovirus (MOI911 ~ 0.4). Cells were analysed by flow cytometry 72 hours 
post infection. iLOV signal is plotted on the Y-axis (FITC-A) against the PE-A signal on 
the X-axis. 
B. CPE induction in the cell lines upon mock infection or upon infection with wtT3D 
 reovirus or rS1His-2A-iLOV (MOI911 ~1). Micrographs were taken 4 days post infection, 
prior to WST-1 assay.
C. Cell viability, as measured by WST-1 assay, of the various cell lines upon mock  infection 
or infection with wtT3D reovirus or rS1His-2A-iLOV (MOI911 ~1). Relative WST values 
are calculated as percentages of OD450 values of the infected cells over the mock treated 
cells. The error bars represent the SD (n=4). *** P<0.0001 and * P<0.01.
D. Capsase-3/7 activity in mock-infected culture or cell cultures (911) infected with wtT3D 
reovirus, jin-3, and rS1His-2A-iLOV at an MOI911 ~ 5. Caspase 3/7 activity was measured 
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cell line has a low JAM-A expression (data not shown) and as a result is weakly 
permissive to wtT3D reovirus. In contrast to the wtT3D reoviruses the rS1His-2A-
iLOV reovirus induces marked cell death in the U251 cells. Finally, the chicken 
hepatoma cell line LMH does not express a functional JAM-A receptor and there-
fore resists wtT3D reovirus infection. It is however sensitive to rS1His-2A-iLOV 
 (Figure 5C). 
The wtT3D reovirus induces apoptosis in many transformed cells ([3]). The 
viral spike protein σ1 has been implicated in the induction of the programmed cell 
death ([26]). To study whether the rS1His-2A-iLOV viruses, which lack the head 
domain of the σ1 spike protein, induce apoptosis we measured the activity of the 
caspases 3/7 upon reoviruses exposure in 911 cells. The cells were exposed to 
rS1His-2A-iLOV and, as controls, to wtT3D and jin-3 reoviruses at an MOI=1. 
 Caspase-3/7 activity was measured 24 or 48 hours post infection (Figure 5D). In 
the 911 cells infected with rS1His-2A-iLOV the induction of caspase-3/7 activity is 
evident at 24 hours and 48 hours post infection, although in a lesser extent than 
upon wtT3D reovirus infection. Also in cell exposed to jin-3 caspase-3/7 activity is 
induced albeit somewhat delayed.
Taken together, these results demonstrate that the rS1His-2A-iLOV reovirus is 
cytotoxic in JAM-A deficient as well as in JAM-A-expressing cell lines. In 911 cells 
an increase in caspase-3/7 activity is detected upon rS1His-2A-iLOV infection, 
suggesting that these viruses can exert their cytolytic activity by the induction of 
classic apoptosis. 
Lec2 cells are less sensitive for rS1His-2A-iLOV infection than the 
parental CHO cells
The JAM-A independent cell entry of rS1His-2A-iLOV is possible by the inter-
action of the jin-3 derived sialic-acid binding region in the tail region of σ1. To 
confirm that sialic-acids are involved in binding of rS1His-2A-iLOV to cells, we 
exposed Lec2 cells to this virus. Lec2 cells are Chinese Hamster Ovary mutant 
cells that have a defect in the translocation of CMP-sialic-acid into the Golgi com-
partment causing a 90% reduction of sialic acids on their cell surface [27]. To verify 
this phenotype in Lec2 cells we exposed Lec2 and normal CHO cells to 
FITC-A-conjugated Wheat Germ Agglutinin (WGA-FITC) and measure the bind-
ing of WGA-FITC to the cells by flow cytometry (Figure 6A). The FITC signal of 
WGA-FITC exposed CHO cells is stronger than in Lec2 cells (Median FITC-A 
value in WGA-FITC CHO cells is 18349 and for WGA-FITC-exposed Lec2 cells 
2012), confirming the sialic acids-deficient phenotype of the Lec2 cells.
Next we assessed the sensitivity of Lec2 cells to infection with reovirus 




The fraction of iLOV-positive cells upon reovirus rS1His-2A-iLOV exposure of Lec2 and 
CHO cells.
A. Lec2 cells and CHO cells were exposed to WGA-FITC and WGA-binding was evaluated 
by flow cytometry analysis. Lec2 cells have a ~90% reduction in WGA-FITC binding.
B. Flow cytometry analysis of 911, CHO, and Lec2 cells following infection with  
rS1His-2A-iLOV, jin-3 (MOI911~0.5) or mock infected cells, 48 hours post infection.  
iLOV signal is plotted on the Y-axis against the PE-A signal on the X-axis. Gates for iLOV 
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rS1His-2A-iLOV, or with jin-3 at an MOI911 of 0.5 and 48 hours post infection the 
iLOV- positive cells were detected by flow cytometry (Figure 6B). As expected 
exposure to jin-3 did not result in detectable green fluorescence. This confirms the 
absence of autofluorescence upon infection with reovirus. In Lec2 cells infected 
with rS1His-2A-iLOV only 14% of the cells are iLOV positive, while the CHO and 
911 cells infected with rS1His-2A-iLOV contain over 70% of iLOV positive cells. 
These data demonstrate that the reduction of the sialic-acids concentration on the 
surface of the Lec2 cells correlates with a decreased sensitivity to rS1His-2A-iLOV 
virus infection.
rS1His-2A-iLOV reoviruses retained the preferential cytolytic 
 activity in tumor cells
To verify that the preferential cytolysis of transformed cells is maintained for 
rS1His-2A-iLOV, cultures of diploid human skin fibroblasts (VH10 cells) were 
used as a model. VH10 cells were exposed to rS1His-2A-iLOV, and jin-3 reo-
viruses or mock infected. Compared to the 911-control infection (same as in 
 Figure 6B) only a few iLOV positive cells (3.19%) were detected in the VH10- 
infected cells (Figure 7A). To further demonstrate that the VH10 cells resist rS1H-
is-2A-iLOV-induced cell death, cells were exposed to rS1His-2A-iLOV and jin-3 
reoviruses at an MOI911~5, or mock infected. Viability was measured four days 
post infection. As a positive control, 911 cells were included in the assay  (Figure 
7B). Whereas in 911 cells both reoviruses induce significant cell death in the 
mono layer cultures, the viability of the VH10 cell cultures is not affected. These 
results confirm that similar to the jin-3 and wtT3D reoviruses, the rS1His-2A-iLOV 
viruses do not infect and lyse normal diploid skin fibroblasts.
Characterization of two deletion mutants that lost the iLOV gene
In two batches of the rS1His-2A-iLOV reoviruses, derived from independent 
transfection experiments, we noted the loss of transgene expression and the 
appearance of deletion mutants upon prolonged passaging. The viruses had been 
propagated for 10 rounds on 911 cells (Experiment 1) and 911scFvHis cells (Exper-
iment 2). RT-PCR analysis revealed the presence of deletion mutants in the 
 rS1His-2A-iLOV stocks (data not shown). This was confirmed by the gel electro-
phoresis of RNA isolated from infected cells (Figure 8A). Already at passage 3 of 
the reovirus on 911 cells, the deleted segment could be seen as an aberrant RNA 
segment migrating faster than the smallest S segment. On gel, both the full-length 
S1His-2A-iLOV segment and the S1 deletion segment are visible, suggesting a 
 heterogeneous population of viruses. In RNA isolated from passage 10 only the S1 
deletion segment could be detected, suggesting that this deletion mutant over-




Detection of iLOV positive cells and viability of VH10 cells exposed to rS1His-2A-iLOV.
A. Flow cytometry analysis of 911 and VH10 cells exposed to rS1His-2A-iLOV, jin-3 
(MOI911~0.5) or mock treated cells, 48 hours post infection. The panel of 911 cells is 
 copied from fig 6 b (VH10 samples were included in the same FACS experiment). iLOV 
signal is plotted on the Y axis against the PE-A signal on the X-axis. Gates for iLOV 
 positive cells are set per cell line.  
B. Cell viability, as measured by the WST-1 assay, four days post infection with 
 rS1His-2A-iLOV, jin-3 (MOI911~1) or mock infected. Relative WST values are calculated  
as percentages of OD450 values of the infected cells over the mock treated cells. The error 
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In a batch of rS1His-2A-iLOV reovirus propagated on 911scFvHis cells a dele-
tion mutant was observed after 10 passages with an even smaller S1 segment. 
 Sequence analyses of PCR products of the deletion mutants revealed that in both 
mutants the iLOV encoding region had been deleted resulting in S1 segments of 
1001 nt (dl1, S1His-2A-iLOVΔnt 877-1261) and 922 nt (dl2, S1His-2A-iLOVΔnt 
751-1214) in length, respectively (Figure 8B). In dl2, the 6xHis-tag and the 2A 
 sequence had also been deleted. Interestingly, in dl2 the A-box, and in dl1 the 
A-box and the B-box, which both have been implicated in encapsidation of reo-
virus RNA into the viral capsid [24], were deleted, while the C-box element had 
been retained in both mutants. This suggests that the A and B boxes are dispensa-
ble for packaging the S1 segment RNA into the viral capsid.
The results from the RNA analyses were further verified at the protein level in 
911scFvHis-cell lysates from cells infected with the reovirus batches containing 
the deletion mutants (Figure 8C). In passage 2 of both batches and passage 10 of 
the first batch, the σ1 protein contains the 2A element, whereas 2A is no longer 
detectable in passage 10 of batch 2. As expected the truncated σ1 protein migrates 
at an apparent molecular mass of 26 kDa instead of 30 kDa.
Taken together our data indicate that it is possible to insert the iLOV coding 
 region in the S1 segment. However care should be taken to test the integrity of the 
transgene containing segment if the recombinant viruses are passaged to high 
passage number. Notably, apart from these deletions no other mutations were 
found in the S1 segment. This suggests that the sequence encoding the N-terminal 
252 amino acids of the jin-3 σ1 is sufficient for cell entry. 
5.4 Discussion
Our data suggests that the S1 segment encoding σ1 is suitable for insertion of a 
transgene encoding a heterologous protein. We demonstrate that the S1 segment 
can harbor heterologous sequences that encode the fluorescent protein iLOV. In 
this construct, the iLOV-encoding sequence was preceded by the codons for the 
porcine teschovirus-1 2A peptide. Upon translation this yields separate proteins 
from the fused open reading frame. To reduce the size of the transgene-containing 
S1 segment, the sequences encoding the head-domain of σ1 were deleted. The 
head domain harbors the amino acids that interact with the JAM-A receptor. The 
head-domain could be removed by employing the σ1 sequences from the jin-3 
mutant [12]. This mutant is one of a series of reovirus T3D mutants that can infect 
cells in a JAM-A receptor-independent fashion. The mutations in these jin- 
mutants lead to amino-acid alterations close to the sialic-acid binding site in the 




Deletion mutants are detected in two batches of the rS1His-2A-iLOV virus.
A. RNA electrophoresis of 3 rS1His-2A-iLOV isolates from 2 independent experiments.  
In P3 of experiment 1 (Exp1) the deletion in the S1 segment (dl1) is already present next 
to the full-length (fl) S1His-2A-iLOV segment, while in P10 only S1-dl1 is present.  
Size of S1-dl1 is 1001 bp. Size of S1-dl2, derived from second experiment (Exp2) after 
10 passages in 911scFvHis cells is 922 bp.
B. Schematic overview of the two S1-deletion mutants compared to the full length  
S1His-2A-iLOV.
C. Detection of σ1 protein in infected 911scFvHis cells in two independent batches of  
rS1His-2A-iLOV reoviruses containing deletion mutants. Lysates were made 48 hours 
after infection and equal amounts of protein were loaded on 12% SDS-PAGE gels and 
detected with antibodies directed against σ1 (S1R3), P2A (ABS31) or actin. The predicted 
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To release the S1-His protein from the iLOV protein, the porcine teschovirus-1 
2A element was introduced. The length of the fragment encoding the 2A peptide 
is only 66 nt, and it also includes the codons for a GSG-linker to improve the 
 efficiency [28, 29]. The 2A mediated separation is highly efficient and results in 
reo virus particles that do not contain the iLOV protein.
The S1His-2A-iLOV RNA was found to be packaged in the reovirus particles in 
911 and 911scFvHis cells and transferred to target cells as was evident from 
RT-PCR analyses. The truncated σ1-His protein fragment was detected in infected 
cells and in CsCl-gradient purified reovirus particles. 
The utility of the σ1 head domain-coding region as a locale for the transgene 
was further supported by the observation that an attenuated T3D reovirus 
derived from persistently infected HT1080 cells carries a mutation in S1 which 
resulted in a stop codon near the codons encoding the trypsin-sensitive site at 
amino acids 245 of the spike protein. This mutation results in truncation of the σ1 
protein leading to attenuation of the virus upon inoculation of immune-deficient 
mice [30]. While the size of the S1 segment in this isolate was not altered, the σ1 
protein lacks the head domain. This mutant reovirus replicated efficiently in L929 
cells. As in our experiment the truncated σ1 protein was detected by immunoblots 
in purified particles produced on of L929 cells. The truncated protein consisted of 
the first 251 amino acids of σ1, and still contained the sialic-acid binding domain 
and the open reading frame encoding the σ1S protein [15, 31, 32].
In our modified S1 segment, the last 195 nucleotides of wild-type S1 segment 
were left intact. This region has been predicted to contain three cis-acting 
sequences required for packaging of the reovirus plus-strand RNA in the core; A, 
B and C-boxes [24]. In a deletion mutant characterized in our study we found that 
the A and the B-box were deleted. This suggests that the A and B box are dispen-
sable, reducing the length of the region required for packaging to only 36 nt. The 
5’-end of the S1 segment has been left intact. In our initial experiments, we tried to 
 include the ORF encoding the Discosoma sp. red fluorescent protein (DsRed). This 
ORF is 678 nt in length, and was placed in-frame, downstream of the 6xHis-tag 
and the porcine teschovirus-1 2A element. Although we noticed the formation of 
replicating reoviruses, none of these transferred an intact copy of the DsRed trans-
gene, as was evident from the complete absence of red fluorescence in the infected 
cells, despite the presence of marked cytopathicity. In this construct the total 
length of the modified S1 segment was 1722 nt, and we speculated that our inabil-
ity to generate the recombinant dsRed-gene containing reoviruses was due to the 
larger size of the S1-dsRed segment. So far, limited data is available on the factors 
that restricts the packaging capacity of foreign sequences into the reovirus 
 genome. In a recent study the insertion of long unmodified Simian Immuno-
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deficiency Virus derived gag sequences in the reovirus M1 and L1 segments were 
not compatible with replication [9]. The failure to recover the recombinant reo-
viruses with the longer gag inserts was explained by the formation and stability of 
the RNA secondary structures of the inserted gag sequence. Upon reduction of the 
stability of the predicted RNA structure by wobble-mutagenesis, infectious 
 recombinant reoviruses with the longer gag inserts could be obtained. 
To circumvent the problem of possible size constraints, we evaluated the use of 
the smaller reporter iLOV. The coding region of this reporter is only 333 nucleo-
tides in length. With the S1His-2A-iLOV construct we could generate replicating 
reoviruses harboring the iLOV ORF as a reporter gene. The iLOV signal could be 
detected in infected cells by fluorescence microscopy, but the signal was often 
weak and bleached rapidly. Nevertheless, the signal was detectable by flow 
cytometry. The iLOV sequence was based on a codon-optimized version of the 
iLOV protein sequence described in 2008 [20]. A codon-optimized iLOV has been 
used to generate an infectious recombinant foot-and-mouth disease virus [33]. 
Here too, the fluorescent signal of iLOV was reported to be relatively weak. 
Recently, more stable iLOV variants were generated that provided a stronger sig-
nal in bacterial and mammalian cells [34]. 
We have used a similar strategy for the expression of a small viral protein 
fused to the 2A sequence. Viable recombinant viruses could be generated and our 
preliminary results demonstrate the absence of deletions in the virus preparation 
upon prolonged passaging (up to 7 passages) (data not shown). These data further 
suggest that our head-replacement approach for expressing heterologous trans-
genes is feasible. It may be warranted that the integrity of the viruses should be 
 tested regularly to avoid the presence of deletion mutants lacking the transgene 
product.
Based on the identification of the two viable S1-deletion mutants in our batches 
of rS1His-2A-iLOV reoviruses, the truncated S1 RNAs are effectively packaged 
into the reovirus cores. Smaller M1 deletion fragments were detected upon serial 
passages of reovirus Type 1 x Type 3 reassortants [35]. The smallest deletion 
mutant of M1 that was assembled into progeny viruses was approximately 350 
nucleotides in length. The M1-deletion mutants are defective and rely on the 
 presence of helper viruses that contain the full-length M1 to complement the 
 deficiency. Based upon the analyses of different deletion mutants the authors 
 concluded that the deletions do not occur randomly, instead they depend on the 
presence of particular sequence elements. In avian reoviruses, which are more 
 distant members of the orthoreovirus genus [36], high MOI passaging yielded 
 defective interfering (DI) particles containing S1-deletion mutants in which the 
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increase in the presence of the S1-deletion segment coincided with a decrease in 
full-length S1 RNA in purified avian virus particles. In infected chick embryo 
fibroblasts (CEF), the presence of the DI particles decreases the viral yields. As 
with the mammalian M1-deletion mutants, the replication of these DI mutants in 
cells relies on the presence of viruses with the full-length S1. Our S1-deletion 
 mutants are distinct from these DI particles by virtue of their capacity to replicate 
autonomously and hence independently of wild-type helper viruses. Therefore 
such mutants may pave the way for generating recombinant reoviruses with even 
larger replacements of the S1 segment by heterologous sequences. The replace-
ment of the head domain allows the insertion transgenes up to 522 nucleotides in 
length without exceeding the size of the wt S1 segment. It remains to be estab-
lished whether the occurrence of deletion mutants in reoviral vectors constitutes a 
 limitation for their use as oncolytic agents in clinical applications. Whereas dele-
tion mutants are detected, in our hands the frequency of their occurrence is low 
enough to prevent them from impeding the preclinical experiments with these 
transgene containing viruses. Stocks containing deletion mutants can just be dis-
carded. In both cases the deletion mutants could be traced back to low passage 
number stocks, suggesting that they may have been produced already during the 
generation of the recombinant viruses. The methodology to generate these viruses 
involves the generation of non-polyadenylated RNA molecules in the cells using 
T7 polymerase and ribozymes and such transcripts are known to be instable. This 
is supported by the observation that the rS1His-2A-iLOV virus could be stably 
propagated for 10 passages after expansion of a clonal isolate (data not shown). 
So far, the yields of the head-domain replacement reovirus vectors is 10 - 30-fold 
lower than those of the wtT3D reoviruses on a per-cell basis. Several mechanisms 
could contribute to the reduced yields. The initial infections of the producer cells 
may be more asynchronous than with head-domain containing viruses,  leading to 
reduced yields in single-step growth cultures. However, delaying the harvest did 
not compensate for this and did not normalize the yield (data not shown). Alter-
natively, the region of the wtT3D S1 segment that was deleted in the rS1His-2A-
iLOV virus may contain cis-acting elements that negatively affect the virus yields 
when deleted. So far we have found no evidence for such mechanism. Also it 
could be conceivable that the iLOV transgene contains sequences that inhibit effi-
cient production of particles. This seems unlikely, since the mutants from which 
the iLOV transgene had been deleted did not yield higher titers. Also, reoviruses 
with other small transgenes did yield similar titers (data not shown). Prolonged 
passaging of the rS1His-2A-iLOV virus did not yield other mutations in S1 than 
the deletion mutants mentioned above. This suggests that the jin-3 mutation lead-
ing to the G196R substitution is stable and does not evolve further to further 
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enhance reovirus yields. Our current efforts to improve the yields employ reo-
viruses carrying therapeutic transgenes and involve bioselections.
The virus retained the capacity of the parental jin-3 mutant to infect cells in the 
absence of the JAM-A receptor on the target cells, which is evident from the virus’ 
capacity to infect JAM-A negative U118MG cells and chicken LMH cells in mon-
olayer cultures The virus rS1His-2A-iLOV induces caspase 3/7 activity in 911 cells. 
This demonstrates that the induction of apoptosis by reovirus is independent of 
the virus’ capacity to bind JAM-A. This is consistent with roles of either sialic-acid 
binding by the reovirus spike protein, or the σ1S protein in this process [18, 26], as 
both of these functions are retained in the reovirus vectors described in our study. 
The modification of the S1 segment in the rS1His-2A-iLOV does not result in a 
loss of preference for transformed cells. Neither rS1His-2A-iLOV virus nor the 
jin-3 virus induce CPE or apoptosis in human diploid skin fibroblasts. This, 
 together with the virus’ capacity to induce cytopathic cell death makes the modifi-
cation strategy particularly suited for arming oncolytic reoviruses with transgenes 
that encode immune stimulatory molecules, antigenic proteins, or anti-tumor 
 polypeptides. This strategy may be suitable for generating replication-competent 
reoviruses carrying a transgene for use as a vaccine vector or for boosting the anti-
tumor-efficacy of oncolytic reoviruses.
5.5 Materials and methods
Cell lines and viruses
The cell lines U118MG, U251, LMH, CHO, Lec2 (all obtained from ATCC) and 
911 were cultured in high-glucose Dulbecco’s Modified Eagle Medium (DMEM; 
Invitrogen, Life Technologies, Bleiswijk, The Netherlands), supplemented with 8% 
fetal bovine serum (FBS; Invitrogen) and with penicillin and streptomycin (pen-
strep) as described [13, 38]. LMH cells were cultured on dishes coated with 0.1% 
gelatin (Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands). Lec2 cells 
were cultured in alpha-MEM, supplemented with 8% FBS and pen-strep. The 
911scFvHis cells were generated by transduction of 911 cells with the lentivirus 
vector pLV-scFvHis-IRES-Neo as described before [8]. The resulting polyclonal 
cell line was cultured in DMEM containing 8% FBS, pen-strep and 200 μg/ml 
G418. The T7-RNA polymerase expressing cell line BSR-T7 [39] was provided by 
K. Conzelman and cultured in DMEM, 8%FBS, pen-strep and 400 μg/ml G418. 
 Normal foreskin fibroblasts (VH10), were provided by B. Klein [40] and cultured 
in high-glucose DMEM supplemented with 8% FBS and pen-strep. All cells are 
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The wild-type T3D virus strain R124 was isolated from reovirus T3D stock 
VR-824 from the American Type Culture Collection (stock VR-824) by two rounds 
of plaque purification and propagated on 911 cells. In text this virus is referred to 
as wtT3D reovirus. The viruses were quantitated by plaque assay on 911 cells as 
 described and virus concentrations and multiplicities of infection were defined on 
the bases of these titers, e.g. MOI911.
Cloning of S1His-2A-iLOV in pBacT7 backbone
The S1His-2A-iLOV segment was designed in silico and a DNA copy was syn-
thesized by Eurofins MWG Operon (Ebersberg, Germany). The total length of this 
synthetic segment is 1386 bp (Figure 1). The segment sequence is assembled to 
contain the following features: 1) nt 1 to 768 from the S1 segment of reovirus 
mutant jin-3; this includes the 5’ UTR, entire σ1s ORF, and the first 252 amino 
acids of the jin-3 σ1, including the codons for the G196R change near the 
 sialic-acid binding domain [12]; 2) the codons for a 6xHis-tag (18 bp) which is 
placed in frame with the σ1 part; 3) the codons for the porcine teschovirus-1 2A 
sequence (66 bp + 3 additional bp); 4) the iLOV-encoding sequence (333 bp) which 
was reverse translated and human-codon optimized from the amino acid 
 sequence published by Chapman et al. [20] using the web-based Encor Biotechnol-
ogy Inc. (http://www.encorbio.com/protocols/Codon.htm); 5) the stop codon and 
3’ end of S1 segment from nt 1219 to 1416 of reovirus T3D, which include A-, B-, 
and C-box elements predicted for encapsidation of the reovirus ssRNA in the cap-
sid [24, 41], as well as the 3’ UTR. The resulting sequence was manually edited to 
remove or include specific restriction enzyme recognition sites in the designer 
DNA fragment. 
The synthetic S1His-2A-iLOV fusion construct was inserted in a pBluescript 
plasmid by Eurofins MWG Operon (to generate pBSmwg-S1His-iLOV). The 
S1His-2A-iLOV part was further PCR amplified from this construct using forward 
primer T7S1For (5’-TAATACGACTCACTATAGCTATTGGTCGGATGGATCC-
TCGCCTACGT-3’) and reverse primer S1iLOVendR (5’-ACGTGATATCCCTCG-
CGATGAAAT-3’) with PFU polymerase (Fermentas, FisherScientific, Landsmeer, 
The Netherlands). The underlined sequences are the parts complementary to the 
sequence in the pBSmwg-S1His-2A-iLOV construct. The PCR product was 
 digested with SacII and purified with SureClean (Bioline; GC Biotech BV, Alphen 
aan den Rijn, The Netherlands) according to the manual. The PCR product was 
inserted in the pBACT7 backbone of pBacT7-S1T3D [7]. Plasmid pBacT7-S1T3D 
was purchased at Addgene (plasmid 33282, www.addgene.org). The wt S1T3D 
was removed by digestion with SmaI and SacII and the pBACT7 backbone was 
isolated from a 1% agarose gel and purified by JetSorb (Genomed; ITK Diagnos-
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tics BV, Uithoorn, Netherlands) according to the manufacturer’s manual. The 
 SacII-digested S1His-2A-iLOV-containing PCR product was inserted in the SmaI 
and SacII digested pBACT7 DNA with T4 DNA ligase (Fermentas, FisherScien-
tific, Landsmeer, The Netherlands), resulting in construct pBT7-S1His-2A-iLOV.
Generation of reovirus rS1His-2A-iLOV
For generation of recombinant reoviruses we used the procedure described by 
Boehme et al. [42] with some modifications. Whereas the original article employs 
10 plasmids for providing the full complement of reovirus segments [7], our 
 system uses five plasmids. In addition to pBT7-S1His-2A-iLOV, we used the 
 following plasmids which were all obtained from Addgene: pT7-L1T1L (plasmid 
33286), pT7-L2-M3T3D (plasmid 33300), pT7-L3-M1T3D (plasmid 33301) and 
pT7-M2-S2-S3-S4T3D (plasmid 33302). For generating recombinant reoviruses the 
five plasmids were transfected into BSR-T7 cells using the TransIT-LT1 transfec-
tion  reagent (Mirus; Sopachem BV, Ochten, Netherlands), according to the manu-
facturer’s manual. Two μg of each of the plasmids was mixed and added to the 
cells with 30 μl TransIT reagent. Two-day post-transfection the cells were har-
vested and lysed by three cycles of freeze-thawing. After pelleting the cell debris, 
the  cleared supernatant containing the recombinant reoviruses was added to 
911scFvHis cells in a 6-well plate. Upon the first appearance of cytopathic effects 
(CPE) the cells were harvested and the rS1His-2A-iLOV reovirus was released 
from the cells by three cycles of freeze-thawing. The cell debris was removed from 
the reovirus-containing lysate by centrifugation (10’ at 3000xg), and stored at 
-20°C until further use. The virus was routinely passaged by exposing fresh 
semi-confluent cultures to dilutions of the cleared lysates. 
A medium-sized batch of cesium chloride-purified rS1His-2A-iLOV was 
 prepared by loading the cleared freeze-thaw lysates onto a discontinuous CsCl 
gradient (1.45 g/cm3 and 1.2 g/cm3) in PBS. After centrifugation in a SW28 rotor at 
95000xg for 4 hours at 16°C, the lower band, containing the infectious particles, 
was harvested and desalted in an Amicon® Ultra 100K device according to manu-
facturer’s manual (Millipore, Merck Chemicals BV, Amsterdam, Netherlands). 
The CsCl-purified reovirus was recovered in reovirus storage buffer (10 mM Tris.
HCl pH 7.5, 150 mM NaCl, 10mM MgCl2.6 H2O, 5% sucrose) was aliquoted and 
stored at -80°C until use. The amount of particles was calculated based on the 
OD260 values [43].
Reverse transcriptase PCR and sequence analysis
Cells (911scFvHis, 1*105) in 24 well plates were infected with rS1His-2A-iLOV. 
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2A-iLOV) obtained in experiment 1, 1/20th part of the isolated reovirus was used 
for exposure to the cells. Total RNA was extracted with the Absolutely RNA mini-
prep kit (Stratagene, Agilent Technologies, Amstelveen, The Netherlands) from 
the infected cells according to the manual. cDNA was synthesised with the 
S1endR primer (5’-GATGAAATGCCCCAGTGC-3’) and SuperScript III reverse 
transcriptase (Invitrogen, Life Technologies, Bleiswijk, The Netherlands). In the 
PCR the following primers were used to detect 1) S1 (S1For: 5’-GCTATTGGTCG-
GATGGATCCTCG-3’ and S1endR); 2) iLOV (forward primer: 5’-ATGATC-
GAGAAGAACTTCGTGATC-3’ and reverse primer:  5’-CACGT GG TCG CTG CCG- 
T CCAG CTG-3’) and 3) S1Head part (S1testFor: 5’-GAGCATGTGGATAG-
GAAT TG-3’ and S1endR) with GoTaq polymerase (Promega, Leiden, The Nether-
lands). The positions of the primer binding sites are shown in Figure 3B.
For sequence analysis PFU was used as the polymerase and the PCR products 
of the S1 segments (full-length in early passages and S1-dl1 and –dl2) were sent to 
our LGTC department (LUMC, Leiden, the Netherlands). Primers used in the 
 sequence reactions: S1endR and S1For. 
Western blot analysis
Cell lysates were prepared in Giordano Lysis Buffer (50 mM Tris-HCl pH 7.4, 
250 mM NaCl, 0.1% Triton, 5 mM EDTA) supplemented with protease inhibitors 
(Complete mini tablets, Roche Diagnostics, Almere, The Netherlands). Total 
amount of protein in the lysates was measured by Bradford assay (Biorad, 
Veenendaal, The Netherlands). Equal amounts of lysate (30 μg) were loaded into 
the wells of a 12% polyacrylamide-SDS gel after addition of western sample buffer 
(final concentrations: 10% glycerol, 2% SDS, 50 mM Tris-HCl pH 6.8, 2.5% β- mer-
captoethanol and 0.025% bromophenol blue). 
For electrophoresis of CsCl purified reoviruses ~5*109 particles were mixed 
with the above-mentioned western sample buffer and added to a 12% polyacryla-
mide SDS gel. The proteins were transferred to Immobilon-P (Millipore, 
 Etten-Leur, The Netherlands) and visualized using standard protocols. For every 
antibody a different polyacrylamide-SDS gel was used unless otherwise stated.
The antibodies used in this study were S1R3, a monospecific polyclonal rabbit 
serum directed against the synthetic peptide glaelrvdhdnlvarv, representing 
amino acids 115-130 of the σ1-tail (generated by A. D. Lipińska, University of 
Gdańsk, Gdańsk, Poland). The peptide was glutaraldehyde-conjugated to glu-
tathione S-transferase purified from the pGEX system, according to the manufac-
turer instructions (Amersham) and used to immunize rabbits. Mouse monoclonal 
antibody 4F2, directed against reovirus σ3 obtained from the Developmental 
Studies Hybridoma Bank developed under the auspices of the NICHD and 
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 maintained by The University of Iowa, Department of Biology, Iowa City, IA 
52242 [44]. Antibody (mouse) directed against β-Actin: ImmunO anti-Actin clone 
C4 (MP Biomedicals, Eindhoven, The Netherlands). And rabbit anti-P2A peptide 
serum ABS31 (Merck-Millipore, Amsterdam, The Netherlands).
Flow cytometry analysis
Cells (911scFvHis, 911 or U118-MG) were infected with rS1His-2A-iLOV 
(MOI911’s are indicated in the text). Cells were detached from the 24-well plates 
with trypsin and fixed in 4% paraformaldehyde at 72 hours post infection. After 
three washes in FACS buffer (PBS with 0.5% BSA and 2 mM EDTA) cells were 
 assayed in FACS buffer for iLOV presence on a BD LSRII flow cytometer. ILOV 
signal was measured by selecting the blue laser (excitation at 488 nm) with the 
green fluorescence channel (FITC A in the plots) and the yellow fluorescence 
channel for PE (negative) signal. For the detection of iLOV positive cells in 
 relation to sialic-acid binding or normal diploid cells 911, CHO, Lec2 or VH10 
cells were mock infected, infected with rS1His-2A-iLOV or jin-3 as an additional 
control. Both viruses were added to cells with the same MOI911 (see text) and 48 
hours post infection prepared for FACS analysis as described above. In both 
experiments, gates for iLOV positive cells were set per cell line, depending on the 
population of the negative mock infected cells. Data were analysed with FACS-
Diva software (BD Bioscience, Breda, The Netherlands).
Detection of WGA-FITC binding
CHO and Lec2 cells were transferred by trypsin treatment to tubes. Trypsin 
was inhibited by adding the cell suspension to DMEM containing 2% FBS. After 
one centrifugation step for 3 min. at 350xg, cells were resuspended in PBS (mock) 
or WGA-FITC (1 μg/ml in PBS) to a final concentration of ~7.5*105 cells per 500 μl. 
Cells were placed at room temperature for 15 min. to initiate binding of WGA-
FITC, followed by three washes with FACS buffer (3 min. at 350xg) to remove 
 excess of unattached WGA-FITC. Detection of FITC-positive cells was done in 500 
μl FACS buffer on a BD LSRII flow cytometer. Data were analysed with FACS-
Diva software (BD Bioscience, Breda, The Netherlands).
Reovirus RNA electrophoresis
For reovirus RNA analyses the method used is adapted from a rotavirus proto-
col described by Navarro et al. [45]. Cells in 6-well plates were infected with 
wtT3D or rS1His-2A-iLOV reoviruses. Upon the first appearance of CPE, the cells 
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in 100 μl PBS containing 2% FBS. For the dsRNA isolation, SDS was added to the 
samples to a final concentration of 1%, boiled for 3 minutes, and placed on ice for 
at least 1 minute before 1 μl RNAse free DNAse (Fermentas, FisherScientific, 
Landsmeer, The Netherlands) was added. The samples were then incubated for 30 
 minutes at 37°C. Subsequently Proteinase K (Fermentas, FisherScientific, Lands-
meer, The Netherlands) was added to a final concentration of 2 mg/ml and left at 
37° C for 2 hours. RNA was extracted by 1 volume of Trizol reagent (Ambion, Life 
Technolgies, Bleiswijk, The Netherlands) followed by isopropanol precipitation. 
RNA was taken up in 25 μl RNase free water. To separate the RNA segments 10 
μl was used and loaded on a 12% polyacrylamide-SDS gel after addition of 2x 
RNA loading dye (Fermentas, FisherScientific, Landsmeer, The Netherlands). 
Electrophoresis was carried out with 20 mA for ~12 hours, before staining with 
SYBR gold (Invitrogen, Life Technologies, Bleiswijk, The Netherlands) and photo-
graphed on a BioRad Gel Doc™ XR+ System (BioRad, Veenendaal, The Nether-
lands).
Viability assay
WST-1 reagent (Roche, Woerden, The Netherlands) was used to assay the via-
bility of cells after reovirus infections. Cells were grown in 96-well plates and 
mock infected or infected with wtT3D reovirus or early passage (P2) rS1His-2A-
iLOV reovirus with an MOI911 of 1, in quadruple. Four days post infection the 
WST-1 reagent was added to the wells according to the instructions. The mock 
 infected cells were set to 100% viability. The statistical significance was deter-
mined with GraphPad Prism v6 using the 2-way ANOVA with Dunnett’s multiple 
comparison test. The results are considered significant for P<0.05. 
 For the viability assay with the VH10 cells and 911 cells as a control, cells 
were infected with rS1His-iLOV, jin-3 (MOI911~1) or uninfected in quadruplicate 
and four days post infection the viability of the cultures was determined by 
WST-assay.
Caspase-3/7 activity assay
For measuring caspase activity, the 911 cell line was cultured in 96-well plates 
(1.5*104 cells per well in quadruplicate) and mock infected, infected with reovirus 
containing lysates of wtT3D reovirus, rS1His-2A-iLOV, or jin-3 mutant reovirus at 
an MOI911~5. Twenty four hours and 48 hours post infection caspase-3/7 activity 




Determination of rS1His-2A-iLOV by TCID50 (50% tissue culture 
infective dose) assay
One day prior to the assay, 911 cells were plated in 96-well plates. The next 
day cells were infected with 10-fold serially dilutions of rS1His-2A-iLOV virus, 
starting with a 100-fold dilution up to 10-9 in DMEM with 2% FBS. Of each 
 dilution 50 μl/well was added to 10 wells containing 911 cells in 50 μl DMEM plus 
2% FBS per well. The last 2 wells of each row were used as uninfected controls. 
After ~7 days, CPE was scored under a light microscope and titer was determined 
using the Reed-Müench method [46] and expressed as Infectious Units (IU911)/ml.
Nucleotide sequences 
The sequence of the S1His-2A-iLOV segment is deposited in Genbank under 
accession number KJ806995. The GenBank ID’s of our wtT3D (R124) segments are: 
R124 L1 GU991659; R124 L2 GU991660; R124 L3 GU991661; R124 M1 GU991662; 
R124 M2 GU991663; R124 M3 GU991664; R124 S1 GU991665; R124 S2 GU991666; 
R124 S3 GU991667; R124 S4 GU991668.
Genbank ID of jin-3 S1segment is: KJ806994.
Acknowledgements
We thank Dr. Danijela Koppers-Lalic and Leithe Buedel for helpful discussions 
and suggestions. Aitor Navarro is gratefully acknowledged for providing us the 










Tweaking Reovirus T3D to Boost the Oncolytic Potency
1.  Marcato P., Shmulevitz M., Pan D., Stoltz D., 
Lee P.W.K. Ras Transformation Mediates 
 Reovirus Oncolysis by Enhancing Virus 
 Uncoating, Particle Infectivity, and 
 Apoptosis-dependent Release. Mol Ther. 
2007;15(8):1522-1530.
2.  Smakman N., Van den Wollenberg D.J.M., 
Borel Rinkes I.H.M., Hoeben R.C., 
 Kranenburg O. Sensitization to apoptosis 
 underlies KrasD12-dependent oncolysis of 
 murine C26 colorectal carcinoma cells by 
 reovirus T3D. J Virol. 2005;79(23):14981-14985.
3.  Tyler K.L., Squier M.K., Rodgers S.E., 
 Schneider B.E., Oberhaus S.M., Grdina T.A., 
et al. Differences in the capacity of reovirus 
strains to induce apoptosis are determined by 
the viral attachment protein sigma 1. J Virol. 
1995;69(11):6972-6979.
4.  Tyler K.L., Squier M.K., Brown A.L., Pike B., 
Willis D., Oberhaus S.M., et al. Linkage 
 between reovirus-induced apoptosis and 
 inhibition of cellular DNA synthesis: role of the 
S1 and M2 genes. J Virol. 1996;70(11):7984-7991.
5.  Kyula J.N., Roulstone V., Karapanagiotou 
E.M., Melcher A.A., Harrington K.J. Oncolytic 
reovirus type 3 (Dearing) as a novel therapy in 
head and neck cancer. Expert Opin Biol Ther. 
2012;12(12):1669-1678.
6.  Harrington K.J., Vile R.G., Melcher A., 
 Chester J., Pandha H.S. Clinical trials with 
 oncolytic reovirus: Moving beyond phase I into 
combinations with standard therapeutics. 
 Cytokine Growth Factor Rev. 2010:1-8.
7.  Kobayashi T., Antar A.A., Boehme K.W., 
 Danthi P., Eby E.A., Guglielmi K.M., et al.  
A plasmid-based reverse genetics system for 
animal double-stranded RNA viruses. Cell Host 
Microbe. 2007;1(2):147-157.
8.  Van den Wollenberg D.J.M., Van den Hengel 
S.K., Dautzenberg I.J.C., Cramer S.J., 
 Kranenburg O., Hoeben R.C. A strategy for 
 genetic modification of the spike-encoding 
 segment of human reovirus T3D for reovirus 
targeting. Gene Ther. 2008;15(24):1567-15678.
9.  Demidenko A.A., Blattman J.N., Blattman 
N.N., Greenberg P.D., Nibert M.L. Engineering 
recombinant reoviruses with tandem repeats 
and a tetravirus 2A-like element for exogenous 
polypeptide expression. Proc Natl Acad Sci 
USA. 2013;110(20):1867-1876.
10.  Brochu-Lafontaine V., Lemay G. Addition of 
exogenous polypeptides on the mammalian 
reovirus outer capsid using reverse genetics.  
J Virol Methods. 2012;179(2):342-350.
11.  Roner M.R., Joklik W.K. Reovirus reverse 
 genetics: Incorporation of the CAT gene into  
the reovirus genome. Proc Natl Acad Sci USA. 
2001;98(14):8036-8041.
12.  Van den Wollenberg D.J.M., Dautzenberg I.J., 
Van den Hengel S.K., Cramer S.J., De Groot 
R.J., Hoeben R.C. Isolation of reovirus T3D 
mutants capable of infecting human tumor cells 
independent of Junction Adhesion Molecule-A. 
PLoS ONE. 2012;7(10):e48064.
13.  Dautzenberg I.J., Van den Wollenberg D.J.M., 
Van den Hengel S.K., Limpens R.W., Barcena 
M., Koster A.J., et al. Mammalian ortho reovirus 
T3D infects U-118 MG cell spheroids independ-
ent of Junction Adhesion Molecule-A. Gene 
Ther. 2014;21:609-617.
14.  Barton E.S., Connolly J.L., Forrest J.C., 
 Chappell J.D., Dermody T.S. Utilization of 
 sialic acid as a coreceptor enhances reovirus 
attachment by multistep adhesion strengthen-
ing. J Biol Chem. 2001;276:2200-2211.
15.  Reiter D.M., Frierson J.M., Halvorson E.E., 
 Kobayashi T., Dermody T.S., Stehle T. Crystal 
Structure of Reovirus Attachment Protein -s1 in 
Complex with Sialylated Oligosaccharides. 
PLoS Pathog. 2011;7(8):e1002166-e1002166.
16.  Dermody T.S., Nibert M.L., Bassel-Duby R., 
Fields B.N. Sequence diversity in S1 genes and 
S1 translation products of 11 serotype 3 
 reovirus strains. J Virol. 1990;64(10):4842-4850.
5.6 References chapter 5
148
CHAPTER 5
17.  Hoyt C.C., Richardson-Burns S.M., Goody 
R.J., Robinson B.A., Debiasi R.L., Tyler K.L. 
Nonstructural Protein σ1s Is a Determinant of 
Reovirus Virulence and Influences the Kinetics 
and Severity of Apoptosis Induction in the 
Heart and Central Nervous System. J Virol. 
2005;79(5):2743-2753.
18.  Poggioli G.J., Keefer C., Connolly J.L., 
 Dermody T.S., Tyler K.L. Reovirus-Induced 
G2/M Cell Cycle Arrest Requires σ1s and 
 Occurs in the Absence of Apoptosis. J Virol. 
2000;74(20):9562-9570.
19.  Boehme K.W., Hammer K., Tollefson W.C., 
Konopka-Anstadt J.L., Kobayashi T., Dermody 
T.S. Nonstructural Protein sigma1s Mediates 
Reovirus-Induced Cell Cycle Arrest and 
 Apoptosis. J Virol. 2013.
20.  Chapman S., Faulkner C., Kaiserli E., 
 Garcia-Mata C., Savenkov E.I., Roberts A.G., 
et al. The photoreversible fluorescent protein 
iLOV outperforms GFP as a reporter of plant 
virus infection. Proc Natl Acad Sci USA. 
2008;105(50):20038-20043.
21.  Leone G., Maybaum L., Lee P.W. The reovirus 
cell attachment protein possesses two inde-
pendently active trimerization domains: basis 
of dominant negative effects. Cell. 1992;71: 
479-488.
22.  Chappell J.D., Barton E.S., Smith T.H., Baer 
G.S., Duong D.T., Nibert M.L., et al. Cleavage 
susceptibility of reovirus attachment protein 
sigma1 during proteolytic disassembly of 
 virions is determined by a sequence 
 polymorphism in the sigma1 neck. J Virol. 
1998;72(10):8205-8213.
23.  Alain T., Kim T.S., Lun X., Liacini A., Schiff 
L.A., Senger D.L., et al. Proteolytic disassembly 
is a critical determinant for reovirus oncolysis. 
Mol Ther. 2007;15:1512-1521.
24.  Roner M.R., Roehr J. The 3’ sequences required 
for incorporation of an engineered ssRNA into 
the Reovirus genome. Virol J. 2006;3:1-11.
25.  Kobayashi T., Ooms L.S., Ikizler M., Chappell 
J.D., Dermody T.S. An improved reverse 
 genetics system for mammalian orthoreo-
viruses. Virology. 2010;398(2):194-200.
26.  Connolly J.L., Barton E.S., Dermody T.S. 
 Reovirus binding to cell surface sialic acid 
 potentiates virus-induced apoptosis. J Virol. 
2001;75(9):4029-4039.
27.  Deutscher S.L., Nuwayhid N., Stanley P., 
 Briles E.I.B., Hirschberg C.B. Translocation 
across golgi vesicle membranes: A CHO 
 glycosylation mutant deficient in CMP-sialic 
acid transport. Cell. 1984;39(2, Part 1):295-299.
28.  Kim J.H., Lee S.-R., Li L.-H., Park H.-J., Park 
 J.-H., Lee K.Y., et al. High Cleavage Efficiency 
of a 2A Peptide Derived from Porcine 
 Teschovirus-1 in Human Cell Lines, Zebrafish 
and Mice. PLoS ONE. 2011;6(4):e18556.
29.  Szymczak-Workman A.L., Vignali K.M., 
 Vignali D.A. Design and construction of 2A 
peptide-linked multicistronic vectors. Cold 
Spring Harb Protoc. 2012;2012(2):199-204.
30.  Kim M., Garant K.A., Zur Nieden N.I., Alain 
T., Loken S.D., Urbanski S.J., et al. Attenuated 
reovirus displays oncolysis with reduced host 
toxicity. Br J Cancer. 2011;104(2):290-299.
31.  Chappell J.D., Gunn V.L., Wetzel J.D., Baer 
G.S., Dermody T.S. Mutations in type 3 
 reovirus that determine binding to sialic acid 
are contained in the fibrous tail domain of viral 
attachment protein sigma1. J Virol. 
1997;71(3):1834-1841.
32.  Chappell J.D., Duong J.L., Wright B.W., 
 Dermody T.S. Identification of Carbo hydrate-
Binding Domains in the Attachment Proteins of 
Type 1 and Type 3 Reoviruses. J Virol. 
2000;74(18):8472-8479.
33.  Seago J., Juleff N., Moffat K., Berryman S., 
Christie J.M., Charleston B., et al. An 
 infectious recombinant foot-and-mouth disease 
virus expressing a fluorescent marker protein. 
J Gen Virol. 2013;94(7):1517-1527.
34.  Christie J.M., Hitomi K., Arvai A.S., Hartfield 
K.A., Mettlen M., Pratt A.J., et al. Structural 
 tuning of the fluorescent protein iLOV for 
 improved photostability. J Biol Chem. 
2012;287(26):22295-22304.
35.  Zou S., Brown E.G. Identification of sequence 
elements containing signals for replication and 
encapsidation of the reovirus M1 genome 










Tweaking Reovirus T3D to Boost the Oncolytic Potency
36.  Bodelon G., Labrada L., Martinez-Costas J., 
Benavente J. The avian reovirus genome 
 segment S1 is a functionally tricistronic  
gene that expresses one structural and two 
 nonstructural proteins in infected cells. 
 Virology. 2001;290(2):181-191.
37.  Ni Y., Kemp M.C. Subgenomic S1 segments  
are packaged by avian reovirus defective 
 interfering particles having an S1 segment 
 deletion. Virus Res. 1994;32(3):329-342.
38.  Fallaux F.J., Kranenburg O., Cramer S.J., 
 Houweling A., Van Ormondt H., Hoeben R.C., 
et al. Characterization of 911: a new helper cell 
line for the titration and propagation of early 
region 1-deleted adenoviral vectors. Hum Gene 
Ther. 1996;7:215-222.
39.  Buchholz U.J., Finke S., Conzelmann K.K. 
 Generation of bovine respiratory syncytial virus 
(BRSV) from cDNA: BRSV NS2 is not essential 
for virus replication in tissue culture, and the 
human RSV leader region acts as a functional 
BRSV genome promoter. J Virol. 1999;73(1): 
251-259.
40.  Klein B., Pastink A., Odijk H., Westerveld A., 
Van der Eb A.J. Transformation and immor-
talization of diploid xeroderma pigmentosum 
 fibroblasts. Exp Cell Res. 1990;191(2):256-262.
41.  Roner M.R., Steele B.G. Features of the 
 mammalian orthoreovirus 3 Dearing l1 
 single-stranded RNA that direct packaging  
and serotype restriction. J Gen Virol. 
2007;88(12):3401-3412.
42.  Boehme K.W., Ikizler M., Kobayashi T., 
 Dermody T.S. Reverse genetics for mammalian 
reovirus. Methods. 2011;55(2):109-113.
43.  Transfiguracion J., Bernier A., Voyer R., 
Coelho H., Coffey M., Kamen A. Rapid and 
 reliable quantification of reovirus type 3 by 
high performance liquid chromatography 
 during manufacturing of Reolysin. J Pharm 
 Biomed Anal. 2008;48(3):598-605.
44.  Virgin H.W., Mann M.A., Fields B.N., Tyler 
K.L. Monoclonal antibodies to reovirus reveal 
structure/function relationships between  capsid 
proteins and genetics of susceptibility to anti-
body action. J Virol. 1991;65(12):6772-6781.
45.  Navarro A., Trask S.D., Patton J.T. Generation 
of genetically stable recombinant rotaviruses 
containing novel genome rearrangements and 
heterologous sequences by reverse genetics. 
J Virol. 2013;87(11):6211-6220.
46.  Reed L.J., Muench H. A simple method of 










6.1 Overall conclusion 153
6.2 Reovirus in relation to sialylated glycans 153
6.3 Reovirus and cell entry 154
6.4 Reovirus and host immune response 156
6.5 Reovirus and its next generation  157










Tweaking Reovirus T3D to Boost the Oncolytic Potency
6.1 Overall conclusions
The clinical evaluation of reovirus T3D as an anti-cancer agent for the treat-
ment of cancers revealed several obstacles. The antiviral immune response and 
the inefficient delivery of reovirus to the tumour site are identified as the main 
hurdles that limit efficacy [1]. The work described in this thesis is focused on this 
last barrier; the resistance of cancer cells to reovirus induced cell death [2, 3] and 
enhancing the oncolytic properties of reovirus T3D. The studies follow two basic 
approaches: 1) bioselection and 2) genetic modification.
The results of the work led us to the following conclusions:
1. The high mutation rate of the dsRNA of reoviruses is applicable for generat-
ing viruses that are capable of infecting cells that resist infection with wild-
type reovirus due to the lack of the JAM-A receptor. The new viruses have 
expanded their tropism.
2. In more complex culture conditions such as spheroid cultures, reovirus T3D 
is not dependent on the interaction with the JAM-A receptor for cell entry.
3. The spike protein σ1 tolerates the insertion of small heterologous proteins 
including a teschovirus-1 2A element and permits the removal of the JAM-A 
binding domain of σ1.
4. It is possible to insert a small heterologous transgene into the S1 segment of 
reovirus T3D without the need to use helper cell lines or wild-type reo-
viruses to rescue the recombinant reovirus.
6.2 Reovirus in relation to sialylated glycans
Reovirus T3D has been applied in several clinical trials and has been well 
 tolerated and safe in humans (e.g. see website of Oncolytics Biotech for the latest 
developments and trials; http://www.oncolyticsbiotech.com). So far, the bio-
selected jin reoviruses described in Chapter 2 of this thesis and the rS1His-2A-
iLOV  recombinant reovirus (Chapter 5) have only been studied in tissue culture 
conditions. The next step would be to test them in an experimental animal cancer 
model. A problem is that for neonatal mice [4] and severe immunodeficient mice 
[5], reoviruses can be fatal. Most of the animal experiments in reovirus research 
are therefore performed in adult nude mice [6, 7]. 
One of the important determinants for reovirus pathogenesis in the central 
 nervous system of newborn mice is the binding of σ1 to sialic acids. In contrast to 
our jin mutants with an enhanced binding to sialic acids an amino acid substitution 
of R202W in σ1 is no longer capable of binding to sialic acids [8]. The T3D-σ1R202W 
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virus was less neurovirulent in 2-day-old mice. In the spinal cords of mice 
infected with T3D-σ1R202W less apoptotic cells were detected than in the spinal 
cords of mice infected with the wild-type T3D virus. In this respect it is  interesting 
to see what happens with our jin mutants or the head-less rS1His-2A-iLOV virus 
in newborn mice. 
In 911 cells, the caspase 3/7 activity induced after infection of the recombinant 
rS1His-2A-iLOV virus is less than in the wild-type reovirus infected 911 cells. In 
jin-3 infected 911 cells, the induction of caspase 3/7 is delayed, but at 48 hr post 
 infection the activity is higher than in the recombinant virus infected cells 
 (Chapter 5, Figure 5C). The paper by Danthi et al. [9] mentions that reovirus 
strains containing both JAM-A and sialic acid binding domains are the most 
potent inducers of apoptosis. This can explain our observations of a reduced 
caspase 3/7  activity in 911 cells with the headless rS1His-2A-iLOV virus. 
Binding of σ1 to sialic acids (α2,3; α2,6 or α2,8-linked sialylated glycans) is 
 specific for reovirus strain T3D. It was found that strain T1L utilizes ganglioside 
GM2 as a coreceptor [10]. While the glycan binding domain of T3D-σ1 is located 
in the tail part of the protein, in T1L-σ1 the glycan binding domain is located in 
the head domain, near the JAM-A binding site. Noteworthy in this respect is the 
location of the amino acid change Q336R in σ1 of jin-1 and jin-2 (Chapter 2, Table 
1). The alignment of the glycan binding domain of T1Lσ1 with T3Dσ1 and jin-1σ1 
is depicted in Figure 1. It is possible that the alteration of Q336R in the two 
jin-mutants renders a conformation that allows binding to a glycan at this 
 position. Generating the T3D-σ1Q336R protein would allow interaction studies 
with different glycans.
6.3 Reovirus and cell entry
Since the discovery that the three reovirus strains (T1L, T2J and T3D) attach to 
JAM-A it is generally accepted that JAM-A is the high affinity receptor, at least in 
cells cultured in vitro. The situation in vivo is more complex, as is explored in 
JAM-A-/- mice infected with reovirus T1L, T3D and a strain defective of binding to 
sialic acids (T3SA-) [11]. In this report it is concluded that JAM-A is not involved 
in reovirus replication in the intestine and the brain of mice infected with the 
T3SA- strain. Based on findings that specific regions in the brains of both WT and 
JAM-A-/- mice are infected with reovirus T3D and T3SA- it is hypothesized that in 
neurons a different receptor is involved in reovirus T3D uptake. In 2014 this 
 receptor was identified as the Nogo receptor, NgR1; a leucine-rich repeat protein 
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reovirus-induced CNS disease. This can be explained by the preference for reo-
virus T3D to infect only the unmyelinated CNS of newborn mice in which the 
NgR1 receptor is not yet fully associated to myelin and therefore available for reo-
virus binding. This age-dependent pathogenesis had already been reported previ-
ously [13]. More research is needed to identify the reovirus protein that is 
involved in binding to NgR1. It seems that σ3 or part of σ1 that stays associated 
with virions, but not with the conformationally changed σ1 in ISVPs, binds NgR1 
[12].
In the intestine where many proteases are present, reovirus particles may be 
extracellular digested to ISVPs and the ISVPs no longer depend on JAM-A for cell 
entry [14-16]. Also in U118MG cells grown in 3D-cultures we found that JAM-A is 
dispensable for cell entry. The sensitivity for reovirus acquired by the cells when 
grown in spheroids, is dependent on cathapsins secreted by the U118MG sphe-
roids (Chapter 3). In the microenvironment of tumours many proteases are 
 present, including different cathapsins, that can promote tumour progression (for 
a review see Alain et al. [17]) and may help reovirus to enter the tumour cells 
 independent of the JAM-A receptor. 
JAM-A and CAR (coxsackievirus and adenovirus receptor) are both membrane 
proteins involved in adhesive junctions (AJs) on epithelial and endothelial cells. 
Many viruses utilize different families of the membrane proteins in AJs as 
 receptor to enter cells. Adenoviruses use CAR for cell entry in a similar fashion as 
reovirus exploits JAM-A [18, 19]. In 2002 a report appeared with evidence that 
adenoviruses not only use CAR for cell entry but also for their escape [20]. Cells 
infected with adenovirus produce an excess of fibers (the spike protein of adeno-
virus that attaches to the CAR receptor) that are not all incorporated in the nas-
cent virions. The produced fibers may bind CAR, thereby competing with the 
CAR-CAR interactions that mediate cell-cell adhesion. This may allow the adeno-
viruses to escape and cross tissue barriers. Based on the similarity in structure of 
the adenovirus fiber and the reovirus spike it is possible that also reoviruses may 
use secretion of excess amounts of spike protein to facilitate viral escape into the 
FIGURE 1. Amino Acid alignment of the glycan binding domain of T1L-σ1 (350-380) with 
the corresponding region of T3D-σ1 and jin-1-σ1 (333-360). The glycan- binding sites in 
T1L-σ1 are highlighted by yellow boxes. The altered amino acid of jin-1 (R336) is  displayed 
in red. Adapted from [10].
 T1Lσ1 (350-380) WR ANVT LNLMKVDDWLVLSF SQMT TNSIMAD
 T3Dσ1 (333-363) WR VQVN S D I F I V D D Y I H I C L  PAFD GFSIADG
 jin-1σ1 (333-363) WR VRVN S D I F I V D D Y I H I C L  PAFD GFSIADG
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bloodstream by disrupting JAM-A homodimer interactions [21]. The data summa-
rized here indicates that reoviruses can use several strategies and receptors for 
their replication in different circumstances. 
6.4 Reovirus and host immune response
Administration of oncolytic viruses to patients with an intact immune system 
has been a challenge. The viruses have to overcome many barriers before reaching 
their potential target, the tumour site [22]. In the early days of oncolytic virus 
 delivery, the focus was on direct intratumoral delivery. This, of course, is only 
possible if the tumour site is easily accessible for direct injection of the oncolytic 
agent. For a more general solution, including reaching metastasis, the preferred 
method is by systemic delivery. In the oncolytic viral field, many strategies are 
being developed to deal with acquired immune responses against the virus 
[23-25]. 
One of the obstacles is the pre-existing immunity against reovirus in the major-
ity (± 90%) of the human population. In most of the patients enrolled in clinical tri-
als neutralizing antibodies (NABs) are detected prior to administration of the reo-
virus [26-28]. Experiments in reovirus-immune tumour bearing mice revealed that 
intravenous injected reovirus, antitumour therapy was completely ineffective [29]. 
The same research shows that delivery of the reovirus on carrier cells  (mature 
Dendritic Cells (mDC) and T-cells) protects the virus against the circulating NABs 
resulting in clearance of the cancer cells. Furthermore, when reoviruses were 
delivered by T-cells an anti-tumour immune response was triggered resulting in 
long-term tumour clearance. These findings imply that besides the negative effect 
of the immune response towards the reovirus, there is also a beneficial effect of 
the immune system on the reovirus mediated anti-tumour effect. This  observation 
is not new to the field of oncolytic virus therapy. It is shown that  uninfected 
tumour cells in tumours treated with vesicular stomatitis virus (VSV) were also 
killed despite the initial poor delivery of the VSV to the tumours in a mouse 
model [30]. Over the years, more is published on the topic of oncolytic  viruses and 
the complex interaction with the host immune system and the anti- tumour 
response [22, 25, 31].
In the human situation the circumstances for reovirus are different compared 
to mouse models. Despite the presence of NABs, reovirus could be detected in 
 tumour biopsies of patients after intravenous administration [27, 32, 33]. One 
 hypothesis is that reoviruses in the bloodstream bind to and/or infect blood cells 
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sites, shielded from the circulating NABs. To further test this, a study was per-
formed that includes stimulation of the potential carrier cells prior to systemic 
reo virus delivery [28]. They confirmed that cytokine stimulation of the recipient 
cells (monocytes/macrophages) in vivo enhanced the viral delivery to the tumour 
cells. This cytokine conditioning therapy was even more effective in reovirus- 
immune mice with pre-existing NABs. More research is needed to fully under-
stand the complex interaction of the immune system with oncolytic viruses and 
the anti- tumour effect. For reovirus therapy it is at least promising that also in the 
presence of pre-existing NABs the viruses can find their way to the tumours.
6.5 Reovirus and its next generation 
A proof of concept for adding a therapeutic transgene is described in this 
 thesis (Chapter 5). Here we describe the introduction of a gene encoding a fluores-
cent reporter protein in the segment encoding the reovirus spike protein. Based on 
the observations that it may be useful to enhance the immune response to 
 tumours in combination with reoviruses, next generation reoviruses would carry 
immune-stimulating molecules. This would give the virus a dual-acting function 
for inducing tumor cell death. 
Already GM-CSF is used in the context of an oncolytic herpes simplex virus for 
the treatment of melanoma [34]. The study shows that intratumoral administra-
tion of the so called OncovexGM-CSF virus induced an immune response in meta-
static melanoma lesions. This could be used in the field of anti-cancer immuno-
therapy, which is developing towards personalized peptide vaccination as a novel 
treatment [35]. 
Another, related, strategy based on our recombinant reoviruses is to enhance 
the oncolytic potency by adding anti-tumor proteins [36]. There are many candi-
dates, among others the viral proteins apoptin [37], the adenovirus-derived 
E4Orf4 [38], or even non-viral anticancer peptides [39, 40]. One of those anticancer 
peptides, LyP-1 is already exploited in combination with baculovirus [41]. 
In our initial design of the rS1His-2A-ilOV virus we found several viable dele-
tion mutants. In those deletion mutants, sequences in the untranslated region (A 
and B-boxes) were deleted, suggesting that these two conserved elements are not 
necessary for incorporation of the recombinant S1 segment. This provides another 
52 nucleotides for adding foreign sequences, for example codons for a tumour- 
homing sequence, like LyP-1 (27 nucleotides long). For a targeting strategy, the 
codons could be directly fused with the S1His codons to ensure incorporation of 
the targeting peptide into the viral capsid.
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Summary
In the war against cancer many viruses have been tried as bullets. Even viruses 
that cause diseases in humans have been adapted to destroy cancer cells. Such 
 viruses were rendered less pathogenic and thereby reduced their fitness and 
 reproductive capacity. Some viruses discriminate by default between normal cells 
and transformed cells: such viruses are named ‘oncolytic viruses’. They preferen-
tially infect, multiply and destroy transformed cells for their release and disper-
sion to the surrounding cells. One of these viruses is the mammalian orthoreo-
virus T3D, or reovirus, in short. Chapter 1 gives an introduction on the character-
istics of reoviruses and their potential use as oncolytic agents. 
Cancer cells have developed various strategies to escape control of normal 
 regulators in tissue. This may have consequences for oncolytic viruses if their 
strategy involves evading cell death pathways. For their anti-tumour effect onco-
lytic viruses need to attach to receptors on the surface of the cell before their entry 
into the cell. In some tumour cells the canonical reovirus receptors may not 
always available. Reovirus cell entry is a multiple step process. The first step 
involves attaching to sialic-acid residues on the cell surface. It is followed by a 
higher affinity binding to Junction Adhesion Molecule-A (JAM-A). Chapter 2 
describes the isolation of reovirus mutants that are able to infect cells that lack 
JAM-A, the JAM-A independent (in short: jin) reovirus mutants. The jin mutants 
harbour mutations in the S1 segment resulting in amino acid changes in the tail of 
the spike protein σ1, and in two mutants (jin-1 and jin-2), also in the head domain 
 region. The changes in the three jin mutants in the tail of σ1 are located in close 
proximity of the region that is implicated in sialic-acid binding. Our hypothesis is 
that the changed affinity for sialic-acids underlies the expanded tropism of the jin 
viruses. The question remains how important this is in tumours in vivo.
The tumour microenvironment in vivo differs strongly from the conditions in 
cell culture. This is noticeable when cells are grown as spheroids. Chapter 3 
 reveals that JAM-A is dispensable for reovirus infection when cells are grown in a 
3D cultures. The U118MG cells that are reovirus resistant under normal cell 
 culture conditions, due to the absence of JAM-A, are susceptible to reovirus infec-
tion when grown in spheroid cultures. The increased infection is mediated by the 
presence of extracellular cathepsins in the U118MG spheroids. Cathepsins are pro-
teases that can convert the reovirus particles to so-called intermediate subviral 
particles (ISVPs). ISVPs have been described to be capable of infecting cells inde-
pendent of the JAM-A receptor. 
The tumour microenvironment contains many proteases secreted by the 
 tumour cells. These proteases promote tumour progression by modulation of key 
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processes such as angiogenesis, metastasis, and composing the extra-cellular 
 matrix (ECM). The presence of proteases in tumour could be enhance reovirus 
 infection and replication. 
Genetic modification of the segmented dsRNA genome of reoviruses is more 
complicated than modification of dsDNA viruses such as Herpes Simplex virus or 
Adenovirus. Based on previous research in the group on Adenovirus and modifi-
cations to its capsid proteins to expand the tropism, Chapter 4 describes the modi-
fication of the reovirus S1 segment that encodes for the spike protein σ1 in the 
viral capsid. This approach requires the presence of wild-type reovirus to rescue 
the genetically modified virus. The only segment that was changed is S1 and 
 included the codons for a 6xHis-tag at the 3’end of the open reading frame for the 
σ1 protein. Our results demonstrate that the C-terminus of σ1 is a suitable 
 location for adding heterologous peptides and that the S1His segment stably 
 delivered with a lentivirus into 911 cells is encapsulated in the reovirus particles. 
A drawback of this system is the presence of wild-type reovirus necessary to 
 provide the other reovirus segments. Although a selection system is used that 
 consists of cells that are resistant to wild-type reovirus and are only sensitive to 
the His-tagged reovirus, the mutation rate of this dsRNA viruses interferes with 
the reliability of the system and the chance that revertant viruses are isolated is 
 relatively high (see Chapter 2).
In 2007 a plasmid-based reverse genetics system for mammalian reoviruses 
was described which allowed generation of recombinant reoviruses without the 
requirements of wild-type reovirus as a helper. In Chapter 5, this system was 
used for generating a recombinant reovirus that carries a gene that encodes for a 
small fluorescent protein (called iLOV) and replaces the head domain of the σ1 
protein. The choice for this location was based on the knowledge that the jin-3 
virus, with only one point mutation in the tail of σ1, efficiently infects cells inde-
pendent of the JAM-A receptor. The S1His-2A-iLOV segment encodes the first 252 
amino acids of σ1, including the point mutation in the tail of jin-3 σ1 which lead to 
the G196R substitution fused to the His-tag and a teschovirus-1 2A peptide that 
ensures the synthesis of a separated iLOV protein in infected cells. The data pre-
sented in this chapter demonstrate for the first time that σ1 tolerates replacement 
of the head domain of the spike protein by a small heterologous proteins. With 
this system, next generation reoviruses could be generated that are armed with 
therapeutic transgenes to enhance the oncolytic efficacy of these viruses.
Finally, Chapter 6 provides a general discussion on some of the aspects 
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Nederlandse samenvatting
‘Sleutelen aan Reovirus T3D om de Oncolytische Effectiviteit te Verhogen’
Om de strijd te winnen in de oorlog tegen kanker worden zelfs virussen 
 gebruikt als kogels. Ook virussen die ziekten kunnen veroorzaken bij de mens: zij 
worden zodanig aangepast dat ze kankercellen vernietigen en minder ziektever-
wekkend zijn. Dit heeft soms tot gevolg dat deze virussen minder levensvatbaar 
zijn en zich slechter kunnen vermenigvuldigen. Een aantal virussen is van nature 
in staat om te discrimineren tussen gezonde cellen en kankercellen: de zoge-
noemde oncolytische virussen. Deze virussen vermenigvuldigen zich voor-
namelijk in de kankercellen en bij de ontsnapping uit de cellen waarbij deze cellen 
worden vernietigd. Eén van die virussen is “Mammalian Orthoreovirus T3D”, 
hier verder reovirus genoemd. Hoofdstuk 1 geeft een inleiding in de biologie van 
reovirussen en hoe ze worden ingezet bij behandeling van kanker. Kankercellen 
hebben strategieën ontwikkeld om aan de normale regulatoren van celdeling te 
ontsnappen. Dit heeft ook gevolgen voor de oncolytische virussen als kanker-
cellen niet meer reageren op prikkels voor celdood, waar virussen op rekenen in 
hun strategie om te ontsnappen uit de cellen. 
Voordat de oncolytische virussen een anti-tumor effect kunnen veroorzaken 
zullen de virussen eerst de cellen binnen moeten komen. Dit doen virussen door 
te hechten aan bepaalde receptoren die aanwezig zijn op de oppervlakten van de 
cellen. Helaas zijn niet bij alle typenkanker deze receptoren aanwezig. Het reo-
virus komt de cellen binnen met een proces dat meerdere stappen kent. Als eerste 
bindt het reovirus aan siaalzuren die op de oppervlakte van cellen aanwezig zijn 
om vervolgens aan de “echte” receptor te binden, genaamd JAM-A (Engelse 
 afkorting voor Junction Adhesion-Molecule A). In hoofdstuk 2 wordt beschreven 
hoe reovirus mutanten werden geïsoleerd die in staat zijn om cellen te infecteren 
die geen JAM-A receptor bevatten; deze aangepaste reovirussen worden jin-
mutan ten genoemd. Jin staat voor JAM-A onafhankelijk (JAM-A independent). Jin 
reovirussen bevatten puntmutaties in het S1 genoom. Deze leiden tot aminozuur 
veranderingen in het σ1 eiwit, verantwoordelijk voor hechting van de reovirussen 
aan de cellen. De drie geïsoleerde jin reovirussen hebben veranderingen in de 
staart van het σ1 eiwit en twee van de drie (jin-1 en jin-2) ook nog in het kop-
domein. De veranderingen in de staart van σ1 liggen allemaal in de buurt van de 
regio die verantwoordelijk wordt gehouden voor de binding aan siaalzuren op 
het celoppervlake. Onze hypothese is dat de jin reovirussen zich sterker binden 
aan siaalzuren door deze veranderingen en daardoor meer verschillende gastheer-
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cellen kunnen infecteren, ook aan de cellen die geen JAM-A receptor hebben. De 
vraag blijft of dit in tumoren van het menselijk lichaam ook geldt.
Het micromilieu in tumoren is anders dan van cellen die in het laboratorium 
op plastic worden gekweekt. Er is al een verschil waarneembaar als cellen in 3D 
klompjes (spheroids) worden gegroeid. Hoofdstuk 3 geeft aan dat JAM-A niet 
nodig is voor het infecteren van U118MG spheroids door reovirus. Onder normale 
celkweek omstandigheden kan reovirus, door het ontbreken van JAM-A, de 
U118MG cellen niet infecteren, maar in de 3D spheroids zijn deze cellen ineens 
wel gevoelig voor reovirusinfectie. Een verklaring voor de verhoogde gevoelig-
heid is de aanwezigheid van bepaalde enzymen die in staat zijn om andere eiwit-
ten af te breken, cathepsins. Cathepsins behoren tot een groep enzymen die in 
staat zijn om reovirussen af te breken tot zogenoemde ISVPs (Intermediate Sub-
viral Particles). Een eigenschap van deze ISVPs is dat het binnendringen van 
 cellen onafhankelijk is van de aanwezigheid van JAM-A op het celoppervlak. In 
het micromilieu van tumoren is bekend dat veel van dit soort enzymen (proteases 
in dit geval) aanwezig zijn. De proteases zijn mede verantwoordelijk voor de 
 ontwikkeling van de tumor naar een agressievere vorm door bijvoorbeeld het aan-
leggen van bloedvaten (angiogenese), en hebben een rol bij het vermogen om te 
metastaseren en ze zijn belangrijk voor het remodeleren van de extracellulaire 
 matrix van de tumor. De aanwezigheid van deze proteasen kunnen reovirussen 
helpen om de tumorcellen binnen te komen. 
Genetische modificatie van het reovirus genoom is door de aanwezigheid van 
meerdere dsRNA segmenten een stuk moeilijker dan bij dsDNA virussen, zoals 
bijvoorbeeld herpes simplex virus en adenovirus. Gebaseerd eerder ervaringen in 
ons lab met het modificeren van adenoviruscapside eiwitten om het tropisme te 
veranderen wordt in hoofdstuk 4 beschreven hoe het S1 segment van reovirus 
 genetisch wordt veranderd. S1 codeert voor het capside eiwit σ1, dat de spike 
vormt waarmee het virus de JAM-A receptor bindt. Om het veranderde reovirus 
te vermenigvuldigen is er echter wild-type reovirus nodig. Het enige segment dat 
wordt veranderd is S1. Hier wordt de sequentie coderend voor een 6xHis-tag 
 geplaatst dat er zo voor te zorgen dat aan de C-terminus van het σ1 eiwit een His-
tag vast zit. De experimenten tonen aan dat deze locatie geschikt is voor het aan-
brengen van heterologe peptiden en dat het S1His genoom dat wordt aangeleverd 
door een 911 cellijn die was getransduceerd met een lentivirus, wordt ingepakt in 
de nieuwe reovirussen. Een nadeel van het systeem is dat er wild-type reovirus 
nodig is om de andere negen segmenten te leveren. Ondanks het gebruik van een 
selectiesysteem tegen het wild-type reovirus is de hoge mutatiesnelheid van reo-
virus een bedreiging voor de betrouwbaarheid van dit systeem, waardoor de kans 
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Het beschikbaar komen van een plasmide systeem voor het modificeren van 
reovirus (in 2007) heeft ertoe geleid dat er geen wild-type reovirus meer nodig is. 
In hoofdstuk 5 is dit systeem gebruikt voor het maken van een recombinant reo-
virus met een S1 segment waarin het coderende gedeelte voor het kopdomein van 
σ1 wordt vervangen door de codons van een klein fluorescerend eiwit (iLOV). De 
keuze van deze locatie kwam voort uit de kennis dat jin-3, met maar één 
 aminozuursubstitutie in de staart van σ1, niet langer JAM-A nodig heeft om cellen 
 binnen te komen. Het nieuwe S1His-2A-iLOV segment codeert de sequentie voor 
de eerste 252 aminozuren van σ1, met de puntmutatie resulterend in de G196R 
verandering, gefuseerd aan de codons voor een His-tag en die voor het tescho-
virus-2A peptide dat ervoor zorgt dat het iLOV eiwit wordt gescheiden van het 
σ1-His eiwit. Uit de gegevens van dit hoofdstuk blijkt voor het eerst dat σ1 de 
toevoeging van een klein heteroloog eiwit tolereert en daarbij het hoofddomein 
niet nodig heeft. Met deze kennis is het mogelijk om nieuwe generaties reovirus-
sen te maken die gewapend zijn met therapeutische genen die de oncolytische 
effectiviteit kunnen verhogen. 
Het laatste hoofdstuk, hoofdstuk 6, vat de algemene conclusies samen en 
 bespreekt een aantal onderdelen die van belang zijn bij het binnenkomen van de 
reovirussen in cellen en de reactie van het immuunsysteem op de aanwezigheid 
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